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Abstract
Peroxisome proliferator-activated receptors (PPARs) belong to a nuclear receptor
superfamily; two major isoforms, PPARa and PPARy, are primarily involved in lipid and
glucose homeostasis. However, evidence also suggests roles for PPARs in regulating
inflammation and atherosclerosis, and prompted investigation into the efficacy of PPAR
agonists in parenchymal rejection (PR) and transplantation-associated arteriosclerosis
(TxAA). Four different PPAR agonists (fenofibrate and Wy 14643 for PPARa;
BRL69453 and 15-deoxy-A 4' 16 Prostaglandin-J2 for PPARy) in an in vitro model of the
alloresponse all demonstrated a robust and substantial attenuation of IFNy, a cytokine that
critically affects both rejection and TxAA. This occurred in a dose-dependent manner,
independent of known IFNy-inducing cytokines. At the same times, PPAR activation
increased the overall expression of chemokines but substantially decreased expression of
two relevant chemokine receptors. Of the four agonists tested, fenofibrate, a largely
PPARa-specific agonist, had the best profile of IFNy production to chemokine and
chemokine receptor expression. At early time points after cardiac transplantation,
fenofibrate administration showed findings consistent with those seen in vitro, including
a tendency to reduce IFNy. However, long-term fenofibrate treatment significantly
increased graft IFNy expression and inflammatory cell infiltration, thereby augmenting
PR without ameliorating TxAA. Congenital deficiency of PPARa confirmed that the
receptor plays a regulatory role in IFNy expression but is not necessary for graft
infiltration by inflammatory cells. The findings constitute the first examination of the
efficacy of PPAR agonists in solid-organ transplantation and suggest that in order to fully
realize the beneficial anti-inflammatory effects of fenofibrate, additional strategies must
be employed to inhibit graft inflammatory cell infiltration. Finally, a novel immunologic
research tool based on the boron neutron capture reaction is proposed.
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Associate Professor of Pathology, Harvard Medical School
Associate Director, Health Sciences and Technology
Thesis Readers: Andrew H. Lichtman, MD, PhD
Jorge Plutzky, MD
Mehmet Toner, PhD
Otto K. Harling, PhD
Page 2
Acknowledgements
I would first like to sincerely thank my supervisor, Dr. Rick Mitchell, for giving me the
opportunity to do this thesis. These last five years have been a truly incredible learning
experience. I appreciated his suggestions and easy-going style, as well as his holiday
spirit and frequent lab lunches to local restaurants.
I would also like to thank the other members of my thesis committee. Dr. Andy Lichtman
made insightful suggestions at critical stages and gave helpful feedback on preparation of
the thesis defense and manuscript. Dr Jorge Plutzky contributed PPAR expertise and
donated PPARca knock-out breeding pairs. Dr. Mehmet Toner offered a scientifically
objective and constructive point of view. Professor Harling was supportive and enabled
me to receive free reactor beam time.
Many others deserve acknowledgement: from the Mitchell lab, Jessica Allen and Dr.
Yasushi Uchida for experimental assistance; from the HST administrative office, Ron
Smith for expert guidance through the MIT/HST system, as well as Cathy Modica and
Dr. Fred Bowman, for their assistance with defense logistics; from the Lichtman lab, Dr.
Chiara Buono-Dalton for introducing me to statistical software and for organizational
help during my defense; from the Plutzky lab, Dr. Ouliana Ziouzenkova for introducing
me to the handling and storage of PPAR agonists; from the Toner lab, Lynn Stubblefield
for scheduling assistance; from the Harling group, Dr. Kent Riley for reorientation to the
facilities; from the Pathology Department, Keith Anderson for assisting with the new hot
room setup and Dr. Arlene Sharpe for allowing us to keep critical equipment; from Ohio
State University, Dr. Werner Tjarks for donating the boronated thymidine compounds
and, together with Dr. Ashraf Al-Madhoun, providing advice on their use.
And last, but definitely not least, I would like to express profound gratitude to my family.
Without their immense love, unfailing support, and constant encouragement, this thesis
could not have been accomplished.
Page 3
Emanuela Binello HST
Contents
1. Introduction................................................................................... 16
2. Background................................................................................... 18
2.1 Mechanisms of rejection in heart transplantation .............................. 18
2.1.1 General characteristics ................................................. 18
2.1.2 In vitro models ........................................................ 21
2.1.2 In vivo models ......................................................... 24
2.2 Peroxisomal Proliferator Activated Receptors (PPARs) ..................... 30
2.2.1 General characteristics ................................................. 30
2.2.2 In vitro effects............................................................. 34
2.2.3 In vivo effects .......................................................... 39
2.3 Boron neutron capture............................................................. 42
2.3.1 General characteristics ................................................. 43
2.3.2 Current applications .................................................... 44
2.3.3 A new application ....................................................... 46
3. In vitro evaluation of PPAR agonists ..................................................... 48
3.1 Introduction ..................... ............................ 48
3.2 Methods ................................................................... 50
3.3 Results . ............................................................ 53
3.4 Discussion .................................................................. 72
4. In vivo evaluation of a PPARa agonist .................................................. 81
4.1 Introduction .................................................................. 81
4.2 Methods ......... ............................................... 82
4.3 Results . ............................................................ 86
4.4 Discussion .................. ............................. .. 97
5. Role of PPARa in vitro and in vivo ................................................ 104
5.1 Introduction ............................................................... 104
5.2 Methods ................................................................... 105
5.3 R esults ................................................. 107
5.4 Discussion ................................................. 119
6. A novel tool for examining mechanisms of rejection ................................ 123
6.1 Introduction ......... ......... ......... ....................... 123
6.2 Methods ........... ................................................ 126
6.3 Results ........................... ................................. 130
6.4 Discussion ............................................................... 133
7. Summary and recommendations for future work .................................... 135
References . ................................................. 138
Page 4
Emanuela Binello HST
Figures
2.1: Sample photomicrograph of parenchymal rejection (PR): Histologically, PR
is characterized by a diffuse interstitial inflammatory infiltrate with associated
myocyte necrosis, hemorrhage and edema. Despite the responsiveness to cellular
therapy, PR remains an important cause of mortality in heart transplant
recipients ............................................................. 19
2.2: Sample photomicrograph of transplantation-associated arteriosclerosis
(TxAA): Histologically, TxAA is characterized by concentric lesions, formed by
intimal proliferation of vascular smooth muscle cells and associated extra-cellular
matrix proteins, admixed with inflammatory mononuclear cells. Despite
improvements in immunosuppressive regimes, TxAA remains refractory to
treatment and has emerged as major limitation to long-term survival of heart
transplant recipients ........................................................................... 20
2.3: A one-way mixed leukocyte response (MLR): Spleens are extracted from two
allogeneically different mice, and after lysis of the red blood cells, leukocytes are
isolated. In order to observe the response of the leukocytes separately, one
population can be inactivated by either gamma irradiation or treatment with the
antimitotic drugs, so that it does not proliferate. Cells from this population are
called "stimulators" and are analogous to the transplant donors, while the cells
from the untreated population are called "responders" and are analogous to the
transplant recipient. The proliferative response is measured by adding
radioactively labeled thymidine. Cell-free supernatant may be tested for the
presence of various molecules elaborated during proliferation ........................ 23
2.4: Murine heterotopic cardiac transplantation model: a) Schematic showing the
native heart of the donor transplanted to the recipient, such that recipient has two
hearts, its own native own and the allograft; b) photomicrographs showing, on the
left, the recipient mouse, and, on the right top and bottom panels, schematics of
the ligations and allograft itself ................................. ............................. 25
2.5: PPAR structure: There are four domains in the receptor. The first is the A/B
domain that contains a ligand-independent transactivating factor called activation
factor (AF) 1. The second is the C domain that is responsible for binding to the
DNA and is referred to as the DNA-binding domain. The third is the D domain
that contains a hinge region. The fourth is the E/F domain (containing a ligand-
dependent activating factor called AF-2) and is generally referred to as the ligand-
binding domain .................................................................. 32
2.6: PPAR activation: Upon ligand binding, PPAR undergoes a conformational
change that allows the release of co-repressors and interactions with co-activators.
This change stabilizes the interaction between PPAR and RXR for binding of the
PPAR:RXR complex to the PPRE and results in the interaction of the activated
heterodimer with the promoter, thereby stimulating the transcription of target
genes .............................................................. 32
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2.7: The boron neutron capture reaction: After a '°B nuclei captures a thermal
neutron, compound B* nuclei are formed, which disintegrate into alpha (a) and
7Li particles; the average energy released is 2.34 MeV (with 0.85 MeV carried by
7Li and 1.49 MeV carried by the a) ......................................................... 44
2.8: Boron neutron capture therapy for brain tumors: In this type of radiation
treatment, patients are first given a boron compound either orally or intra-
vascularly, then the tumor is irradiated with neutrons, inducing the boron neutron
capture reaction in boron-loaded cells. Traditionally, the tumor has three times the
boron concentration of surrounding tissue, such that upon irradiation, the tumor
will receive three times the dose given to surrounding tissues .......................... 45
2.9: Approach to boron neutron capture-based research: Parameters must be
optimized so as to have a sufficient boron concentration in target tissue to induce
cell death and appropriate neutron irradiation parameters so as not to harm
surrounding tissue ............................................................................. 46
3.1: Schematics of the structures of the four PPAR agonists evaluated: Two
agonists are directed towards PPARca, namely fenofibrate (FENO) and Wy 14643
(WY), while the other two agonists are directed toward PPARy, namely
BRL49653 (BRL) and 15-deoxy A'2 '4 Prostaglandin J2 (PGJ2) ........................ 49
3.2: Proliferation and IFN¥ concentration as a function of time: a) ConA
stimulation, proliferation peaks at day 2 and IFNy levels become significantly
elevated by day 2; b) MLR, proliferation peaks on day 4 and IFNy levels become
significant on day 3. Proliferation peaks earlier and is of higher magnitude in
ConA cultures compared to MLRs. Furthermore, IFNy production begins earlier
and is also of higher magnitude in the ConA cultures compared to MLRs. Results
are expressed as the mean and standard deviation of three experiments plated in
triplicate to quadruplicate ............ 54.................................................. 5
3.3: Dose-dependent effects of FENO on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that FENO concentrations up to 20
FiM have no significant effects on cell proliferation, while concentrations of 100
tM and above significantly decrease it; IFNy production is significantly
decreased at concentrations beginning with 20 EtM; b) MLR, FENO concentration
of 20 M significantly decreases IFNy without effects on proliferation, while
higher concentrations diminish both proliferation and IFNy production. These
results indicate 20 FtM as the "therapeutic" FENO concentration. Results are
expressed as the mean and standard deviation of one representative experiment
from a set of three, plated in triplicate to quadruplicate. The thickened plot
markers () indicate the day of peak proliferation and the first day of elevated
IFNy production ......... .. ..................................................... 55
3.4: Dose-dependent effects of WY on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that WY concentrations up to 100
tM tend to increase cell proliferation, while concentrations of 250 EtM and above
significantly decrease it; IFNy production is significantly decreased at
concentrations beginning with 100 tM; b) MLR, WY concentration of 100 M
significantly decreases IFNy without effects on proliferation, while higher
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concentrations diminish both proliferation and IFNy production. These results
indicate 100 tM as the "therapeutic" WY concentration. Results are expressed as
the mean and standard deviation of one representative experiment from a set of
three, plated in triplicate to quadruplicate. The thickened plot markers ()
indicate the day of peak proliferation and the first day of elevated IFNy
production. ..................................................................................... 56
3.5:Dose-dependent effects of BRL on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that BRL concentrations up to 50 [tM
have no significant effects on cell proliferation, IFNy production is significantly
decreased at concentrations beginning with 10 tM; b) MLR, BRL concentration
of 10 tM and above significantly decrease IFNy without significant effects on
proliferation. These results indicate 10 tM as the "therapeutic" BRL
concentration. The concentration range tested did not include any toxic doses,
based on results from proliferative assays. Results are expressed as the mean and
standard deviation of one representative experiment from a set of three, plated in
triplicate to quadruplicate. The thickened plot markers () indicate the day of
peak proliferation and the first day of elevated IFNy production ....................... 57
3.6:Dose-dependent effects of PGJ2 on proliferation and IFNy production a)
ConA simulation, proliferation assays show that while PGJ2 concentrations up to
3 tM have no significant effects on cell proliferation, while 10 FtM results in a
marked decrease; IFNy production is significantly decreased at 3 MLM and above;
b) MLR, similarly, PGJ2 concentrations of 3 [tM significantly decrease IFNy
without significant effects on proliferation, while 10 [tM decreases both
proliferation IFNy production. These results indicate 3 tM as the "therapeutic"
PGJ2 concentration. Results are expressed as the mean and standard deviation of
one representative experiment from a set of three, plated in triplicate to
quadruplicate. The thickened plot markers () indicate the day of peak
proliferation and the first day of elevated IFNy production .............................. 58
3.7: Cell viability after two hours of incubation with four PPAR agonists: flow
cytometric analysis of propidium iodide staining with a) FENO at 20 and 500 [tM;
b) WY 100 and 500 [tM; c) BRL, 10 ¢tM and 50 [tM; d) PGJ2 at 3 and 10 tM.
There are no significant effects on cell viability with any of the agonists. The
filled areas represent the cells incubated with the designated agonist
concentration, while the green line represents cells incubated with medium alone.
An increase in the area under the M1 marker represents cells with increased
membrane permeability allowing the dye to bind, and thereby denoting cell death. 60
3.8: Cell viability after twelve hours of incubation with four PPAR agonists: flow
cytometric analysis of propidium iodide staining with a) FENO at 20 and 500 tM;
b) WY 100 and 500 tM; c) BRL, 10 and 50 tM; d) PGJ2 at 3 and 10 AtM. There
are no significant effects on viability at the therapeutic concentrations, while there
is increased cell death at the supratherapeutic levels. The filled areas represent the
cells incubated with the designated agonist concentration, while the green line
represents cells incubated with medium alone. An increase in the area under the
M1 marker represents cells with increased membrane permeability allowing the
dye to bind, and thereby denoting cell death .............................................. 61
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3.9: Cytokine mRNA expression as a function of time: a) ConA stimulation, IFNy
is the dominant cytokine, with a peak at day 1, followed by a return to baseline
and a potential beginning of a second wave of cytokine production on day 3; b)
MLR stimulation, IFNy is also the dominant cytokine in this culture, with a peak
occurring at day 2. As a technical note, cultures for the top and bottom of the
figure were set up simultaneously, such that comparison between them shows that
IFNy at peak times is significantly higher for ConA mitogenic stimulation .......... 63
3.10: Effect of PPAR agonists on cytokine mRNA expression on the day of
maximal IFNy mRNA expression: a) ConA, day 1; b) MLR, day 2. The most
marked effect of PPAR agonists as a group is decreased IFNy expression.
Statistical significance (p<0.05) relative to cultures without PPAR agonist
treatment is denoted by an asterisk (*). Legend key is as follows: 0 for 0 tM
(control, no PPAR agonist), F for FENO, W for WY, B for BRL, J for PGJ2 ........ 64
3.11: Effect of PPAR agonists on IL-4 and IL-10 mRNA expression in the MLR
over time: mRNA expression of a) IL-4 and b) IL-10 in the MLR changes in
response to the addition of PPAR agonists to the cultures as a function of time.
While the other cytokines tend to increase IL-4 mRNA, WY is the only one that
consistently results in increased IL-4 mRNA expression. On day 4 of the MLR,
WY continues to sustain a significant increase in the expression of IL-4 mRNA.
Expression of IL-10 mRNA is not significantly affected by WY, but is
significantly decreased by FENO and PGJ2, and not affected by BRL .............. 65
3.12: Chemokine mRNA expression as a function of time: a) ConA, mRNA
expression decreases as a function of time, with MIP-13 and RANTES as the
chemokines with highest levels of mRNA expression at the peak time of 12 hours;
b) MLR, chemokine mRNA expression peaks on day 2 (with the exception of
MCP-1), with RANTES appearing to be the most dominant cytokine on the day of
peak mRNA expression ........................................ ...................... 67
3.13: Chemokine receptor mRNA expression as a function of time: a) ConA
stimulation, CCR5 and CCR4 are the two most abundantly expressed receptors
over all days except the third and last day, where CCR4 levels falls to similar
levels as CCRland CCR2; b) MLR stimulation, CCR5 appears to be the dominant
receptor, with mRNA expression peaking on days 2 and 4; CCR2 emerging as the
second most abundantly expressed receptor by the fourth and last day of culture... 68
3.14: Effect of PPAR agonists on chemokine mRNA expression: a) ConA, 12
hours, decrease in all chemokines except MCP-1 by all agonists (exception IP-10
by F); b) MLR, day 2, no significant changes by any of the agonists tested.
Statistical significance (p<0.05) relative to cultures without PPAR agonist
treatment is denoted by an asterisk (*). Legend key is as follows: 0 for 0 ¢tM
(control, no PPAR agonist), F for FENO, W for WY, B for BRL, J for PGJ2 ........ 69
3.15: Effect of PPAR agonists on chemokine receptor mRNA expression: a)
ConA, day 1, PPARa agonists increase CCR1 and CCR2, while PPARy agonists
increase CCR2 and decrease CCR5; b) MLR, day 2, WY increases all chemokine
receptors, while FENO increases CCR2 and PGJ2 decreases CCR5. Statistical
significance (p<0.05) relative to cultures without PPAR agonist treatment is
denoted by an asterisk (*). Legend key is as follows: 0 for 0 tM (control, no
PPAR agonist), F for FENO, W for WY, B for BRL, J for PGJ2 ...................... 70
Page 8
Emanuela Binello ST
Ernanuela Binello HST
3.16: Late effects of PPAR agonists on chemokine and chemokine receptor
mRNA expression on day 4 of the MLR: a) chemokines, marked increase in MIP-
la and MIP-13 by all agonists, except fenofibrate, which, increases RANTES,
while other agonists decrease it; b) chemokine receptors, uniform decrease in
CCR2 and CCR5. Statistical significance (p< 0.05) relative to cultures without
PPAR agonist treatment is denoted by an asterisk (*). Legend key is as follows: 0
for 0 tM (control, no PPAR agonist), F for FENO, W for WY, B for BRL, J for
PGJ2 .................................................................. 71
4.1: Fenofibrate-induced effects on livers of murine cardiac transplant recipients:
Appearance (via routine hematoxylin & eosin staining) and PMP-70 expression
(via immunohistochemical staining). Fenofibrate treatment results in increased
granularity and hypereosinophilia in sections stained with hematoxylin and eosin,
and increased peroxisomal proliferation as shown by diffusely increased PMP-70
staining. These photomicrographs are representative of sections from livers
harvested at both 2 and 8 weeks after transplantation .................................... 85
4.2: Effect of fenofibrate on liver weight and enzymes at 2 weeks: Liver weight
increased by a factor of 2, while ALT and AST also increased, but not
significantly. Statistical significance between the control (, n=3) and treated (::,
n=4) groups was determined using Student's t test (p<0.05); the bar indicates the
mean value ............................................................... 88
4.3: Effect of fenofibrate on plasma markers at 2 weeks: There was no statistically
significant effect on any markers. However, it should be noted that fibrinogen and
glucose demonstrated downward tendencies. Triglyceride levels remained
unchanged and cholesterol levels tended to rise. Statistical significance between
the control (n, n=3) and treated ( , n=4) groups was determined using Student's t
test (p<0.05); the bar indicates the mean value ........................................... 88
4.4: Effect of fenofibrate on graft expression of selected cytokines. chemokines
and chemokine receptors at 2 weeks: Fenofibrate reduces the expression of IFNy,
as well as the other cytokines tested (IL-4, IL-6, IL-10). Accordingly, fenofibrate
also substantially reduces IP-10. Despite the decrease in IFNy, however,
fenofibrate does not affect the expression of RANTES. Finally, fenofibrate
reduces expression of both CCR2 and CCR5. The lack of statistical significance
may be attributable to the low numbers of transplants in this group. Results are
normalized to the expression of GAPDH. Statistical significance between the
control (, n=3) and treated ( , n=4) groups was calculated using the Student's t-
test (p < 0.051) .........o: .......... ......... .................................. 89
4.5: Effect of fenofibrate on the graft expression of activation markers at 2 weeks:
Fenofibrate treatment had no effect on MHC-II. It tended to decrease VCAM-1
and ICAM-1. The Kruskal-Wallis test was used to ensure that there were no
significant differences between the three, blinded observers. Statistical
significance (*) between control (, n=3) and treated (:, n=4) groups was
determined using the Mann-Whitney test (p<0.05). Results are expressed as the
mean and standard error of the mean ....................................................... 90
4.6: Effect of fenofibrate on graft infiltrating cells at 2 weeks: Fenofibrate
treatment significantly reduced the numbers of CD4+ and CDIlb+ cells, while
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not affecting CD8+ cells. For each cell type, five fields per section were counted
by two, blinded observers. Statistical significance (*) between the control (,
n=3) and treated (:::, n=4) groups was calculated using the Student's t-test ........ 90
4.7: Effect of fenofibrate on recipient splenocyte proliferation and IFN
production ex vivo at 2 weeks: a, b) restimulated with bml2; c,d) stimulated with
B/c; e,f) stimulated with ConA. Fenofibrate shifts the peak of the proliferation
curve from day 2 to day 3, upon restimulation with bml2 and ConA. It increases
proliferation on days 3 and 4 of B/c stimulation. The concentration of IFNy is
significantly decreased in all cultures on days 3 and 4. Furthermore, IFNy is also
decreased on days 2 and 5 in the bml2 cultures, as well as on day 5 in the ConA
culture. Results are presented as the mean and standard error of the mean of all
recipients in triplicate to quadruplicate samples. Statistical significance (*)
between the control (, n=3) and treated ( , n=4) groups was calculated using
the Student's t-test (p<0.05) .................................................................. 91
4.8: Effect of fenofibrate on liver weight and enzymes at 8 weeks: Liver weight
increased by a factor of 3, while ALT and AST also significantly increased.
Statistical significance between control (, n=12) and treated (, n=10) groups
was determined using Student's t test (p<0.05), and the bar indicates the mean
value ........................................................................................... 92
4.9: Effect of fenofibrate on plasma markers at 8 weeks: Fenofibrate treatment
significantly increases mean levels of total cholesterol, and significantly decreases
the mean levels of both triglyceride and glucose. Fibrinogen levels are not
significantly affected. Statistical significance between the control (, n=12) and
treated (, n=10) groups was determined using Student's t test (p<0.05); the bar
indicates the mean value .............. 9.................................. .............. 2
4.10: Effect of fenofibrate on the intragraft mRNA expression of selected
cytokines at 8 weeks: Fenofibrate treatment statistically increased expression of
IFNy, IL-4, IL-6 and IL12-p40, while not affecting the expression of other
cytokines (IL-10 and IL12-p35). In control allografts, IFNy was the cytokine with
the highest expression, while IL12-p35 is that with the lowest. IL-6, IL-10 and IL-
12p40 had comparable expression, while IL-4 was approximately an order of
magnitude lower. All mRNA expression levels are normalized to GAPDH.
Statistical significance between control (, n=9) and treated (, n=9) groups
were determined using Student's t test (p<0.05); the bar indicates the mean value.. 93
4.11: Effect c)f fenofibrate on intragraft expression of chemokines and chemokine
receptors at 8 weeks: a) RANTES; b) IP-10; c) CCR2; d) CCR5. Fenofibrate
statistically increased IP-10, while not affecting RANTES, CCR2 and CCR5.
Statistical significance between control (, n=9) and treated (, n=9) groups was
determined using Student's t-test (p<0.05); the bar indicates the mean value ...... 94
4.12: Effect of fenofibrate on graft infiltrating cells at 8 weeks: there was a small,
but statistically significant (p< 0.05) increase in CD4+ cells, and dramatically
increased the number of CD1 lb+ cells (p < 0.05). There was no difference in the
number of CD8+ cells. Five fields were counted per section (two blinded
observers). Statistical significance (*) between the control (, n=12) and treated
(0l, n=10) groups was calculated using the Student's t-test ........................... 94
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4.13: Effect of fenofibrate on splenocyte proliferation and IFN, production ex
vivo at 8 weeks: a, b) recipient splenocytes restimulated with bml2; c,d) recipient
splenocytes stimulated B/c; e,f) comparison to results with splenocytes from
C57/BL6 mice who were taken off the fenofibrate chow 1 week before harvest
(denoted as "off 1 wk") and stimulated with B/c. Fenofibrate does not
significantly affect proliferation on any day, while significantly reducing IFNy
production on day 3. Please see text for more details. Statistical significance (*)
was calculated using the Student's t-test (p < 0.05). Results are presented as the
mean and standard error of the mean of quadruplicate samples for the control (,
n=10), treated (, n=9) and ""off 1 week" (, n=6) groups ............................ 95
4.14: Effect of fenofibrate on allograft activation at 8 weeks: Representative
photomicrographs of isotope control and examples of high expression show that
the distribution of MHC-II tends to be diffuse, while the distribution of the
VCAM-1 and ICAM-1 adhesion molecules tends to be localized to large vessels.
Fenofibrate treatment results in a small but significant decrease in the expression
of MHC-II. It does not significantly affect the expression of VCAM-1 or ICAM-
1. Sections were evaluated (three, blinded observers) according to the following
scheme: 0, no staining; 1 focal weak; 2 focal moderate, diffuse weak; 3 focal
strong, diffuse moderate; 4 diffuse strong. The Kruskal-Wallis test was used to
ensure that there were no significant differences between the three, blinded
observers. Statistical significance (*) between control (, n=12) and treated (l,
n=10) groups was determined using the Mann-Whitney test (p<0.05). Results are
expressed as the mean and standard error of the mean ................................... 96
4.15: Effect of fenofibrate on allograft pathology at 8 weeks: Fenofibrate did not
ameliorate TxAA, but significantly increased PR. Photomicrographs show
representative vessels with TxAA scores ranging from 0 to 4. Statistical
significance (*) between control (, n=12) and treated (, n=10) groups was
determined using the Mann-Whitney test (p<0.05). Results are expressed as the
mean and standard error of the mean ....................................................... 97
5.1: Varying doses of fenofibrate in vitro with 129WT and PAKO responders:
MLR with B/c stimulators and a, b) 129WT responders or c, d) PAKO
responders. For both, the left panel represents proliferation, while the right panel
represents IFNy production. No effect is seen on either proliferation or IFNy
production at 4 EtM. At 20 tM, however, fenofibrate significantly reduces the
production of IFNy in cultures with both 129WT and PAKO as responders. This
indicates that fenofibrate either "cross-talks" with other PPARs (notably PPARy
or PPAR6) or has drug-specific and thus completely PPAR-independent effect. At
doses higher than 20 [tM, fenofibrate reduces both proliferation and IFNy
production, indicating potential toxicity (to be specifically addressed in the next
figure). The bolded lines represent the day of peak proliferation and initial IFNy
production, respectively. Representative results are shown as the average and
standard deviation of triplicate samples .................................................... 109
5.2: Cell viability after a 12 hour incubation with fenofibrate: flow cytometric
analysis of PI staining of ConA-stimulated a) 129WT and b) PAKO splenocytes.
The light-colored line represents control cultures (with no fenofibrate) while the
Page 11
mannela inello IqCT
Emanuela B I
filled area, represents splenocytes incubated with varying fenofibrate doses. A
shift toward the M1 marker represents increased cell membrane permeability,
allowing the propidium to bind, and thereby denoting cell death. Doses of 4 and
20 tM of fenofibrate did not affect cell viability in any culture, while doses of
100 and 500 [iM resulted in significant cell death ................. .............. 110
5.3: Influence of PPAR deficiency on cytokine mRNA expression in vitro:
When stimulated by allomismatched B/c splenocytes, PAKO splenocytes express
substantially higher levels of IFNy compared to WT, indicating a regulatory role
in the expression of IFNy. Similarly, PPARa also significantly increases
expression of IL-6 and significantly decreases expression of IL-12-40, thereby
denoting regulatory role in the expression of both of these cytokines. The lack of
an increase in IL-12p35 indicates that there is no increase IL-12 and corroborates
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Chapter 1. Introduction
The last decades have seen significant improvement in immunosuppressive therapy,
rendering heart transplantation a clinically feasible therapeutic modality. Currently, heart
transplantation has been adopted as a treatment for end-stage cardiac diseases including
coronary artery disease and cardiomyopathy. Rejection pathology may involve the
parenchyma and/or vasculature of the transplanted heart. Parenchymal rejection (PR),
which may occur from days to months (to sometimes even years) post-transplantation, is
characterized histologically by a diffuse interstitial inflammatory infiltrate (mostly
composed of T cells and macrophages) with associated myocyte necrosis, edema, and
hemorrhage. Although responsive to treatment, PR remains an important cause of
morbidity and mortality in heart transplant patients. Transplantation-associated
arteriosclerosis (TxAA), which may be seen as early as several months after
transplantation but more typically develops on the order of years, is characterized by
concentric vascular lesions formed by the intimal proliferation of smooth muscle cells
and associated extra-cellular matrix proteins, admixed with inflammatory mononuclear
cells (including T cells and macrophages). Unlike PR, TxAA is not responsive to
immunosuppressive therapy and has thus emerged as the major limitation to long-term
survival in heart transplant recipients.
Peroxisome proliferator-activated receptors (PPARs) belong to a superfamily of nuclear
hormone receptors that act as gene transcriptional regulators. Of the three isoforms that
have been identified to date (a, /68, y), two of them, the a and y isoforms, are most well
understood. Traditionally, PPARa is associated with the regulation of fatty-acid
catabolism. PPAR agonists (e.g. fenofibrate/Tricor) are in clinical use for the treatment
of hypertryglyceridemia. PPARy is known to be essential for adipocyte differentiation
and is also involved in glucose metabolism. PPARy agonists (e.g. rosiglitazone/Avandia
and pioglitazone/Actos) are in current clinical use as insulin sensitizing agents (acting as
oral hypoglycemics) for patients with type II diabetes mellitus. Over the last several
years, however, PPARs have also emerged as immunomodulatory agents. They are
expressed in most cells of the vascular and immune systems, including vascular
endothelial and smooth muscle cells, as well as macrophages and T cells. The majority of
the literature on PPAR ligand-mediated activation suggests anti-inflammatory activity in
the relevant cell types listed above. In addition, experimentation in rodent models of
various chronic and inflammatory diseases, most notably atherosclerosis, shows
therapeutic benefits independent of glucose and lipid profiles upon treatment with PPAR
agonists. Based on the reported effects of PPAR activation both in vitro and in vivo, there
was reason to hypothesize beneficial effects of PPAR agonists on rejection, namely PR
and TxAA. Moreover, given the current broad use of several PPAR ligands in the clinical
setting, a demonstration of benefit in transplant rejection could translate rapidly into
clinical application.
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Thus, the overall goal of this thesis was to investigate the role of PPARs in mechanisms
of rejection in heart transplantation. This thesis is organized in the following order.
Chapter 2 presents background information on mechanisms of rejection and PPARs,
including general characteristics and evidence from in vitro and in vivo studies in the
literature. It also introduces the boron neutron capture reaction that serves as the basis for
a proposed novel immunologic research tool. Chapter 3 describes the in vitro experiments
performed to assess the effect of PPAR agonists on an alloresponse (relative to mitogenic
stimulation not dependent on major histocompatibility complex disparity), while chapter
4 describes the effect of PPARca agonist treatment in vivo in a murine heterotopic model
of cardiac transplantation. The availability of mice congenitally deficient in PPARa
allowed the examination of PPARca requirement both in vitro and in vivo, as described in
chapter 5. A novel immunologic tool is presented in chapter 6, along with preliminary
experiments., to explore the timing of transplant commitment to a particular outcome.
Lastly, chapter 7 provides a summary of relevant conclusions and recommendations for
future work.
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Chapter 2. Background
This chapter contains background information on mechanisms of cardiac rejection and
peroxisome proliferator-activator receptors, as well as the fundamental basis of the
proposed novel immunologic research tool. Section 1 discusses mechanisms of cardiac
rejection, including an overview of the pathology and evidence from both in vitro and in
vivo studies. Section 2 reviews the general characteristics of the peroxisome proliferator-
activated receptors and implications for the vasculature. Finally, section 3 introduces the
boron neutron capture reaction and its current applications, as well as its proposed use as
an immunologic research tool.
2.1 Mechanisms of cardiac rejection
Heart transplantation has been adopted as a treatment for end-stage cardiac diseases
including cardiomyopathy and coronary artery disease. Since the first human heart
transplant in the 1960s, more than 48,000 transplants have been performed worldwide
i ' i ~tj :S ''h.-,:'a 200 ~i 1. In the United States alone, over 2,000 heart transplants are
performed annually, leaving approximately 4,000 patients on the waiting list ..'.S
~ ~i' i. The following section describes the pathological features of the different forms of
rejection and introduces fundamental concepts in the pathogenesis of rejection as a
whole. Then, evidence from both in vitro and in vivo studies is discussed with respect to
the elucidation of mechanisms involved in rejection.
2.1.1 General characteristics
Contrary to the relatively subtle changes in surgical techniques since the beginning of
clinical cardiac transplantation '!,,vihl .t 1' . 21i, !, the last decades have seen
significant expansion and improvement in immunosuppressive therapy, including
cyclosporine, OKT3, tacrolimus, and mycophenolate mofetil among others
These powerful drugs have been a primary reason behind transplant
survival rates of over 80% at one year post-transplant I X,,enpt:, .Ki a is 196
Hyperacute rejection, characterized by graft failure within 24 hours and by the histologic
appearance of interstitial hemorrhage, edema and fibrin thrombi, occurs only in about
0.5% of cardiac transplants .I iqmesnxo '. 'ac D'.nee:3rl; ~s'> . This condition is often fatal
3i(,'''1t'I,,d Jn'inEs 01s¢1~ .'2 I but if the patient lives long enough, is further characterized by
myocyte and vascular degeneration with eventual necrosis and neutrophilic responses
, t%· i ir<c'2.. !.e.. :l It is generally believed that circulating preformed antibodies
are the cause of this type of rejection; however, occasional lesions exhibiting similar
pathology, in the absence of apparent immune reactions, suggest that non-immune factors
may also be involved .ILAO . 1 )9,3 . Immunosuppression, targeting the immune system's
cellular components, has no effect on hyperacute rejection.
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Parenchymal rejection (PR), which may occur from days to months (to sometimes even
years) post-transplantation, is generally responsive to immunosuppressive agents. As
shown in figure 2. 1, PR is characterized histologically by diffuse interstitial inflammatory
infiltration (largely composed of T cells and macrophages) with associated myocyte
necrosis, edema and hemorrhage i I . Despite the responsiveness to
cellular immune therapy, PR remains an important cause of morbidity and mortality in
heart transplant recipients ' l ndt c l An A `Sui t:10 ?l) I. Study is ongoing to determine
antigen-specific and nonspecific mechanisms involved in the development of the
inflammatory infiltrate, as well as the resulting myocyte necrosis.
Occasionally, rejection may be primarily vascular and therefore characterized by
endothelial swelling and necrosis, extensive infiltration of the blood vessel wall and
deposition of fibrin plugs both along the vascular wall and the extravascular spaces t Pt~<at
995 i. Given the unresponsiveness of acute vascular rejection to cellular immune
therapy, it is hypothesized that recipient antibodies mediate this relatively uncommon
type of rejection (termed acute vascular or humoral rejection) ! { i. t. . I 1
Figure 2.1: Sample photomicrograph of parenchymal rejection (PR): Histologically, PR
is characterized by a diffuse interstitial inflammatory infiltrate with associated myocyte
necrosis, hemorrhage and edema. Despite the responsiveness to cellular therapy, PR
remains an important cause of mortality in heart transplant recipients.
With improvement in immunosuppressive agents and concomitant decreases in acute
rejection, transplantation-associated arteriosclerosis (TxAA) has emerged as the principal
limitation to long-term survival of heart transplant recipients. At Stanford, where over
750 heart transplants have been performed and where the five and ten year survival rates
compare favorably to international rates, TxAA accounts for approximately 30% of
deaths after the first year of heart transplantation i¢ii-iIt',l'm l i99. TxAA may be
present as early as several months after transplantation but more typically develops on the
order of years. As shown in figure 2.2, TxAA is characterized by concentric lesions
formed by the intimal proliferation of smooth muscle cells and associated extra-cellular
matrix proteins, admixed with inflammatory mononuclear cells I i tIIt.mit n9s i
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Figure 2.2: Sample photomicrograph of transplantation-associated arteriosclerosis
(TxAA): Histologically, TxAA is characterized by concentric lesions, formed by intimal
proliferation of vascular smooth muscle cells and associated extra-cellular matrix
proteins, admixed with inflammatory mononuclear cells. Despite improvements in
immunosuppressive regimes, TxAA remains refractory to treatment and has emerged as
major limitation to long-term survival of heart transplant recipients.
The proliferation of smooth muscle cells results in diffuse arterial occlusion that is
difficult to detect via conventional angiographic means until relatively late in the process.
This may be due to compensation in vessel enlarging and remodeling of missing branches
I e:*,a .I ,ii; ! ai.  It' 2id ,IX0. Despite the difficulty in lesion visualization, it is estimated based
on conventional angiographic data that approximately 40% of heart transplant patients
will develop TxAA by 5 years post-transplant i995 ilitg m I%)!. This may be an
underestimate based on the sensitivity of angiography compared to intravascular
ultrasound. A review of diagnostic methods for TxAA has found that, although its role in
therapeutic decision-making remains to be firmly established, intravascular ultrasound is
more sensitive than conventional angiography l...\rdI 11"iI' 20C)t. In fact, studies
using intravascular ultrasound show that TxAA lesions are already detectable in 60% to
75% of the patients at year post-transplant { Y et99 i i 5, Jui. i i; :7 1,I/2(!i' t.
The pathogenesis of TxAA is firmly grounded on the immunological differences between
donor and recipient. This leads to the creation of an inflammatory reaction that result in
the endothelial cell activation, smooth muscle cell proliferation, mononuclear cell
infiltration and fibrosis typically seen in TxAA lesions. The suggestion that TxAA is a
form of delayed type hypersensitivity was initially decades ago It3re'~ 1 t97 and still
holds in current times 2 t. int .! Ict:~.' 2 10t I. In this model, the offending agent is the
presence of the allograft; delayed would refer to the slow development, while
hypersensitivity refers to the inappropriate damage of tissues by the immune system.
There is evidence that persistent graft parenchymal rejection is not required for the
development of TxAA ,i~ utati ef ?' N..l" tl i !a i981  although studies have
found that episodes of parenchymal rejection may potentiate the development of TxAA
f I..iil...> ;., f.S. i A..}((, N: ·-2kaitu;@\.N~·t c·,r i, Is-).% -
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Certainly, non-immunologic factors also contribute to the development of TxAA. In fact,
some authors question whether TxAA is an immunologic or non-immunologic disease
.M\Ch'.a e.Tllt' [.t')ei' 2'!,3 I0, while others go even further and contend that the failure is not
due to an immunologic process but to failure of the microvessels to remain open and that
TxAA is nothing more than a particular form of atherosclerosis f t .rzcc 2 'i ,:: 2('~(3 I.
One other paradigm is to ascribe endothelial injury the central role in spurring the
development of TxAA l S,,,t r )2.~ '.ig 2'r!l') I. Ischemia-reperfusion injury,
pre-existing atherosclerosis, dyslipidemia, infection and hypertension have all been
identified as potential contributing factors i, f d '.'.inx< 2,( i) it'.' ' l
An in-depth understanding of the mechanisms of rejection is motivated by the hope that it
will lead to the identification of novel therapeutic targets and development of effective
agents to decrease the morbidity and mortality associated with heart transplantation.
Study of the mechanisms of rejection may take place at both the in vitro and in vivo
levels. The following sections describe the models used in this thesis, as well as selected
findings from the literature.
2.1.2 In vitro models
The recognition of non-self, or allorecognition, is fundamental to the immunology of
transplantation. The mainstay in vitro assay for measuring allogeneic responses in vitro is
the mixed leukocyte reaction (MLR), where leukocytes from two individuals, or animals,
are mixed together in culture. The proliferative response measures T cell reactivity
against alloantigen. The MLR is a convenient, relatively straightforward assay to perform
and may be relatively useful predictors of the in vivo response X tSi''?- . l i:3.: j j .995 .
The response seen in the MLR is based on differences in major histocompatibility (MHC)
molecules. There are two types of MHC molecules: class I and class II. MHC class I
molecules are expressed on all nucleated cells while MHC class II are expressed
primarily on professional antigen presenting cells (APCs) such as B cells, dendritic cells
and macrophages. Both MHC I and II present protein antigens, albeit originating in
different cell compartments: proteins synthesized in the cytoplasm are classically
presented via MHC I, while proteins originating from the outside of the cytoplasm and
degraded within acidic endosomal vesicles are classically presented via MHC II.
The MHC classes are recognized by T cell receptors of different T cell subsets that are
identified by the presence of two markers called CD4 and CD8. Typically, CD4
molecules associate with the non-variable region of MHC-II, while CD8 molecules
associate with the non-variable region of MHC-I. The variable portion of the MHC
molecule contains a processed antigen that is recognized by T cell receptors. Although it
is generally believed that T cells are self-MHC restricted (i.e. reactive to antigen
presented only in the context of their own MHC molecules), T cells may cross-react with
foreign MHC, with or without antigen. Thus, antigen recognition may be direct, where T
cells recognize alloantigen in the context of allogeneic APC, or indirect, where
alloantigen recognition takes place in the context of self-MHC; the presence of two sets
of APCs in a graft is unique to the transplantation setting i .LAiltitrl,c i ).95 .
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If there are differences in MHC expression between the two populations of leukocytes in
an MLR, a proliferative response will ensue within three to five days. In order to observe
the response of the leukocytes separately, i.e. a one-way MLR, one population can be
inactivated by either gamma irradiation or treatment with the antimitotic drugs, generally
mitomycin (:3, so that it does not proliferate. The cells from this population are called
"stimulators" and are analogous to the donor in the setting of a transplant, while the cells
from the untreated population are called "responders" and are analogous to the transplant
recipient. The proliferative response is typically measured by adding radioactively
labeled thymidine to the culture for a specified amount of time to assess incorporation as
a measure of new DNA synthesis. Cell-free supernatant from the culture may be tested
for the presence of various molecules elaborated during proliferation. It should be noted
that the activated T cell response is not only dependent on differences in MHC, but is
also dependent on the existence of a functional T cell receptor and costimulatory
molecules. DFor example, stimulators lacking the B7 costimulatory molecules induce
hyporesponsiveness, or diminished proliferation, in murine T cells .... ! :)t> i. Figure
2.3 shows a schematic of a one-way MLR, where the stimulators (Balb/c) and responders
(C57/BL6) are mismatched in both MHC-I and MHC-II.
The MLR was first described in 1964 by two independent groups who co-cultured blood
leukocytes from two unrelated individuals and led to the discovery that the lymphocytes
generated in mixed cultures were cytotoxic to stimulator cells K 1`!3,r I S1It7 . Since then
the MLR has served to elucidate not only mechanisms of allorecognition, but also the
interplay between the various chemical mediators produced by lymphocytes, namely
cytokines (protein hormones with both local and systemic effects) and chemokines
(chemotactic cytokines). For example, following the discovery of a naturally occurring
interleukin (IL)-1 receptor antagonist, it was found that its addition to an MLR decreased
production of the IL-8 chemokine I ktiRkcs 1t9, t " i. On the other hand, addition of a
competitive inhibitor of L-arginine-dependent nitric oxide synthase to an MLR increased
levels of IL-8 t IOY'W: c/.: : 1994 t.
Although in vitro assays may be useful and convenient, there are several limitations in
the translation of the in vitro results to the in vivo setting of transplant rejection. One is
that the responder lymphocytes are reacting to stimulator lymphocytes, rather than
endothelial cells or other parenchymal cells as would be present in an allograft. This may
result in the expression of different surface molecules and subsequently different
signaling pathways. Also, notably absent from the MLR are the vascular smooth muscle
cells, which play an important role in the development of the proliferative lesions that are
characteristic of TxAA. Another is that in vitro, cells are placed in close proximity and
static setting, while, for example, in a cardiac allograft, the responder (or host) cells
would be coursing through the bloodstream. As a consequence, cellular interactions are
enhanced; contact-dependent mechanisms may artificially dominate and/or lower
quantities of proteins may be required for downstream effects. Finally, cells are generally
not cultured for more than seven days, such that late effects, potentially important in the
rejection process, may not be recapitulated.
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Figure 2.3: A one-way mixed leukocyte response (MLR): Spleens are extracted from
two allogeneically different mice, and after lysis of the red blood cells, leukocytes are
isolated. In order to observe the response of the leukocytes separately, one population can
be inactivated by either gamma irradiation or treatment with the antimitotic drugs, so that
it does not proliferate. Cells from this population are called "stimulators" and are
analogous to the transplant donors, while the cells from the untreated population are
called "responders" and are analogous to the transplant recipient. The proliferative
response is measured by adding radioactively labeled thymidine. Cell-free supernatant
may be tested for the presence of various molecules elaborated during proliferation.
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The literature abounds with examples of findings that do not translate from the in vitro to
in vivo setting. One particularly interesting example is the antibody to CD3. In vitro, it is
commonly used to stimulate T cell responsiveness. Its addition to T cell cultures results
in massive proliferation and cytokine elaboration. This would lead one to expect a similar
effect in vivo. However, in vivo, it acts as a T cell suppressor. In fact, the common
immunosuppressive agent, OKT3 is an anti-CD3 antibody. When administered to
patients, it acts by one of two mechanisms; it either activates complement-mediated lysis
of T cells or it renders T cells susceptible to phagocytosis by macrophages. Thus, the
same substance may serve as an activator in vitro and a suppressor in vivo, completely
opposite functions.
Therefore, while the MLR is most appropriate as an in vitro model to understand the
effect of a potentially therapeutic intervention on allorecognition (and its downstream
consequences), for an accurate reflection on mechanisms of rejection, it needs to be
evaluated in an in vivo setting. The next subsection discusses the in vivo model and
results relevant to the development of PR and TxAA. Animal models are the next logical
progression following cellular assays, although even with those, translation to the clinic is
far from assured since even slight immunologic differences may lead to vastly different
results.
2.1.3 In vivo models
To evaluate the contribution of selected components of the immune system to cardiac
rejection in vivo, a murine heterotopic cardiac transplantation method has been
developed; the heart is removed from the donor mouse following heparinization and
ligation of both the vena cava and pulmonary veins; it is then transplanted into the
abdomen of the recipient mouse via ligation of the donor aorta and pulmonary artery to
the abdominal aorta and inferior vena cava of the recipient mouse, respectively lC'rox. i~
1;:Ii lt"'73 . The recipient thus has two hearts; its original heart performing the essential
cardiac functions and the donor heart (in the abdomen) perfused with recipient blood.
Since the donor heart is not involved in cardiac function, evaluation of cardiac output and
other physiologically relevant parameters are not germane. Nevertheless, the heart is
perfused at normal aortic systolic pressures and beats; cessation of allograft beat, as
assessed by manual palpation, is defined as the point of allograft failure. Figure 2.4, on
the next page shows a schematic, as well as photomicrographs, of this murine heterotopic
cardiac transplantation model.
Development of phenotypes characteristic of either PR or TxAA may be achieved by
manipulating the expression of MHC molecules on both donor and recipient. Transplants
performed between donors and recipients that are mismatched in MHC-I and MHC-II
(thus a total allomismatch) develop severe PR, constituting an acute rejection model.
Transplants performed between donors and recipients that are mismatched in MHC-II
function long-term without immunosupression and result in vascular lesions that are
characterized by endothelial cell activation, vascular smooth muscle proliferation,
mononuclear cell infiltration and fibrin deposition, thereby constituting the TxAA model.
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Figure 2.4: Murine heterotopic cardiac transplantation model: a) Schematic showing the
native heart of the donor transplanted to the recipient, such that recipient has two hearts,
its own native own and the allograft; b) photomicrographs showing, on the left, the
recipient mouse, and, on the right top and bottom panels, schematics of the ligations and
allograft itself.
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Mismatches in MHC classes have implications for the type of T cell mediating effector
functions since typically CD4+ cells are restricted by MHC-II and CD8+ cells recognize
MHC-I. Although exceptions have been noted, CD8+ cells are classically ascribed
cytolytic activity, while CD4+ cells are classically ascribed the function of immune
modulation. Administration of antibodies to CD4+ cells (anti-CD4) in strain
combinations mismatched in both MHC class I and II should be analogous to an MHC-I
mismatch while antibodies to CD8+ cells (anti-CD8) to an MHC-II mismatch. This
analogy in fact holds true with respect to the histologic appearance of the graft following
anti-CD4 and anti-CD8 administration separately, although interestingly, survival times
do not follow the pattern and are variable, demonstrating that graft failure may not
correlate to the histological appearance of the graft i s W/ 9 > ) I
The next two subsections discuss the role of cytokines and chemokines, respectively, in
allograft rejection. In order to increase the applicability of the following discussion to the
work contained in this thesis, inclusion of the literature will emphasize those reports
using the murine vascularized heteroropic cardiac allograft model as described above, as
much as possible.
Role of cytokines
There is ample evidence in the literature that many different cytokines and/or their
receptors may play important roles in mechanisms of transplant rejection I::"iccouti ,:; il;
i `.. Cytokine manipulation has varying results on cardiac allograft pathology, ranging
2041. Cytokine manipulation has varying results on cardiac allograft pathology, ranging
from beneficial to harmful. For example, prolongation of murine cardiac allograft
survival has been reported with selective blockade of IL-15 Sith ei 20020o and the
complete absence of tumor necrosis factor-a (TNFc) receptors on donors significantly
reduced the development of TxAA S aiz .i :k i e? 200(t0 . On the other hand, the adoptive
transfer of IL-4 secreting T cells into immunodeficient mice bearing cardiac allografts
had no effects on survival \'t:rI:-~,.skirlk I:' 1:/i%~5g. Furthermore, the exogenous
administration of IL-10 to murine cardiac allograft recipients augmented both PR and
TxAA j .. p ic\gw: -. I .99;}t. IL-2 is a target of many clinical immunosuppressive agents
but the complete absence of IL-2 does not prolong graft survival, suggesting the
important of other growth factors 1, a;i,,l s.< 1:;i /2()4.j
However, of the multitude of cytokines, interferon-y (IFNy) has emerged as particularly
important in the setting of cardiac rejection, presenting a potential therapeutic target as
well as illustrating the mechanistic dichotomy between the development of PR and TxAA
!2i 2 ~ e} n i' 2tI)4)I .a :~:~: a:'ssd . ta:ii , 2 )(2 fl. Several properties render IFNy
important in the development of immune responses. It is a potent activator of
macrophages N!'e:s c' ,i 199S5 i. Activated macrophages have effector functions that
include phagocytosis, destruction of foreign organisms and potentiation of inflammation
through the secretion of additional pro-inflammatory cytokines. Macrophage-derived
products modulate the tissue environment by inducing the deposition of connective
tissue. Finally, IFNy increases the expression of MHC Skosiew i cz ' i 1985] .
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Examination of the role of IFNy in cardiac transplantation has been greatly facilitated by
the use of mice genetically engineering to congenitally lack IFNy I I'IAtoL f .ti/ '.~ 99-1 1 or
IFNy receptors It -g (' ? i9,,. The mice whose IFNy gene has been knocked-out,
denoted as GKO mice, allow identification of the physiological role of IFNy in the
transplant setting relative to wild type mice whose IFNy is naturally regulated.
The role of IFNy in acute or parenchymal rejection was evaluated via allomismatched
heterotopic transplants of Balb/c (B/c) hearts into C57BL/6 (B6) wild-type (WT) and
GKO recipients, respectively I N.'; , / 9 . At the time of harvest (ranging from 6
to 7 days), allografts of B6WT recipients exhibited severe parenchymal rejection, while
those of GKO recipients exhibited coagulation necrosis and arterial thrombosis, in
addition to parenchymal rejection. Given that thrombosis and coagulative necrosis are not
typical features of parenchymal rejection, the presence in GKO recipients suggest
activation of a pro-thrombotic pathway normally suppressed by IFNy. Potential
mechanisms include an upregulation of IL-6 t Si '/u Nitd t or platelet factor 4
tS:~il - 0::/ 022 . Thus, results indicate that IFNy is not required for the development of
PR; on the contrary, its absence results in an accelerated rejection phenotype.
The role of IFNy is vastly different in TxAA. Transplants performed across MHC-II
mismatches result in moderate parenchymal rejection and early TxAA when the recipient
is WT; however, when the recipient is GKO, there is no TxAA, despite similar levels of
parenchymal rejection iN,N;,.?~:n t al 1.'t99X I. The absence of IFNy results in abrogation of
TxAA, in the face of persisting parenchymal rejection. Conversely, as was shown in
severe combined immunodeficient murine recipients of human arterial transplants, the
addition of IFNy, without the presence of leukocytes, can induce TxAA (".'i-. ?
2)0}() . Consistent with this finding, the adoptive transfer of IFNy deficient T cells into
recombinatio)n-activating gene (RAG)-1 deficient recipients of MHC-II mismatched
grafts, does not induce TxAA, compared to wild type cells that do ti'u4,: c' ' 2'4.
Thus, IFNy is both necessary and sufficient for the development of TxAA. Given the
central nature of the role of IFNy in mechanisms of rejection, this particular cytokine
represents a principal point of interest throughout this thesis.
Role of chemokines
Interest in chemokines has grown. Together with their receptors, chemokines have been
the subject of numerous general reviews (,:'.,cciei aitd $?ng'1,cr 20i00. Nirdoci anl':' ilun
)C C~,(' rar,, e  Ouxi I:'sdc R~.fIi ;'~ -'200J ?¥..~ .... '10, I , N1 o a, a~ mn I .oeische r L 0(X) as well as
reviews detailing their roles in transplant rejection tI icoci<, 0 f ' <:i 00(). \5ilson n
K' 0'Jo :2(0 .,I " ( ' I hc~'" I .!!. '~ I ...
i t Structurally, chemokines may be separated into two major subgroups based on the
spacing of the first cysteine pair in their structure; chemokines in which the cysteine
residues are adjacent are termed CC chemokines, while those in which the residues are
separated by a single amino acid are termed CXC chemokines. There also exist two
additional, smaller, and less well studied subgroups; the C group (where the first cysteine
is missing) and the CX3C subgroup (where the cysteine residues are separated by three
amino acids). Discussion in this thesis is limited to selected CC and CXC chemokines.
Page 27
HST
Emanuela Binello
Although there is evidence for migration-unrelated functions, such as lymphocyte
differentiation l 'w.e a<tl (,'?stwr 2(0i , monocyte adhesion J(ers.z'ter) :: " 1: and
smooth muscle cell proliferation Shiti-lmi:' <!d MitchteI 201', the main task of
chemokines is leukocyte traffic control Falser 00esctl' 2(t . CC chemokines
include, among others, regulated on activation normal T cell expressed and secreted
(RANTES), macrophage inflammatory protein-lat (MIP-tla), MIP-1pf, macrophage
chemoattractant protein-1 (MCP-1). CXC chemokines include interferon-y-inducible
protein 10 (IP-10) and monokine induced by interferon-y (MIG), among others; these are
particularly germane in TxAA since their expression is profoundly influenced by IFNy.
Chemokine receptors are membrane-bound and coupled to G-proteins NTU{JOK. 'MucI cF1}: 1.
2010 (l. They are named according to the subgroup of chemokines that serve as their
ligands; hence there are the CC-receptors (CCRs) and the CXC-receptors (CXCR). There
have been 11 CCRs and 6 CXCRs identified to date S>~tizi ;Ad it>n;1cliC1 20011'.9
Generally, interactions between chemokines and their receptors are promiscuous. For
example, CCR1, CCR4 and CCR5 bind to RANTES, MIP-la and MIP-3, while CCR2
binds to MCP-1 and CXCR3 to IP-10 and MIG. As can be seen, each of these chemokine
receptors may bind to a variety of ligands and are considered "shared receptors". There
are few chemokine receptors that display unique specificity to one ligand i(¥:,cicen :w<!
!'~i~gne 2'>i. Cellular chemokine receptor expression has been recently summarized
and similar promiscuity appears in vascular and immune cells; notably CCR1, CCR2 and
CCR5 are expressed on T cells, monocytes and smooth muscle cells, while CCR2 is also
expressed on endothelial cells i kli :,t< it ctt11200.3..
Mechanistic examination of chemokines in acutely rejecting murine cardiac allografts has
thus far included IP-10 and MIG. While administration of monoclonal anti-IP-10
antibody prolongs graft survival, congenital deficiency of IP-10 prolongs survival only if
expressed in the donor, rather than recipient, leading to the conclusion that it is the IP-10
derived from the donor that initiates development of acute allograft rejection IA-Il c.: ,k k
<.' 21! l. Treatment of recipients with rabbit antiserum to MIG results in a decrease in T
cell infiltration and a prolongation of graft survival 1\.:1kira a. /20i i t . Eventually
compensatory mechanisms overcome the prolongation in the anti-serum MIG treated
mice I lXi i :l:. 2!t0 ; it is unclear whether the same effect is seen with administration
of the monoclonal antibody to IP-10 i I 1 I3c c (., ' "h,: : : .i I
With respect to chemokine receptors in the acutely rejecting model, examination has been
more extensive and included CCR1, CCR2, CCR5 and CXCR3. Cardiac allografts from
recipients congenitally deficient in CCR1 have significantly prolonged survival times;
furthermore, treatment with cyclosporine-A induces permanent graft acceptance, pointing
to an important role for CCR1 cg_.,) 2. ? '()0'. Graft survival time also increases when
recipients were congenitally deficient in CCR2, concomitant to a decrease in the number
of macrophages in the graft and despite constant numbers of other graft infiltrating cells
and I :.atkV;, ~. '' ilpI l-',9ed UIF. iA more dramatic increase in allograft survival time is
seen with recipient congenital deficiency of CCR5, interestingly with equivalent amounts
of inflammatory cell infiltration J(,<i c.: ' i.~i/ 2/)0 . However, most dramatic, is the
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increase seen in CXCR3 deficient recipients, where further treatment with cyclosporin A
results in permanent graft acceptance (with no TxAA); administration of anti-CXCR3
antibody to WT recipients also increases graft survival 'I fiii:icoc, i a:/ 200)0).
TxAA in murine cardiac allografts may be attenuated by targeting MIG Ytiel  ' :20's2t
but not by RANTES or MIP-la (;1( J i:/ 20f!*)1 i Antibody neutralization of MIG
reduced intimal thickening and the development of TxAA lesions, in the face of a
significantly reduced inflammatory infiltrate (specifically CD4+ T cells), pointing to a
critical role of recipient CD4+ cells in the sustained production of MIG i xl ,:N ,! 20~!2 t.
Surprisingly, based on their potent T cell attractant properties, congenital deficiency of
either RANTES or MIP-la had no significant effect on TxAA i ;.'< '0- , 1  l.
The receptors examined in the murine TxAA MHC-II mismatched model include most of
those discussed in the acute rejection model, namely CCR1, CCR2 and CCR5. Cardiac
allografts from untreated recipients with a congenital deficiency in CCR1 show a
complete lack of TxAA development, as per histologic evidence, when harvested 100
days after transplant 'I U:c: :/2I s ()s . Deletion of CCR2 in the recipient does not have as
pronounced of an effect, but still significantly reduces TxAA, with only transient early
decreases in macrophage infiltration and no other changes in cellular infiltrate
:iFtk;~S;(~ n:s i/ utrs)ntBissll. Finally, congenital deficiency in CCR5 results in
permanent graft acceptance with no sign of TxAA G('I; i  :: 20)'11 . This result, taken
together with the finding that congenital deficiency of RANTES and MIP-lca, both CCR5
ligands, points to the potential advantage in targeting receptors, rather than chemokines
, , ' I. In fact, a recent report documents beneficial effects from administration
of an agent antagonistic to CCR1 and CCR5 ' t a: ~':! 2l0(4 . The effect of combining
immunosuppressive therapy with chemokine or chemokine receptor targeting has yet to
be explored in MHC-II mismatched cardiac allografts. Based on the success in abrogating
TxAA in cardiac allografts in fully allomismatched recipients congenitally deficient in
CXCR3 and receiving cyclosporine A, there may be some promise in this approach.
Factors accounting for the delay in mechanistic studies of chemokines and their receptors
include the deficiency in readily available monoclonal antibodies and until relatively
recently, the lack of congenitally deficient mouse I kIYicock . / 2()0C'"l. This lack of
readily available monoclonal antibodies resulted in the use of imperfectly characterized
polyclonal antibodies, fusion proteins and synthetic chemokines in studies, leading to
potentially confounding results, particularly given the close homology of chemokines and
their receptors } i 'aii~co , l. i: l 2,::,O ,('i.
Caution is advised with respect to the application of results obtained from murine studies
to humans, based on several factors including: differences in cellular receptor expression
(e.g. in mice CCR1 is expressed in neutrophils, while it is not in humans); differences in
specificity (e.g. in mice RANTES does not bind to CCR1, while in humans it does); and
occasional lack of homology (e.g. IL-8 does not have a structural homolog in mice),
along with dichotomous in vitro and in vivo data t t--cock it .d 2() 1 . Nonetheless, the
recent literature regarding chemokines and their receptors offer potential therapeutic
targets for ameliorating graft rejection.
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2.2 Peroxisome proliferator-activated receptors
This section begins by describing some of the general characteristics of the peroxisome
proliferator-activated receptors (PPARs), particularly with respect to structure, activation
and expression. Then, it reviews the literature regarding the role of PPARs in vascular
immunology, first discussing evidence from in vitro studies and then turning to in vivo
models. A detailed review of the clinical literature, which to a large degree focuses on the
role of the PPARs in lipid and triglyceride homeostasis, is beyond the scope of this
section. Suffice it to reiterate that PPAR ligands are in active clinical use. PPARa ligands
(fenofibrate, or Tricor) for hypertryglyceridemia and PPARy ligands (rosiglitazone, or
Avandia and pioglitazone, or Actos) for diabetes mellitus type 2. As the range of the
pleiotropic effects of PPAR expand and become established, particularly with respect to
inflammation, the clinical arena for these ligands is certain to expand.
2.2.1 General characteristics
PPARs belong to a nuclear hormone receptor superfamily, that act as gene transcriptional
regulators. To date, three isoforms are known, ca, y and 13/6. PPARa was the first isoform
to be identified in 1990 1tcslsscr:.: :[t~c G,'::er tw3d:)!rif and is typically associated with
regulation of fatty-acid catabolism, while PPARy is essential for adipocyte differentiation
and may mediate insulin sensitization ic.%c ,dr 2.)? 0((), . The role of the widely expressed
3/6 isoform remains to be elucidated, although recent evidence suggests a role in the
control of triglyceride levels by sensing very low-density lipoproteins i es (d fil2003 '.
This thesis focuses on the PPARca and PPARy isoforms. According to a recently
proposed unifying nomenclature for nuclear receptors, PPARa and PPARy form group C
of the subfamily 1 of the nuclear hormone superfamily, and thus may be identified in the
literature as NR1C1 and NR1C3, respectively I!:ct'i> SarSct \.\.>-,Ii 2)(Ot, However,
throughout this thesis, they are referred to as PPARc and PPARy. The following sections
first discuss PPAR structure and then their activation, including a description of both
synthetic and natural ligands. Finally, a summary of the expression profiles in cells and
tissues is given.
Structure
The structure of the PPARs is well known Noltte ,s ra i 99, (i)l,}t'f'g (. I ct9 . As
shown in figure 2.5, there are four major domains. The known details of each of the four
receptor domains has been recently summarized Ik !sctler' i)~d \tk g-ti 20()0t and, unless
otherwise noted, the statements about PPAR structure in the following paragraphs derive
from this review.
The first is the A/B domain. Poorly conserved between PPAR isoforms, this N terminal
domain varies in both sequence and length and contains a ligand-independent activation
factor (AF), named AF-1. Studies have shown that phosphorylation at specific sites in
this domain, e.g. serine residues, may modulate receptor activity, either intensifying or
decreasing the effect of ligand activation, suggesting interdomain regulation.
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The next domain is the C domain. Highly conserved, it is approximately 70 amino acids
long and comprises the DNA-binding domain of the receptor. It folds into two "zinc
finger"-like structures with a-helical DNA binding motifs. One of the fingers contains
the "P-box" that is involved in recognizing and binding to part of the nucleotide sequence
known as the PPAR Response Element (PPRE); the consensus sequence of the PPRE is
5'-AACT AGGNCA A AGGTCA-3' 'tx;ti h:uI-k .i'd ¥;~l-li ti0.). Mutations in the P-box
can completely abolish transcriptional activity. The other zinc finger contains the "D-
box" that is involved in dimerization of the DNA-binding domain.
The third domain is the D domain, also called the "hinge" domain because it links the
DBD domain to the next one. However, others have also noted that, in addition to its
linking function, this domain is important for co-factor docking l 1 )cb~"it (v 2.v!i t I , that
in turn, is critical for PPAR activation, upon ligand binding.
The last domain is the C terminal, E/F or ligand-binding domain, which contains a
ligand-dependent AF-2. It consists of thirteen a-helices and a small -sheet, forming a
large T-shaped hydrophobic binding pocket and interface for heterodimerization with the
9-cis retinoid X receptor (RXR), its obligate partner i X. ir 2 i l 9 t )1 F. The placement of
the amino acid residues appears to be exquisitely important, such that a change in even
only one amino acid may result in a fourfold lower affinity for a ligand. Overall, there are
two main differences between the PPAR and other nuclear receptors; firstly, its binding
pocket is much larger, such that less than half of the cavity is occupied by any of the
ligands identified to date; and secondly, that it has an extra a-helix, contributing to the
increased size of the pocket, and participating in the entry of the ligand i N1ichalik A:n),d
Activation
Figure 2.6 shows schematic of PPAR activation. In addition to binding by ligand,
receptor activation requires heterodimerization with the RXR, as well as the release of
several co-repressors and interactions with a host of co-activators. Specifically, upon
ligand binding, the LBD undergoes a conformational change, particularly involving AF2,
that allows the release of co-repressors, including the nuclear receptor co-repressor and
silencing mediator of retinoid and thyroid hormone receptor td icVl.i k MiUl. 1'AV;t':i s 9I
and interaction with the co-factor, steroid receptor coactivator-1, that in turn, interacts
with the A/B domain and then recruits two other co-factors, the cAMP-responsive
element-binding protein-binding protein (CBP)/p300 and the p300/CBP-associated
factor, further contributing to histone acetyltransferase activity 1 hscier i:c Wihli 2)0)t.i.
The conformational change also stabilizes the interaction between PPAR and RXR for
binding of the PPAR:RXR complex to the PPRE I )elbr id a./ 0 2001 I. This, combined with
the histone acetyltransferase activity of the co-factors, results in the interaction of the
activated heterodimer with the promoter, stimulating the transcription of target genes. A
functional consequence of this complex regulatory system is that receptor activation may
potentially be influenced by ligand-specific interactions with any one of the co-activators
and/or co-repressors.
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Figure 2.5: PPAR structure: There are four domains in the receptor. The first is the A/B
domain that contains a ligand-independent transactivating factor called activation factor
(AF) 1. The second is the C domain that is responsible for binding to the DNA and is
referred to as the DNA-binding domain. The third is the D domain that contains a hinge
region. The fourth is the E/F domain (containing a ligand-dependent activating factor
called AF-2) and is generally referred to as the ligand-binding domain.
PPAR ligand Co-activators
RXR ligand A Co-repressors
Figure 2.6: PPAR activation: Upon ligand binding, PPAR undergoes a conformational
change that allows the release of co-repressors and interactions with co-activators. This
change stabilizes the interaction between PPAR and RXR for binding of the PPAR:RXR
complex to the PPRE and results in the interaction of the activated heterodimer with the
promoter, thereby stimulating the transcription of target genes.
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Several non-ligand dependent factors may be responsible for receptor regulation. One is
the availability of co-factors; several co-factors exhibit tissue-restricted distribution and
physiological regulation l I;dl't :r "ld .\V.einii '(1(X)!if. Another is the direct phosphorylation
of residues on the receptor, as may occur in the presence of particular kinases 1.>>t5 ebrie c £
: i st¢ I l. Finally, the amount of retinoid acid receptor (RAR) present in a cell, given the
ability of the RXR to also heterodimerize with RAR, such that an increase in RAR can
increase the formation of RAR:RXR complexes and decrease the amount of RXR
available to bind with the PPAR and vice-versa, as has been shown in adipocytes
l 5: :b5 i! ; .i :/' .2(0,)(! .
It has also been noted that the PPAR:RXR heterodimer can also be activated by ligand
binding to the RXR such that, for example, synthetic ligands specific for RXR (namely
LG1069 and LG100268) are under current investigation as alternative treatments to
PPARy ligands _ KD)Hi J.'f ?.i 2i:'i). Nonetheless, the most significant and well studied
activation results from the binding of ligands to the PPAR.
There are natural and synthetic ligands for PPARc. Naturally occurring long-chain
polyunsaturated fatty acids, e.g. linoleic and arachidonic acids, show the highest affinity
for PPARa; additional natural ligands include fatty acid derivatives, such as leukotriene
B4 and 8(S).-hydroxy-eicosatetraenoic acid V licl-n i k a l WdI 99 91, the latter having
the highest affinity I\ jt is''l ' !:~,l r :a 2'ti. With respect to synthetic ligands,
PPARa is the molecular target of a class of drugs called fibrates that are in clinical use
for the treatment of hypertrygliceridemia. This class of drugs includes clofibrate,
fenofibrate, bezafibrate, gemfibrozil and lastly WY14643, with reportedly the highest
affinity si ,i i.:c . Interestingly, it has been noted that, although their
main effects are not mediated through this particular mechanism of action, two non-
steroidal anti-inflammatory agents indomethacin and fenoprofen, may also bind to
PPARa -'SL'' se sIL5  11.d > \V Rd iLtf O
Similarly, PPARy also has both natural and synthetic ligands. Natural ligands for PPARy
also include polyunsaturated fatty acids, as well as components of oxidized low-density
lipoproteins such as the 9- and 13-hydroxy-octadecadienoic acids, and prostaglandins
with their metabolites, particularly 15-deoxy-A 12 14 prostaglandin J2 alnu!!ir s,~.t \\if;.fji
Okts. , one of the most potent tk "',i i. ' il k ,:.'l \ a':lh li 9r'9, although there is controversy
surrounding its relevance as a PPARy agonist i;\.:, 2- t. ; 20(t), ':r':, , i),i Fer".~ e,,ga 
2'.)I:t('), R, '.;i a':7 r!' 20(!.(t. Synthetic ligands for PPARy come from family of agonists
called thiazolidinediones, of which two of the agents (rosiglitazone, also known as
BRL49653, and pioglitazone), are currently used clinically as insulin-sensitizing
hypoglycemics. The first agent in this class, troglitazone, has been withdrawn from the
market secondary to the incidence of hepatotoxicity IlRsie-) a.t~ S:pi",-et ntan 2('!() t.
Although ligands are generally ascribed either PPARa or PPARy specificity, there is
evidence of overlap between receptors. For example, some fatty acids such as arachidonic
and eicosapentaenoic acids bind similarly to both PPARs, while others, such as linolenic
and palmitol.eic acids, bind more strongly to PPARy but also exhibit PPARa binding
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activity 9K:ilst4 20('~() . Potential endogenous ligands, such as dehydroepiandrosterone,
bind to PPARa t Pee', s et al I~9, although a recent study also suggests interaction with
PPARy i K.<titi c :! e (!it.} f. Even in the realm of synthetic ligands, there may be overlap.
At high doses, fibrates, as exhibited by the compound Wy14643, may activate PPARy in
addition to PPARa K : M, '21, W0 : .li ,i!. The non-steroidal anti-inflammatory agents
(indomethacin and fenoprofen) reported above to activate PPARa also activate PPARy,
albeit weakly ::., r I aii , ¥ i 2 () t.
Expression
PPARs have distinct, tissue-specific expression and distribution in human tissues iJ.:i[:-:'lhCi'
;ii~ Wrii iit(f01. PPARa is expressed in primarily in the liver, heart and kidney, while
PPARy is predominantly expressed in white adipose tissue. Accordingly, hepatocytes,
cardiomyocytes and adipocytes express PPARs of various isoforms. Adult rodents show a
similar pattern of expression, with the additional demonstration of PPARy in the spleenit }:!~h ~:-td \ Vkit" 2()0001. One notable exception is that expression of hepatic PPARa
expression is much lower in the human compared to the rodent I EstXr , .~,l VWallt 2)000 ];
in fact, contrary to results using rodent hepatocytes, PPARca agonists do not induce
peroxisome proliferation-associated genes in human hepatocytes i I..r S .; :~ I 2(s i !.
PPAR expression has also been identified in the vasculature and several cells in the
immune system. Vascular endothelial cells express both PPARa iYe : 19 ,)8cI and
PPARy ">1:ix .? </ 1¢;i)as. Similarly, vascular smooth muscle cells also contain both
PPARa ¢S:i:; L:f / I;.S) and PPARy Ki ., 1,' S,8:: / ':.~), .'w c; L: z, 20w '~!iN . With respect
to the immune system, monocytes/macrophages, the most well studied inflammatory
cells, contain both PPARa i'ti dv I:ci 1 9;,L, t and PPARy i : : Ii !9'4 ' M:tt' ':,
i ithi 8t> !. Following the same trend, T cells also express both PPARa i;,!s; tL¢i .2i i
and PPARy It: : ' a./ 2. ',i)\,, l"ii aas t'Sitl 0 !i') }t , I s >,t c ? 2(,21. Contrasting
with the other immune cells discussed thus far, dendritic cells express the PPARy isoform
but not PPARa lf'.l et-, a. /2ii0'.,. Thus, with the exception of dendritic cells, all of
the vascular wall cells, as well as monocytes/macrophages and lymphocytes, express both
PPAR isoforms.
2.2.2 In vitro effects
PPAR activity has been linked to relevant cell types in the vasculature, namely vascular
endothelial cells and smooth muscle cells, as well as immune cells that play important
roles in the vasculature, namely macrophages and T cells. The role of PPARs in the
cardiovascular system is the subject of several reviews 1 19Isioj-p.. 3a1i ey 2 Bicha) ;s iin ~,i
~"~t '!i'0:l, ; :t  .lcis ('> a> :/2~)').~ i. This section discusses evidence of PPAR effects on
vascular immunology, i.e. on cells of the vasculature, as well as on cells of the immune
system that are particularly relevant to the development of vascular disease. Relevant
information from other cell types is also included. Emphasis in this section is placed on
results from in vitro studies, while the next section includes a discussion of relevant
findings from in vivo models.
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Vascular endothelial cells
Reports in the literature on the effects of PPARa agonists on endothelial cells suggest a
broad range, from anti-inflammatory to pro-inflammatory. Anti-inflammatory effects of
PPARca agonists include a reduction in the adhesion of monocytes by diminishing the
expression of vascular cell adhesion molecule-1 (VCAM-1) upon either mitogenic or
cytokine stimulation IC.la..ck ol , : -'9 .L .:/IS(.91 i iei :?{" 2 000.L, Si ?,:al s ci 
2)() i0. A mechanism of this inhibition is by the decrease in nuclear p65 amount, a protein
critical in the nuclear factor-KB (NF-KB) pathway i ii vDar5i ;..i? 2~ f002 . On the other hand,
when stimulated by oxidized phospholipids, however, PPARca agonists increase the
synthesis of selected chemokines l ... ,'f i? r'i ?A(m. The overall effect of PPARca
activation is largely dependent on the setting, particularly the stimulation type and ligand.
For example, PPARcc increases phospholipid-stimulated expression of MCP-1 I re \'' oi i
,!i' , but has no effect if it is stimulated by cytokines ! '0:' X,i 0(i 1. Another
example is the effect of PPARca activation on the expression of plasminogen-activator-
inhibitor- 1 (PAI- 1); modulation is ligand-dependent I N i ssoii ' t',t ?.
PPARy ligands exhibit a range of anti-inflammatory effects in vascular endothelial cells,
again dependent on stimulation type and ligand. With respect to ICAM-1, studies show
that PPARy ligation may either inhibit KI A: ce i ?' ._i (fi?)',or augment l'Ie ?ii ./.l I 99 
its expression. Similar variation in results exists for the expression of VCAM-1, with
evidence showing both no effect ItNIK."hx c: r,:/ )1999!1. Jctin rd Y if 1.; 0 f and a decrease
.s!:. ..:I ¢j:. ~llt '0? ) ! i :- 29991. PPARy ligands inhibit release of endothelin-1, a
potent vasoconstrictor .? <'.;i . .9 9i ,:i !r. The literature on the
effect of PPARy ligands on the expression of PAI-1 also varies with reported increases
1 ~"l I r' Q9..U-. X , 2A/,i ?s:.(2, and decreases i Ka.o ., . t):. ' i. PPARy agonists may
also reduce expression of endothelial cell growth receptors IX K i v' ; 191)i , as well as
the IFNy-induced chemokines IP-10, MIG and ITAC i -`I.ar' ci i.
Vascular smooth muscle cells
PPARca ligands have significant anti-inflammatory effects on vascular smooth muscle
cells without affecting migration. Specifically, PPARa ligands exhibit anti-inflammatory
responses in, vascular smooth muscle cells by repression of NF-KB signaling, thereby
inhibiting IL-1 induced production of IL-6 ISt;w:eis a'r t.? l13;:., cl3e~:iv2. Iv/ ?;Oit.
PPARc ligands also prevent prostaglandin production by inhibiting expression of
inducible cyclooxygenase (COX) or COX-2, as determined by specifically testing its
promoter Si-el s a?' d I9;StX . The PPARca-mediated inhibition of IL-6 gene transcription
occurs by interference with c-jun and p65 iDcIl:i:'~t; , iiiS. Despite this activity,
PPARat agonists do not influence smooth muscle cell migration as evidenced by the lack
of expression of matrix metalloproteinase-9 (MMP-9) or tissue inhibitor of matrix
metalloproteinases (TIMP)-I or TIMP-2 platelet-derived growth factor-BB ..larx ef u
9:.i-iI, , or on interferon regulatory factor-i (IRF-1), a transcriptional factor that mediates
vascular smooth muscle cell proliferation -L, i ,i -g ' ii O2,) j.
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PPARy ligands, on the other hand, have significant effects on vascular smooth muscle
cell migration without affecting inflammatory activity. The effects on vascular smooth
muscle cells are demonstrated by the ability of several different PPARy ligands to inhibit
migration under several stimulation conditions t\'lar.N ; -? u " :998, 1!crlii; ~ e.l ; 20t'0,('i
;!.t":.* i~ i'; , i 199It. PPARy ligands block several events, including downstream of
mitogen-activated protein kinase (MAPK) cytoplasmic activation i>.;t :i X' i.t,1
downregulate growth-factor-induced expression of c-fos iiil i..i ... and
decrease MMP-9 levels and activity '.: :d !'.,*-. . Selected PPARy ligands enhance
IL-1 induced nitric oxide synthesis ! I " 10; i9, increase IRF-1 [Lin et al 2004],
and, via effects on cell calcium mobilization, may attenuate both proliferation I:A-t': i! '
; I. and contractile ability 
..
it5"..' c:'f ;'1 it il;'; . With respect to inflammatory activity,
unlike PPARc ligands, PPARy ligands do not affect IL-1 induced production of IL-6 or
COX-2 expression on vascular smooth muscle cells ! s,-: t t ; !9 g.
Monocytes/macrophages
PPARct activation generally has anti-inflammatory effects on monocytes/macrophages,
although there is some suggestion of potential pro-inflammatory effects. Synthetic
ligands induce apoptosis in cytokine-activated macrophages activated t([C"irilut-i c ,,' a:
.19cg jand regulate the expression of AdipoR2, a receptor for an adipocyte-derived
cytokine, aciiponectin, recently implicated in regulation of macrophage phagocytic
activity, as well as lipid accumulation ('h:i ' cli c ' 2i?.. t. Ligand-activation also
reduces nitrite accumulation, associated with a reduction in inducible nitric oxide
synthase (iNOS) and induction of heme oxygenase 1 'i X ?". Furthermore,
PPARa activation down-regulates platelet-activating factor binding and receptor
expression, suggesting, as a consequence, a reduction in the recruitment and adhesion of
monocytes, in addition to a decrease in the production of inflammatory cytokines
I 1! o.~v 1t .t~ e! 12 ;~ >i . However, using peritoneal macrophages and fluid, the addition of a
synthetic PPARc activator actually enhanced monocyte migration, suggesting that
PPARa inhibitors may also have pro-inflammatory properties :-,lrl'o,,i ,,' i, , I I .
Another potential pro-inflammatory effect of PPARt activation is from the upregulation
of macrophage lipoprotein lipase expression, with the downstream effects of enhancing
monocyte binding to the endothelium and inducing monocyte/macrophage activation,
among a host of other effects '.i c.? ;' 2(0,t 2 i.
PPARy agonists are ascribed a multitude of negative regulatory effects on macrophage
function. Specifically, activation with synthetic ligands reportedly decreases the
expression of iNOS and MMP-9 '. . t ? al . ? . 'x55?5 ' S"?'5P (2'.? 
.' ' K', -? (} \ 'l c; S (' 03 . PPARy agonists also have
anti-inflammatory actions by decreasing the production of several cytokines, includingIL-1 , IL-6, TNFct and IL-12 ' p;, ?i ' " Nde> cf t i .? i' ' ' v 5 ?
\'VeichI -i §9 <'..5' . I. It should be noted that the PPARy mediated effects on cytokines are
not without contention based on results showing a lack of effect with the synthetic
ligands on IL-6 and TNFca !1Yi~iMl,0;~!? c. 0/ 2.'00,0. ) Wetcid ch'. ,f lS('7i. i This led to a
suggestion that the effects seen with natural ligands are independent of PPARy
S........... :li(-C- .. S.i' ZC. .- and subsequent studies supported this notion i Ro:ssi .. ' tS( " ," )0Ot.
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Interestingly, there is evidence in the literature that part of the effect of at least two
commonly available non-steroidal anti-inflammatory drugs are mediated by PPARy
?Ui;--: ? 0!8 , based on a feedback control of COX-2 expression I /,~t et ?S< 2100,,.
Although there is decreased migration upon incubation with PPARy ligands sDlo<>mI li,
F:? 2()i!i i, the effect on chemokine production varies, ranging from a decrease in MCP-1
I ~;~i.. ? '1 , ?:?/ ' 2 IN;i and CCR2 i t: .a'i 2, 000 1, to no effect on RANTES and an increase
in IL-8 f ,: c , 2) i ? 2002 . Ligand-activation of PPARy also induces
apoptosis in macrophages IC?,liti i. 1:d' 9i i  and upregulates lipoprotein lipase,
adipoR2 and thrombomodulin, a receptor that is involved in anti-coagulation I .¢ ci :sl
?2(~0'2~ K :~'~e~;;: l '?I> ~''i' ,?:,' 2i ll '?, ( ? ; Q t g s si ; r )t4' :'. PPARy may act in part by antagonizing
the activities of several transcription factors including activating protein-1 janus kinase
STAT and NF-KB t1Rsi cot, ,:' Ch3i: ,/ 9 .i!.! 2!0. (' he ('',tt c ' 2(ff).3i, as well as
direct interaction with CREB-binding protein coactivator 1 IJ ..5 c,-'! 2./t~) i.
T cells
Overall, PPARa agonists may have anti-inflammatory properties related to effects on T
cells, as demonstrated by a decrease in the production of several inflammatory cytokines.
Following T cell activation with anti-CD3, the production of IL-2, TNF-a and IFNy is
significantly decreased in T cells pre-treated with synthetic PPARa agonists l$ M; x i': 
i)r!2 . A similar effect on IL-2 and IFNy is observed following stimulation with
concanavalin-A I in,: ;.jK Se. 2t('r0;i 1. However, an inhibitory effect on IL-2 production is
not observed upon T cell simulation with phytohemagglutinin after pre-treatment with a
synthetic PPARa ligand ,h ri .20r(), suggesting stimulation pattern dependence.
Interestingly, synthetic ligands may have PPARa independent effects on cytokine
concentration, such as an increase in IL-4 production (.:'i:i d r' .ir 2(002aI. The effect of
PPARct ligand-mediated activation is modest on cell proliferation ' ' s.: e ()¢(i2ar l,
and absent on cell viability 7i·. .; :: 2'!C2I. With respect to the mechanisms of
inhibitory action, experiments show that PPARca ligand-activation may effectively
antagonize the actions of NF-KB, a critical transcription factor mediating cyotkine
production i ' :; s i 20{ i. Following the identification of T-bet, a transcription factor
that affects T cell development by its ability to transactivate IFNy while repressing IL-2
gene expression I.0z.t '. :.i 2(:i!'.i t, recent experiments point to a potential role for
PPARa in the regulation of T-bet through p38 mitogen-activated protein kinase !.l... '2:
The majority of PPARy ligand-mediated effects reported to date are anti-inflammatory,
although there are reports of potential pro-inflammatory actions. Treatment of T cells
with PPARy agonists decreases the stimulation-induced production of IFNy, TNFa and
IL-4 i',' 20}Ol,, .rx: : ,. (, ('Wat-: :.:; ,:?  :C, al : 2003',.
Furthermore, in cultures treated with PPARy agonists, T cell production of IL-2 both
consistently and significantly decreases {iCl:dk c; i 200()0( ¥':l. i.'r ,V : 20'), C'.§i;ard 6.,: r,/
2t;). ',. e,;t, l<: i.(1) 2 . The dose at which this decrease occurs correlates with a modest
decrease in T cell proliferation I(: ,.: / t 20)2.~2a  while high doses of PPARy agonists
show more pronounced inhibition of proliferation lr'!r'l.: d i .ca'ga: 2.0') t.2(0)(!f 01 and
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induce apoptosis .la 'ris ,r,:t p.i,.s)- 2(0i il. Recent evidence demonstrates the ability of
synthetic PPARy agonists to enhance mitochondrial potential and actually promote
cellular survival, when used at concentrations that optimally induce transcriptional
activation, thereby suggesting a possible augmentation of immune responses, or pro-
inflammatory effect \V:'; (I: i '20s()'2 . Although ascribed a PPARy independent
mechanism, consistent with this pro-inflammatory effect is the potential for a natural
PPARy ligand to induce production of the IL-8 chemokine I'kIar'-~is : .' 2.i' 2 . PPARy
regulation of cytokine production by stimulated T cells strongly correlates with the
inhibition of transcription factors activating protein-i (AP-1) and NF-KB i"tin .- ' ''t/
,. I and also involves a physical association between PPARy and the nuclear factor of
activated T cells transcription factor 'tCh iitk. u: `3 d. .: 1 .
Relevant evidence from other cell types
PPARy may also play a role in immune regulation by affecting the maturation and
immunogenicity of dendritic cells t 'fveetrt g1,; O ,' . (ti (";)S' t 7s tii' al.,t0 ' Net ciotl i e,, .
:() i. Dendritic cells are important in the generation of primary immune responses given
their ability to stimulate naive T cells; upon encounter with antigen, dendritic cells
undergo a maturation process that includes upregulation of co-stimulatory molecules and
cytokine production " St in"' i.. ,1 / (?7 I . PPARy ligand activation alters co-stimulatory
expression, upregulating B7-1, while down-regulating B7-2 i(::i; A;l t')I) l Ne.'i a' i
i': i t))2 i, and impairing the expression of CD40, as well as the dendritic cell hallmark
molecule, CDla i4le<ic < ( : ',~i 2.0.02i. PPARy agonists also decrease the dendritic cell
production of cytokines, most notably IL-6, IL-10, IL-15, TNFa and IL-12 I::-.Aecav ti
:' 2..:.. rcr ir i.~ 2t and the production of selected chemokines, I:3Y.>s<,. .. S 
.:,tr E>. Part of these inhibitory effects of PPARy agonists may be due to the blocking of
the RelB protein (a member of the NF-KB family), given the reduced expression of the
nuclear localized RelB protein .N" S,:k'o:il ti c i: :.
Investigation into the mechanistic details of PPAR action continues and recent work,
using rodent islet cells, has added to the understanding of signaling pathways t WVeb er c
'.0' 0j .2t I. With respect to IFNy, the protein factor that binds to the gamma activating
sequence is the STAT1 factor and PPARy ligand-activation attenuates IFNy-induced
STAT1 phosphorylation, nuclear localization and DNA binding 'li\Ya clt < 2: "'3.
Furthermore, results show that the corresponding increase in the expression of heat shock
protein 70 (potentially important for preventing the damaging actions of nitric oxide)
does not affect the PPARy ligand-mediated inhibition of STAT1 activation; the inability
of a cell line overexpressing heat shock protein 70 to modulate STAT1 provides
corroboration that the PPARy-mediated effects on cytokine inhibition are not mediated
via this heat shock protein ' bi., ;;r :'i s Y St i.
Further mechanistic insight is given by experimentation into the activation and
degradation of PPARy in adipocytes I' ..d t S-pluts 2(t;02. Similar to other
transcription factors and members of the nuclear receptor superfamily ei a,:nli' . X
207)' I l, the degradation of PPARy is subject to regulation by the ubiquitin-proteasome
pathway, thereby requiring covalent tagging of the substrate with a polyubiquitin chain
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and the subsequent recognition by the proteasome .::I<;S. a Sphtl 2" 101. Following
IFNy-mediated activation and serine phosphorylation, ubiquitin conjugation increases and
PPARy degradation ensues without requiring export from the nucleus I iL:d ;tm
?'t{;'~:.>>;; '~1)0. Inhibition of extracellular signal-regulated kinases (ERKs) 1 and 2
decreases the rate of degradation and prolongs the half-life of PPARy proteins I t. I.oyl i
Ste)|t'XX~s ~"~ 't0. Studies using adipocyte cell lines also show additional pathways
involving PPAT in the cardiovascular system, namely ligand-activated decrease in the
expression of PAI-I and aromatase, a critical enzyme in estrogen biosynthesis I tra :' im
:,.!t, ;''' 'K.:l f ' :(),0)1. PAI-I promotes both thrombosis and fibrosis, such that its
inhibition may be desirable and has resuscitated interest in the development of PAI-1
therapeutic strategies .. '?:~ :x,!, Alis 2i)i;i. Estrogen has been ascribed many
cardioprotective effects, such as arterial vasodilation, inhibition of cellular response to
vascular injury and prevention of atherosclerosis .i ildl.koe s s )('1,i. '. On the other hand,
in a setting such as breast cancer, where adipocyte-derived estrogen may promote growth,
PPARy-induced decrease in its biosynthesis may be beneficial .i dbi. (t i ,~;1000t  Thus,
as shown in several vascular cell types, PPAR ligands may play both protective and
harmful roles in the cardiovascular system.
Finally, caution is advised with respect to the comparison of rodent and human cellular
results. For example, results show that two potent and synthetic PPARa agonists have
differential induction of peroxisome proliferation-associated gene expression in rodent
and human hepatocytes iv Iaw er c :: ;.;: 2(0t1 i. There are several hypotheses to account
for the difference, including differences in the tissue expression of PPARa or in the
responsiveness of the PPRE 1i : 2( / <;,1 . A human hepatic cell line,
manipulated to overexpress the PPARcaprotein, does not significantly increase the
induction of peroxisome proliferator-activated genes, implying that the failure of human
PPARca in the induction of peroxisome proliferator-activated genes is independent of the
level of receptor expression I o.. ret2!) fii 2(t ! i. The second hypothesis, of differing
PPRE, however, is more consistent with the finding that different synthetic agonists have
dramatically different affinities between rodent and human hepatocytes, as well as
different peroxisome proliferator-activated expression profiles, such that the rodent and
human PPARa may be distinguished pharmacologically t ..,a, :,':-><e 2 .i )0 11. One
potential reason for the difference in binding affinities is postulated to be differences in
two amino acids in the ligand-binding domain of PPARa between the two speciesi I..., .)'ce ¢;! 'i'/ . ,J , ,i. 2 Potential explanations for the differences in PPRE responsiveness
resulting in a change in the induction of peroxisome proliferator-activated genes include
changes in the PPRE, causing a loss of functionality, or a change in one or more of the
transactivating factors (either coactivators or corepressors).
2.2.3 In vivo effects
The role of PPAR agonists in the cardiovascular system is under examination in a number
of in vivo models, ranging from models of ischemia/reperfusion, to myocardial function,
and to atherosclerosis. Furthermore, tudies are elucidating PPAR effects in inflammation.
Results from the literature on PPARs effects in vascular immunology (in vitro and in
vivo) suggest a possible role for PPARs in mechanisms of transplant rejection.
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Although ischemia/reperfusion injury does not cause allograft vasculopathy in syngeneic
grafts, it can exacerbate existing vasculopathy F'It-k,:~wi c, i '(et }:.3 ,. Protection against
ischemia/reperfusion injury and myocardial infarction size may be achieved following
activation of both PPARa and PPARy IVANfc''e(o :. ~ 2()2, Vvn:,, i :,,: 200 .~. ,
0/1' 2., Y.~ : ct? '')03f. Mice congenitally lacking PPARa exhibit increased
susceptibility to ischemic damages and are refractory to treatment with a PPARa agonist
'i ",l ~.:".: : ,'t'~ 5i' ~. i. ? (2.)3 -. Administration of a potent PPARa agonist causes
a reduction in infarction size in rodent models e c. : '0: (}, V.Vxo' r.' _i'" ~
Furthermore, PPAR(c agonist administration also improves endothelial vasodilatation
/I*c''~c't .: . ,,,.. and contractile function '¥tc c a 2K(`(3 I. Similar results are
observed in rat models using the two clinically available PPARy agonists Y!c ' : ,'20(0(}.
.Concomitant to the attenuation of
ischemia/reperfusion injury were decreases in neutrophil and monocyte accumulationt ~; I  e~' '4-2bl 2% i' · ): 2if )Z. If
Increasing evidence suggests a potential role for PPARs in atherosclerosis. Although
TxAA and traditional atherosclerosis differ in several ways with respect to lesion
characteristics (concentric, lipid-poor, diffuse vs. eccentric, lipid-rich, focal), there are
several similarities, including endothelial cell activation, vascular smooth muscle cell
hyperplasia and extracellular matrix synthesis [-{H'Asot 1995 i. Both also have T cell and
macrophage accumulation, and in fact, the immunologic basis of atherosclerosis is being
increasingly appreciated I;:.; 1' '9. The role of lipid homeostasis is less relevant to the
development of allograft vasculopathy than to typical atherosclerosis, such that
potentially pro-atherosclerotic effects, such as the PPARy ligand-mediated conversion of
macrophages to foam cells in atherosclerotic plaques *Tno)z l198ei . '
9'9 i, are less germane. On the other hand, the inflammatory properties of lipids may
affect the translation of anti-inflammatory findings from typical atherosclerosis to TxAA.
The potential benefit of PPAR agonist administration in murine models of atherosclerosis
is under active investigation. One study examining the effect of fenofibrate, a PPARaI
agonist, on a murine model of atherosclerosis based on apoliprotein E (apoE) congenital
deficiency, shows that treatment increases plasma lipid levels and decreases both
cholesterol content and MCP-1 expression H', 'c0. Administration of PPAR.
ligand in apoE mice that overexpress the human apoA-I, also results in a diminished
aortic lesion area i, c: 2001. Similar effects in lesion reduction may be seen with
PPARy agonists. In a study using mice that are congenitally deficient in LDL,
administration of PPARy activators strongly inhibited the development of atherosclerosis
decreases in TNFa L .:/" K)")(". Similar reduction in lesion formation is seen with
PPARy agonists in apoE deficient mice 1Ctc~: 20t} i . Moreover, using an
atherosclerotic model of apoE deficient mice, results show that angiotensin II, a potent
vasoconstrictor implicated in atherosclerosis, is associated with activation of NF-KB
genes and downregulation of PPARs, as well as MCP-1, ICAM-1, VCAM-1, iNOS and
COX-2 throulghout the entire aorta KIhiiin l ': '!0!2 t. Overall, there is strong interest in
the potential use of PPAR agonists in atherosclerosis I 1:'1t.k 20. Ncve al: ? 2 '.
gic~·cs00,0, ..- . . t "0 d-'" ~ -'t* '0" ... ~"'~'~'~
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With respect to inflammation and immunity, PPARct agonists have profound effects.
Following immunization with myelin basic protein, mice treated with PPARc agonist
have an impaired immunoglobulin G response and a decreased number of splenocytes,
which, when restimulated ex-vivo, produce decreased quantities of IL-6, TNFa and IFNy
CQ imi.l r . '2 1?0E l~ . It should be noted that the decrease in the number of splenocytes is
attributed to effects independent of PPARcc, based on the ability of the PPARcL agonist to
induce a similar degree of apoptosis in splenocytes from mice congenitally deficient in
PPARa (PAKO) compared to wild type mice < ,. Aortic explants from
PAKO mice demonstrate dramatically increased production of IL-6, when stimulated by
lipopolysaccharide (LPS), and conversely, treatment with PPARci agonist fenofibrate
results in the reduction of LPS-stimulated aortic IL-6 secretion l I'):.le . , %.
Results also indicate that the inhibition of inflammatory responses involves direct protein
interaction with p65 and c-Jun '.)' .' i .
The above findings naturally lead to the hypothesis that treatment using the same class of
PPARcL agonists can attenuate acute inflammation, as determined by the production of
TNFa. However, in a mouse model of endotoxemia, mice treated with PPARct agonists
have fivefold higher levels of LPS-induced TNFca in the plasma IIl -: u -.)9gt . In
addition, the treated mice had significantly lower glucose levels and, more importantly,
significantly lower lethal LPS dose '- .: s ta' 9)I . Experiments using PAKO mice
confirm that this effect is indeed mediated via PPAR, although, interestingly, and for
reasons unclear, administration of the PPARcc agonist to the PAKO mice resulted in
decreased TNFcx levels and increased glucose levels compared to the wild type mice 1 i 
l. t)iL5. There may be an issue of ligand specificity, with potential effects mediated
by other PPARs. Overall, the results suggest that the cell and tissue specific anti-
inflammatory activity of PPARct (demonstrated by in vitro and in vivo studies) may be
overshadowed systemically ii/ 11 ? / ? ".I via hitherto unrecognized pathways.
Activation of PPARy in vivo also has profound immunomodulatory effects and potential
benefits in inflammatory bowel disease and diabetes mellitus type 1, both of which are
characterized by significant immune components. In a murine model of inflammatory
bowel disease, PPARy agonist administration of a classic molecule attenuated disease and
concomitant inflammation S ' :.i" 90i ). Further investigation, using an intestinal cell
line, shows that the PPARy ligands reduce the nuclear protein binding to the NF-K and
render the IKB-a protein (that works by inactivating the NF-KB factor) resistant to
degradation upon stimulation with IL-1 3 c:,,'r .: :t190)1. Treatment with a PPARy
agonist reduces the incidence of autoimmune diabetes progression in a mouse model,
IA ,' (_'; k..:: ..'/ ( l *X;N 0. In this model, islet cells from the treated mice express significantly
lower levels of IL-1P induced ICAM-1, while the T cell expression remains unchanged
A wSteM....' ' .:' c?-"2'¢(0031. The CD4+ and CD8+ intracellular expression of IL-2, IFNy, IL-4
and IL-10 is also not significantly unaffected by PPARy treatment, although cluster
analysis reveal that mice in the study segregate into groups of IFNy-high and IFNy-low
producing populations, with most of the IFNy-low cells being in the treated group
2 e t?''3 2i 2 ? f ..g2 y2,0t0 . I 
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PPAR activation also has several modulatory effects on hepatic function, in addition to
peroxisomal proliferation. Treatment in mice with PPARc agonists may downregulate
the activity of the 11 -hydroxysteroid dehydrogenase type 1 enzyme, that is important in
the conversion of doexycortisol to cortisol Iir.) 'os:i .I ' . ..:d (' ,t)}. Cortisol is
a potent gluconeogenic hormone with a variety of anti-inflammatory actions, including a
decrease in phospholipase A 2 activity (necessary for the generation of thromboxanes and
prostaglandins), neutrophil migration and phagocytic activity, as well as fibroblast
proliferation and proteolysosome secretion via lysosomal stabilization '" .. }:,, d: eid 20( 1,
such that a decrease in cortisol has a potential pro-inflammatory effect. On the other
hand, treatment with the same PPARa agonist suppresses fibrinogen gene expression and
the levels of plasma fibrinogen, a potentially protective effect given the association
between elevated fibrinogen levels and the incidence of cardiovascular disease IKocks c. ?
,:l; w.~. ,_, . Another PPAR-mediated protective effect may be seen in ethanol-induced liver
injury in rats " . . Treatment with PPARy agonists greatly diminishes
the pathological parameters of hepatic steatosis and necrosis '-orXAOu ,', ,', ","(i .
Kupfer cells from the treated group also produce significantly lower concentrations of
TNFa compared to wild type; in fact, the protective effect of PPARy agonists is ascribed
to the abrogation of Kupfer cell sensitization to LPS it [.'" -'no 2...
Based on the reported effects of PPAR ligand-activation both in vitro and in vivo on
vascular endothelial and smooth muscle cells, as well as on monocytes/macrophages and
T cells, there is reason to hypothesize beneficial effects of PPAR ligand-activation on
parenchymal rejection and transplantation-associated arteriosclerosis. Given the current
broad use of several PPAR ligands in the clinical setting, a demonstration of benefit in
transplantation could translate rapidly to clinical application. Therefore, investigation of
the role of PPAR in rejection at both in vitro and in vivo levels is highly warranted and
represents the overall goal of this thesis.
2.3 Boron neutron capture
Although it has been shown that persistent graft PR is not necessary for the development
of TxAA I :.<:t (d AI' aa 1 a-95, '-n etf a1I 81, it is not known at what time point a
graft becomes committed to a particular outcome. Currently, there are no readily
available tools to determine the minimum amount of time required by alloreactive T cells
(a measure of PR) to initiate the irreversible sequence of events leading to TxAA.
Early technologies have been hampered by several factors. The relationship between PR
and TxAA was first investigated by using immunosuppressive agent [ W At -'i i . 96.
Nlk;''v-l, ' 's :'' i,..d I105 }. These agents, however, have many confounding factors and do
not allow the inhibition of specific immune cell subsets. The use of antibodies to specific
T cell subsets N ', .. ?) I "tX , ' 9S improved upon some of the drawbacks encountered
with immunosuppressive agents. However, T cell depletion occurs mainly in the
periphery such that there is no verification whether the T cells that have already
infiltrated into the graft have also been removed.
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A newer technique to investigate the role of T cells in rejection improved upon some of
the drawbacks listed above. This technique involves the adoptive transfer of allospecific
T cells into an allograft recipient that lacks the recombinase gene (RAG -/-) and thus
cannot make mature T or B cells .i ti':rl:l o ,~ :' / u '20(!.i. l This method allows the transfer
of selected T cell populations that lack specific mediators, thereby permitting the
assessment of individual effector molecules in TxAA development. In fact, this adoptive
transfer method has been recently and successfully employed to compare the effects of T
cells from "WT or GKO mice i : t'l- i l'.." C A :il. However, the method does not allow
the removal of T cells after transfer to examine temporal issues related to subsequent
effector function.
The ability to selectively and rapidly inactivate adoptively transferred cells at specific
times after transfer could yield useful temporal information about requirements of
antigenic stimulation and the relationship between PR and TxAA. After inactivation of
the adoptively transferred cells, the graft could be allowed to function for varying times
in order to assess various stages of lesion formation. Contributions to the general
understanding of T cell dynamics in the development of TxAA can further the
identification of prognostic factors and/or therapeutic targets for transplant patients.
Moreover, the knowledge is of particular value in the accurate assessment of the efficacy
of pharmacologic agents in a murine model of cardiac transplantation. This is particularly
germane for agents where administration may have to be delayed for technical reasons or
in situations where the timing of the desired pharmacologic effect of the agent may
permit transient episodes of PR.
Manipulation of the boron neutron capture reaction may allow this type of detailed
temporal information to be obtained. The following section describes the general
characteristics of the boron neutron capture reaction. The current applications of this
reaction are discussed; given that they are primarily clinical, emphasis is placed on the
description and findings from clinical trials. Finally, boron neutron capture reaction is
proposed as a novel immunologic research tool. Although it is proposed in the context of
elucidating mechanisms of rejection of heart transplantation, it could have a number of
applications in many areas of immunology research.
2.3.1 General characteristics
The boron neutron capture reaction is based on the very high probability of l°'B (non-
radioactive isotope of natural boron) capturing a thermal, or slow, neutron. The thermal
neutron capture cross section of 'B is 3840 barns (1 barn=10 -24 cm) and decreases with
increasing neutron energy. When a °B nucleus captures a thermal neutron, a compound
l"B nucleus is formed. After 10 - 12 second, the compound nucleus disintegrates into an
alpha (a) and 7Li particle, which goes into an excited state 94% of the time, and into the
ground state 6% of the time. The 7Li* nucleus promptly deexcites by emitting a 0.48 MeV
photon. Figure 2.7 schematically illustrates the possible events following capture of a
thermal neutron by 'OB. The average energy release in the reaction, weighted by the event
probabilities, is 2.34 MeV, with 0.85 MeV carried by the 7Li particle and 1.49 MeV
carried by the a particle.
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7Li* + a
94 
'°B + nth ,.~ l"B 7Li + y (0.48 meV)
6% ±o 7Li + a
Figure 2.7: The boron neutron capture reaction: After a 1°B nuclei captures a thermal
neutron, compound B* nuclei are formed, which disintegrate into alpha (a) and 7Li
particles; the average energy released is 2.34 MeV (with 0.85 MeV carried by 7Li and
1.49 MeV carried by the a).
Both the 7Li and a are heavy charged particles giving rise to closely spaced ionizations
with a high linear energy transfer of about 200 keV/tm. The ranges of the 7Li and a
particles in tissue are, on average, 5 and 9 tm, respectively. Assuming the diameter of a
cell to be 10 tm and the intracellular l°B to capture a thermal neutron, the energy that is
released is deposited within that cell (the 0.48 MeV photon emitted by the 7Li* nucleus
does not contribute to the local energy deposition because it has a low linear energy
transfer). The ionization density of both the particles has the potential to cause complex
damage to DNA in association with adjacent intracellular structures, damaging the cells
with little or no possibility of subsequent repair tO <(;`Xdise:d ' %.
Herein lies the basis of the use of the boron neutron capture reaction: by delivering °'B to
selected cells, their death can be induced by irradiation with thermal neutrons. It must be
emphasized that it is the combination of low-energy neutrons with 0°B nuclei that results
in the specific destruction of boron-containing cells. The 0°B nucleus must be activated
(via irradiation with low-energy neutrons) to cause the magnitude of energy deposition
necessary for cell death. Alone, it has no significant deleterious effect. Natural boron,
made of 20% '0°B and 80% "lB, is ubiquitous in rocks, soil and water [w\oldI t9)9.4 and is
also present in foods such as vegetable Nii,:, i%(, t. Moreover, supplementation with
boron alone may improve osteoarthritic conditions i'{'t','r::. ::' i? o %0 i.
2.3.2 Current applications
The main application of the boron neutron capture reaction is as a therapy (boron neutron
capture therapy, hence the acronym BNCT) for brain tumors. Clinical trials examining
efficacy are in progress in the US tftsse X' i 2(;021, Japan Nakaav: ; e a 20i2{,
Sweden ? (.h >t:. ,i ,i 2i j2 i  Finland ,it u a? crO 'v? 2 i, Czechoslovakia JBmia .: ?.
2002t(r }, and the Netherlands [iVa."itl'?g , ,,./ 2' , 0.-l,. In clinical trials, patients are given a
boron compound either orally or intra-vascularly and after some time, to allow
accumulation of the boron in the tumor, irradiation regimens are begun. A schematic of
this procedure is shown in figure 2.8. Generally, patients are adults, although children
may be included tL. ' ? ?i 2.002( '~, and neutron irradiation takes place after surgery,
although intraoperative approaches are also being tested KMVat :s WmraEi , ' ? 2,1201 !.
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Figure 2.8: Boron neutron capture therapy for brain tumors: In this type of radiation
treatment, patients are first given a boron compound either orally or intra-vascularly, then
the tumor is irradiated with neutrons, inducing the boron neutron capture reaction in
boron-loaded cells. Traditionally, the tumor has three times the boron concentration of
surrounding tissue, such that upon irradiation, the tumor will receive three times the dose
given to surrounding tissues.
Thus far, results appear to be encouraging. Follow-up data on 17 patients with either
glioblastoma or intracranial melanoma show that 76% experienced a sizable reduction in
tumor enhancing volumes; division of the patients into two groups based on tumor
volumes show that for volumes less than 30 cc 10/11 patients responded, while for
volumes greater than 30 cc 3/6 patients responded li..s 2.. )L. In a cohort of
patients, including 44 patients with glioblastoma, 17 with anaplastic astrocytoma, and 2
with low-grade astrocytomas, five-year survival significantly improved in most groups,
as defined by recursive partitioning analysis, compared with standard treatment as per the
Japanese brain tumor registry 'c3 'Int f 2AeY~2. With respect to safety, no dose limiting
toxicity has been observed in several Phase I trials of glioblastoma, including one group
of 30 patients ! \V'i' : .W :, c.' ~.0(2 2 , another of 9 patients t ' r f 'fl .:'r 2.0. .:2 and another of
18 patients , o ::/.B : ... . A Phase II trial with 27 glioblastoma patients (who had
no incidence of acute BNCT-related toxicities) is underway i (..;p:RIg-ia e.l: 2i') 0.
To date, there has been only one non-brain tumor clinical experience reported and this
involves the treatment of patient with liver metastases secondary to colon carcinoma
Ii"b·l i i ,': 22, 'C2 . Motivations for approaching this clinical problem are multi-fold and
include the ineffectiveness of standard chemotherapy in significantly prolonging survival,
the unavailability of external radiotherapy due to high risk of actinides hepatitis, and the
high incidence of relapse even after local aggressive therapy due to the difficulty in
nodule detection and localization I:el' Kii o. : . .'2. i. Following extensive neutron beam
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modifications and pre-clinical investigations, clinical experience began with a 48 year old
with diffuse liver metastases from a sigmoid adenocarcinoma; the boron-compound was
slowly injected into the patient's colic vein and after perfusion, the liver was removed,
irradiated, and reconnected to the vascular and biliary stumps I in-el<li h' (E .i)21. The
patient recovered from postoperative complications (including thrombotic occlusion of
the left femoral vein, hepatic and renal insufficiency, and left foot drop) and at 7 months,
is in very good general condition, with normal liver function tests and an absence of
metastatic nodules in the liver I 'i>li Go: 1/, 2() I.
2.3.3 A potential new application
The potential design of an experiment would be as follows: two days after the heterotopic
cardiac transplantation of hearts into Rag -/- mice, T cells would be purified from the
spleens of WT mice and incubated in boronated medium (parameters to be determined
from in vitro work). The boron-loaded T cells would then be injected into the tail veins of
transplant recipients. After a set number of days (e.g. 2 to 4), irradiation would take
place, inducing the boron neutron capture reaction in boron-loaded T cells. At 1, 2 and 8
weeks post transfer, the mice would be sacrificed and the grafts analyzed via biological
techniques. Specific T cell effects can thus be restricted to defined windows of exposure.
Development of TxAA requires 8 to 12 weeks, a short time frame that minimizes the
potential of observing effects resulting from neutron irradiation alone.
Based on the binary nature of the boron neutron capture reaction, the research approach,
as shown in figure 2.9, is two-pronged. On one hand, is the required boron concentration
in the target tissue and on the other hand, the neutron flux parameters (based upon the
concentration of boron in the target). High boron concentrations allow lower neutron
intensities (lower flux or less time), while high neutron intensities allows for a lower
boron concentration. An optimal balance must be reached between the two parameters in
order to design a practical system. In this thesis, emphasis is placed on determination of
the boron concentration achievable in the desired cell type, namely T cells.
evaluation of the A evaluation of neutron
boron concentration energy spectrum and
in target tissue flux requirements
Figure 2.9: Approach to boron neutron capture-based research: Parameters must be
optimized so as to have a sufficient boron concentration in target tissue to induce cell
death and appropriate neutron irradiation parameters so as not to harm surrounding tissue.
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Results from BNCT research in tumors indicates that concentrations of 30 to 50 ppm may
be adequate for induction of the boron neutron capture reaction in a therapeutic setting. In
general, it is desirable to have as large a number of 'OB nuclei as possible, since it would
lower the number of thermal neutrons required and thereby minimize the energy
deposited by the interaction of thermal neutrons with nuclei present in surrounding tissue,
namely from the capture of thermal neutrons by hydrogen and nitrogen, written as
1H(n,y)2 H and 14N(n,p)14C, respectively. While the former reaction does not contribute to
the local deposition of energy, the latter may deposit up to 0.626 MeV within 1 mm as a
result of the recoil proton and carbon nucleus.
With respect to neutron beam parameters, unlike traditional BNCT, where tumors are
often several centimeters deep to the surface of the head and therefore require epithermal
beams, the target in this application sits directly under the skin of the abdomen (i.e.. just a
few millimeters beneath the surface). Based on the shallow depth of the target area, a
thermal neutron is likely required. The target dose is estimated to be 3000 rads based on
the dose delivered to inactivate T cells in vitro for MLRs. Finally, the duration of the
neutron irradiation should be such that a goal of about 90% cell kill should be reached,
that is comparable to T cell depletion experiments, where the reported depletion ranges
from 87% to 98% depending on the timing of the measurement with respect to the
administration of the depleting antibodies i ?,, .: s t :~ I.
It should be noted that the nuclear-related tools required to fully develop the above
technique (i.e. a method for quantifying the boron concentration of cells both in vitro and
in vivo, Monte Carlo simulation and a thermal beam) are in large part available. A
method for quantifying boron concentration of cells in vitro has been developed 1' i:;ete
1,)): 9and is based on prompt gamma neutron activation analysis (PGNAA). A fully
equipped state-of-the-art PGNAA facility ' RAl imc- abwi icti' - . 8 9 is also available for
use at the MIT Reactor. A recent Nuclear Engineering PhD thesis I Moel- -2t00 has
optimized a technique of high-resolution quantitative autoradiography that allows
measurement of the °'B microscopic distribution in thin tissue sections (such as those
from the transplanted hearts) and simultaneous visualization of tissue histology. Monte
Carlo simulation is a readily available calculational tool. A thermal beam is currently
under construction at the MIT reactor.
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Chapter 3. In vitro evaluation of PPAR agonists
3.1 Introduction
As discussed in chapter 2, studies in the literature have documented a number of effects
of PPAR agonists on inflammatory reactions, mediated by cell types of both the immune
and vascular systems. Important among the many markers of inflammation are the
production of cytokines and chemokines, as well as the expression of their cognate
receptors (particularly relevant for chemokines given the multiplicity of ligand-receptor
interactions). Evaluation of the literature demonstrates that following treatment of
immune cells with PPAR agonists in vitro, there is an overall reduction in the production
of pro-inflammatory cytokines 2t(0':~rt1d M<' a'd ' il',x.- e ', \< 6 k, i (! <,/'3 
and variable effects on chemokines and their receptors ai)tS 6 ei (/ _o,.).,o L .ee ., .,)(.
ai:).t'x .. a.' ,_,(), t ~.l.: ' 2 . These findings suggest potential therapeutic benefit
of PPAR agonists in inflammatory pathologies, in addition to their already clinically
documented beneficial effects on lipid and glucose homeostasis.
Inflammation plays an important role in mechanisms of heart transplant rejection. As
highlighted in chapter 2, IFNy is ascribed a particularly important role; congenital
deficiency of IFNy on recipient mice of heterotopic cardiac transplants abrogates TxAA,
while exacerbating PR Na.t3tX '? i-.'o'i I()< i. Antibody targeting of selected chemokines
and/or congenital deficiency has been found to decrease the severity of PR i;~r3C<~c k cir' 
2600icfT. I NltII tX l " 'and attenuate the development of TxAA iI. ? 5,.
Furthermore, congenital deficiency of selected chemokine receptors also ameliorates
TxAA G:1.)() 'z : (i i. The responsiveness of PR to standard immunosuppressive
therapies and concomitant lack of available treatments for TxAA, motivated a search for
readily available agents with modulatory effects on IFNy (as well as on other cytokines,
chemokines and their receptors), that could be extended to the transplant setting.
On the basis of their immunomodulatory properties, PPAR agonists may have beneficial
effects in transplant rejection. A mainstay of the in vitro evaluation of potential
therapeutic agents for transplantation is the primary mixed leukocyte reaction (MLR). In
that model, lymphocyte stimulation is fundamentally based on the phenomenon of
allorecognition, a process central to transplant rejection. The overall goal of the research
presented in this chapter is the characterization of the immunomodulatory effects of
several PPAR agonists (shown in figure 3.1) on the MLR, and, for comparison, on
splenocyte stimulation independent of allorecognition, namely Concanavalin-A
mitogenesis. This encompasses dose response assays on proliferation and cytokine
production, as well as investigation into potential cell viability issues, and detailed
analysis of mRNA expression of a variety of cytokines, chemokines and chemokine
receptors.
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0 CO2 CH(CH3 )2NC
Fenofibrate
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1"r N TrI
H
15-deoxy A12"14 , ProstaglandinJ 2
Figure 3.1: Schematics of the structures of the four PPAR agonists evaluated: Two
agonists are directed towards PPARc, namely fenofibrate (FENO) and Wy14643 (WY),
while the other two agonists are directed toward PPARy, namely BRL49653 (BRL) and
15-deoxy A2"14 Prostaglandin J2 (PGJ2).
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3.2 Methods
Mice
Two inbred strains of mice, C57/BL6 and Balb/c (Jackson Laboratories, Bar Harbor),
approximately six to eight weeks old, were housed in the animal facility of Harvard
Medical School on acidified water and chow ad libitum. Sentinel mice were co-housed in
each room and were surveyed to ensure that that the facility was free of viral pathogens.
Experiments were done according to protocols approved by the animal care committee.
Splenocyte isolation
Spleens were extracted and ground, using the barrel of a 5 ml syringe, against fine silver
mesh screen in a sterile culture dish. RPMI medium (Invitrogen, Carlsbad) supplemented
with 10% fetal bovine serum, non-essential amino acids, L-glutamine, HEPES buffer,
sodium pyruvate, penicillin, streptomycin and mercaptoethanol (denoted as C-10) was
added to the dish and the resulting solution was transferred to a 15 ml conical tube. The
tubes were centrifuged for 5 minutes at 800 g. Supernatants were aspirated and cells were
resuspended in 5 ml of tris ammonium chloride buffer (1:10 dilution of tris buffer and
0.83% NaCl) for 5 minutes at 370 C to lyse the red blood cells. C-10 medium was added
to a volume of 15 ml and the tubes were centrifuged for 10 minutes at 800 g.
Supernatants were aspirated, cells resuspended in 10 ml of C-10, and counted using a
hemocytometer; viability was also assessed by trypan blue exclusion and uniformly
exceeded 98%. Cells were resuspended at a concentration of 107 cells per ml and kept on
ice until plating.
PPAR agonists
For PPARc agonists, the concentrations ranged from 0 to 100 iim for fenofibrate (Sigma,
St Louis), and from 0 to 500 tm WY 14643 (Biomol, Plymouth Meeting). For PPARy
agonists, the concentrations ranged from 0 to 50 tm for BRL49653 (Cayman Chemicals,
Ann Arbor) and from 0 to 10 Etm for 15-deoxyA'2 '14 -Prostaglandin J 2 (Cayman Chemicals,
Ann Arbor). In order to achieve the final concentrations and ensure simultaneous
exposure of cells to the agonists, solutions with prefinal concentrations of double the
desired ones were prepared and serially diluted. This allowed the cells to be resuspended
in C-10 with no drugs.
Proliferation assays
C57/BL6 splenocytes were stimulated both in the setting of a mixed leukocyte reaction
(MLR; via co-culture with radiation-inactivated allomismatched splenocytes from Balb/c
mice), and following the addition of Concanavalin-A (ConA). For both conditions, 100 1
of C-10 with PPAR agonists were first added in quadruplicate to 96-well plates, in the
concentrations as described above. In the MLR, Balb/c splenocytes were inactivated by
3000 rads of gamma radiation and are referred to as "stimulators". To each of the wells
already plated with PPAR agonist-containing drug, 50 l of C57/BL6 splenocytes
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("responders") were added, for a total volume of 200 [tl per well. Responder and
stimulator control sets were plated in quadruplicate by adding 50 Al of the respective cell
type and 50 tl of C-10 to the wells with the PPAR agonist-containing drug. For ConA
stimulation, the culture preparation was similar to the above except that instead of adding
50 [tl of stimulator cells, 50 tl of ConA solution at 4 Dg per ml was added, for a final
ConA concentration of 1 [tg per ml. Furthermore, while responder alone wells were
plated in quadruplicate, as in the MLR, no stimulator alone wells were plated in the
ConA assays. To measure proliferation, 25 tl of 3H-thymidine (NEN, Boston) was added
to the plates every day up to 5 days; after six hours, the plates were placed in the freezer
to stop the reaction. Plates were subsequently thawed and 3 H-thymidine incorporation
assessed by a standard beta scintillation counter.
Enzyme-linked immunosorbent assays
The concentration of IFNy in the supernatants of the proliferation assays was determined
using enzyme-linked immunoassays (ELISAs) as per the manufacturer's protocol
(Pharmingen, San Diego). Unless otherwise noted, all antibodies were from Pharmingen
and all incubations done at room temperature. Specifically, plates were coated by adding
50 tl per well of purified anti-IFNy at 2 tg/ml diluted in carbonate buffer (0.1 M
NaHCO 3 and 0.1M NaCO3, pH 9.0) and incubated overnight at 40 C. Plates were then
washed twice with PBS, that was supplemented with 1% Triton-X (Sigma, St. Louis).
Plates were blocked by the addition of 100 dtl per well of borate buffered saline (0.17M
borate and 0.12 M NaCl in distilled water, pH 8) containing with 2% bovine serum
albumin. After two hours of incubation, plates were again washed two times and samples
were added, in addition to a standard curve made from murine recombinant IFNy diluted
in C-10. Following another overnight incubation, plates were washed four times and 50
Ed of biotinylated anti-IFNy at a concentration of 1 [tg/ml was added to each well. Plates
were incubated for 45 minutes and washed six times, followed by 50 D1l of Avidin-HRP
(at 1:1000) 30 minutes. Plates were washed six times and developed by first adding 100
pl per well of citrate buffer (0.1M citrate) and then adding 50 tl of a solution where 2.17
mg of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (Sigma, St. Louis) and 5 ml of
30% H2 0 2 (Sigma, St. Louis) are dissolved per 5 ml of citrate buffer. The concentration
of IFNy was indicated by development of a green color in the wells. Optical density was
measured using a plate reader and was converted to pg/ml using a calibration curve. Data
analysis of optical density was done using the "Softmax" software (Molecular Devices
Corporation).
Propidium iodide staining and flow cytometry
Spleens were isolated as stated above, plated in 12-well culture plates and stimulated with
ConA at a final concentration of 1 tg/ml with and without PPAR agonists at selected
concentrations. The same volume ratios were maintained as in proliferation assays. After
12 hours, cells were scraped from the bottom of the culture wells and aliquoted into
plastic tubes typically used for flow cytometric assays. Tubes were centrifuged for 10
minutes at 800 g in the Beckton Table Top centrifuge and supernatant was decanted. One
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of the tubes containing the splenocytes cultured in medium alone was kept on ice (serving
as the "unstained" control). To the other tubes (including one with untreated cells and the
others treated with a PPAR agonist), 500 tl of a 1 mg/ml propidium iodide/PBS solution
(Sigma, St. Louis) was added. After incubation in the propidium iodide solution for 5
minutes at room temperature, cells were immediately analyzed by flow cytometry.
RNA isolation
Splenocytes were isolated using the above technique and cultured in bulk for varying
amounts of time with selected PPAR agonist concentrations. Cells were then scraped and
transferred to 15 ml conical tubes, followed by centrifugation. Supernatants were
aspirated and the cell pellets were homogenized in 1 ml of TRIzoL reagent (Invitrogen,
Carlsbad), per manufacturer's instructions. To ensure more complete homogenization,
cells were repeatedly passed through a 1 ml syringe with a 20- or 21- gauge needle. The
homogenized solution was transferred to a 1.5 ml microcentrifuge tube and 0.2 ml of
chloroform per ml of TRIZOL was added. Tubes were shaken vigorously for 15 minutes
by hand to create an emulsification. After a five-minute incubation at room temperature,
tubes were centrifuged for 20 minutes at 14,000 rpm in a microcentrifuge. The upper
aqueous phase was transferred to another microcentrifuge tube and 0.5 ml of isopropanol
per ml of TRIzoL was added. The incubation was carried out for 15 minutes at room
temperature. Samples were centrifuged for 10 minutes at 40 C and the supernatant was
removed before the addition of 1 ml of 75% ethanol per ml of TRIzoL. Samples were
quickly vortexed and centrifuged for 5 minutes at 8,000 rpm. The supernatant was
discarded and samples air dried for 5 to 10 minutes. The RNA pellet was dissolved in 50
to 100 [l of RNase-free DNase-free water and incubated for 10 minutes in a dry water
bath at 55 to 600 C, before being placed on ice. RNA content was quantified by measuring
absorbance at 260 mm. Aliquots with the desired RNA amounts were then prepared for
storage at -700 C until analysis using the RNase protection assay.
RNase protection assays
The mRNA expression of stimulated splenocytes from bulk cultures was determined
using the RNAse protection assay (RPA), per the manufacturer's protocol (Pharmingen,
San Diego). Specifically, the following murine multi-probe templates were used: mcK-1
(containing templates for IL-4, IL-5, IL-10, IL-13, IL-15, IL-9, IL-2, IL-6, IFNy, L32,
GAPDH), mcK-2b (containing probes for IL-12p35, IL12-p40, IL-10, IL-la, IL-1S, IL-
IRa, IL-18, IL-6, IFNy, MIF, L32, GAPDH), mcK-Sc (containing probes for
lymphotactin, RANTES, MIP-13, MIP-lc, MIP-2, IP-10, MCP-1, TCA-3, Eotaxin, L32,
GAPDH) and mcR-5 (with probes for CCR1, CCRlb, CCR3, CCR4, CCR5, CCR2, L32,
GAPDH). In brief, probes were synthesized, using c 32 P-UTP (NEN, Boston) in addition
to RNasin, GACU pool, DTT and T7 RNA polymerase, incubating for 1 hour at 370 C.
The reaction was terminated by the addition of DNase and subsequent incubation for 30
minutes at 370 C. A mixture of EDTA, tris-saturated chloroform-isoamyl alcohol-phenol
and yeast tRNA was added to the probe and vortexed into an emulsion. After a brief
centrifugation, the upper aqueous phase was transferred to a fresh microcentrifuge tube
and the RNA was precipitated by the addition of ammonium acetate and 100% cold
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ethanol, and incubation at -700 C for a minimum of 30 minutes. Following centrifugation
for 15 minutes and a wash of the pellet with cold 90% ethanol, the probe was dried,
dissolved in 50 tl of hybridization buffer and stored at -200 C until use. Probe yield was
quantitated using duplicate 1 ml samples in a scintillation counter, with lower acceptable
activity being approximately 3x10 5 cpm per ml. Given an acceptable probe yield, samples
were dried and (following the addition of 8 Etl of hybridization buffer and 2 l of probe
diluted at the optimal strength, per manufacturer specifications) hybridized for 12 to 16
hours in a dry heat bath ranging in temperature from 55 to 600 C. Samples were then
digested using a mix of RNAse A and T1, and subsequently treated with proteinase K. A
solution containing tris-saturated chloroform-isoamyl alcohol-phenol was added to each
sample. After a quick vortex and centrifugation, the upper phase, containing the protected
RNA fragments, was transferred to fresh tubes for precipitation with 100% cold ethanol
in the presence of ammonium acetate. Samples were incubated for over 30 minutes at
-700 C and, following a 15-minute centrifugation, washed with cold 90% ethanol. After
drying, samples were resuspended in loading buffer, denatured via incubation in a 900 C
dry water bath and loaded onto a 5% acrylamide-urea sequencing gel made using the
Sequagel Sequencing Kit (National Diagnostics, Atlanta). 32 P-labelled probes were also
loaded, serving as band identification markers. Electrophoresis was performed at a
constant power of 50W. The gel was dried under vacuum and exposed on a phosphor
screen. Quantification of band intensities was performed using "ImaqeQuant" (Molecular
Dynamics). The volume integrations of each band were normalized to the bands for
GAPDH in the corresponding lane. Samples were run in triplicate and results are
presented as the average and standard deviation of each group.
Data analysis
Three experiments were performed for each of the four agonists in both ConA and MLR
cultures. Unless otherwise noted, results are expressed as the mean and standard
deviation of the mean of a representative experiment plated in triplicate to quadruplicate.
Statistical analysis was performed using Student's t test, where p<0.05 was considered
statistically significant.
3.3 Results
This section first presents results of increasing PPAR agonist concentrations on
proliferation and IFNy production in splenocyte cultures following stimulation with
ConA and via MLR. Cell viability was addressed with propidium iodide staining and
flow cytometry. Finally, the effects of PPAR agonists on the mRNA expression of a
variety of cytokines and chemokines, as well as chemokine receptors, are also presented.
Figure 3.2 shows lymphocyte proliferation and IFNy production following stimulation
with ConA and in the setting of an MLR. With ConA stimulation, proliferation peaks
around day 2 and is higher in magnitude compared to the MLR, where proliferation peaks
on day 4. IFNy concentrations are higher and seen at day 2 in the ConA cultures, while in
the MLR it is lower and not seen until day 3. Controls of non-stimulated responder cells
and stimulator alone cells (in the MLR) were also performed (not shown for clarity).
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Figure 3.2: Proliferation and IFNy concentration as a function of time: a) ConA
stimulation, proliferation peaks at day 2 and IFNy levels become significantly elevated by
day 2; b) MLR, proliferation peaks on day 4 and IFNy levels become significant on day
3. Proliferation peaks earlier and is of higher magnitude in ConA cultures compared to
MLRs. Furthermore, IFNy production begins earlier and is also of higher magnitude in
the ConA cultures compared to MLRs. Results are expressed as the mean and standard
deviation of three experiments plated in triplicate to quadruplicate.
Dose Response
The effect of varying PPAR agonist dose on both proliferation and IFNy production over
5 days was tested following stimulation with ConA, and in the setting of the MLR.
Figures 3.3, 3.4, 3.5 and 3.6 show the dose response results for fenofibrate (FENO),
Wy14643 (WY), BRL49653 (BRL), and 15-deoxy A'12 14 PGJ 2 (PGJ2), respectively.
Results are expressed as the mean and standard deviation of one representative
experiment from a set of three, plated in triplicate to quadruplicate. The thickened plot
markers indicate the day of peak proliferation and the first day of elevated IFNy
production.
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Figure 3.3: Dose-dependent effects of FENO on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that FENO concentrations up to 20 FiM have
no significant effects on cell proliferation, while concentrations of 100 AtM and above
significantly decrease it; IFNy production is significantly decreased at concentrations
beginning with 20 FiM; b) MLR, FENO concentration of 20 FM significantly decreases
IFNy without effects on proliferation, while higher concentrations diminish both
proliferation and IFNy production. These results indicate 20 M as the "therapeutic"
FENO concentration. Results are expressed as the mean and standard deviation of one
representative experiment from a set of three, plated in triplicate to quadruplicate. The
thickened plot markers () indicate the day of peak proliferation and the first day of
elevated IFNy production.
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Figure 3.4: Dose-dependent effects of WY on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that WY concentrations up to 100 ~tM tend
to increase cell proliferation, while concentrations of 250 EiM and above significantly
decrease it; IFNy production is significantly decreased at concentrations beginning with
100 tM; b) MLR, WY concentration of 100 ytM significantly decreases IFNy without
effects on proliferation, while higher concentrations diminish both proliferation and IFNy
production. These results indicate 100 [tM as the "therapeutic" WY concentration.
Results are expressed as the mean and standard deviation of one representative
experiment from a set of three, plated in triplicate to quadruplicate. The thickened plot
markers () indicate the day of peak proliferation and the first day of elevated IFNy
production.
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Figure 3.5: Dose-dependent effects of BRL on proliferation and IFNY production: a)
ConA simulation, proliferation assays show that BRL concentrations up to 50 tM have
no significant effects on cell proliferation, IFNy production is significantly decreased at
concentrations beginning with 10 EtM; b) MLR, BRL concentration of 10 iM and above
significantly decrease IFNy without significant effects on proliferation. These results
indicate 10 IM as the "therapeutic" BRL concentration. The concentration range tested
did not include any toxic doses, based on results from proliferative assays. Results are
expressed as the mean and standard deviation of one representative experiment from a set
of three, plated in triplicate to quadruplicate. The thickened plot markers () indicate the
day of peak proliferation and the first day of elevated IFNy production.
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Figure 3.6: Dose-dependent effects of PGJ2 on proliferation and IFNy production: a)
ConA simulation, proliferation assays show that while PGJ2 concentrations up to 3 tM
have no significant effects on cell proliferation, while 10 FtM results in a marked
decrease; IFNy production is significantly decreased at 3 M and above; b) MLR,
similarly, PJ2 concentrations of 3 M significantly decrease IFNy without significant
effects on proliferation, while 10 FfM decreases both proliferation IFNy production. These
results indicate 3 M as the "therapeutic" PGJ2 concentration. Results are expressed as
the mean and standard deviation of one representative experiment from a set of three,
plated in triplicate to quadruplicate. The thickened plot markers () indicate the day of
peak proliferation and the first day of elevated IFNy production.
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The PPARa agonists show different "therapeutic" and "supratherapeutic" doses. As seen
in figure 3.3, at fenofibrate (FENO) concentration of 20 tM, there is a significant
decrease in IFNy production, despite comparable proliferation rates. At fenofibrate
concentrations of 100 and 500 tM, no proliferation is measured and no IFNy produced.
Based on these results, 20 FiM is a "therapeutic" concentration, while concentrations
above 100 ptM is toxic. As shown in figure 3.4, the concentrations of WY14643 (WY)
had no significant effects on proliferation at 100 tM, despite significant decreases in
IFNy production at 100 tM. At 250 tM, peak proliferation decreased (as well as
proliferation on all days of the MLR), while at 500 M, no proliferation was observed.
Figure 3.5 shows the results obtained with PPARy agonists. BRL49653 (BRL) had no
significant effects on cell proliferation up to the highest dose tested. Significant
reductions in IFNy concentrations, however, were observed at 10 tM and above. Finally,
experiments with the natural PPARy ligand, (PGJ2), showed no inhibitory effects on
proliferation up to 3 EtM, at which concentration, there was a tendency to increase
proliferation. However, at 3 ~M a significant decrease is observed in IFNy production. At
a concentration of 10 tM, there is a lack of proliferative response, corresponding to lack
of IFNy production. These results indicate that 3 ~FM is a "therapeutic" concentration,
while 10 EtM is "supratherapeutic".
Cell viability
To address potential cell viability issues associated with the use of PPAR agonists in
culture, ConA-stimulated splenocytes were incubated in the selected "therapeutic" and
"supratherapeutic" concentrations of all PPAR agonists for 2 and 12 hours and stained
with propidium iodide. Flow cytometry results for the 2 hours incubation are presented in
figure 3.7, while those for the 12 hours incubation are shown in figure 3.8. After two
hours, there was no significant change in cell viability at any of the doses tested. After 12
hours, however, while the therapeutic doses continued to show no significant changes,
while the "supratherapeutic" concentrations showed increased amounts of cell death, with
FENO and PGJ2 the most dramatic of the three. Therefore, the previously identified
"supratherapeutic" doses that suppressed proliferation and IFNy production correspond to
doses at which significant cell toxicity is observed.
It is stressed that the propidium iodide staining protocol used in this thesis assessed
effects on cell viability rather than cell cycle. Cell cycle analysis requires cell fixation,
membrane solubilization and RNA degradation, such that the levels of propidium iodide
staining accurately reflect DNA measurement. Instead, the determination of cell viability
requires the addition of only propidium iodide to the cells followed by flow cytometry
(without cell fixation, nor membrane solubilization, nor RNA degradation), such that
effects on cell cycle cannot be determined. Thus, in this live/dead version of propidium
iodide staining, any positive staining implies increased membrane permeability, allowing
the propidium to bind and denoting cell death.
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Figure 3.7: Cell viability after two hours of incubation with four PPAR agonists: flow
cytometric analysis of propidium iodide staining with a) FENO at 20 and 500 rM; b) WY
100 and 500 M; c) BRL, 10 FM and 50 FM; d) PGJ2 at 3 and 10 FiM. There are no
significant effects on cell viability with any of the agonists. The filled areas represent the
cells incubated with the designated agonist concentration, while the green line represents
cells incubated with medium alone. An increase in the area under the M1 marker
represents cells with increased membrane permeability allowing the dye to bind, and
thereby denoting cell death.
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Figure 3.8: Cell viability after twelve hours of incubation with four PPAR agonists: flow
cytometric analysis of propidium iodide staining with a) FENO at 20 and 500 tM; b) WY
100 and 500 ItM; c) BRL, 10 and 50 tM; d) PGJ2 at 3 and 10 tM. There are no
significant effects on viability at the therapeutic concentrations, while there is increased
cell death at the supratherapeutic levels. The filled areas represent the cells incubated
with the designated agonist concentration, while the green line represents cells incubated
with medium alone. An increase in the area under the M1 marker represents cells with
increased membrane permeability allowing the dye to bind, and thereby denoting cell
death.
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mRNA expression
Having established effective in vitro doses of the four PPAR ligands with respect to
diminished IFNy production, the same concentrations were used to examine other
potential effects of these four PPAR ligands. Included were analyses of the expression of
other cytokines as a function of time in both ConA and MLR cultures. Figure 3.9 shows
that in both cultures, IFNy is the dominantly expressed. In ConA cultures, it peaks after
one day of stimulation, while in the MLRs, the peak occurs after two days. The extent of
expression at peak time is significantly higher in ConA cultures. By the last day of
culture, the expression of IFNy is comparable to that of other cytokines, e.g. IL-2, IL-4,
IL-6 and IL-10.
There are also distinct effects on other cytokines. For example, IL-2 expression is
several-fold higher in the ConA cultures compared to MLR (although, the proportion to
IFNy, is roughly similar), which may be a major contributing factor to the higher levels of
proliferation observed in splenocytes stimulated with ConA. The expression of IL-12 and
IL-18 up to clay 2 of the ConA cultures and day 3 of the MLR cultures are approximately
two-fold higher in the MLR compared ConA, suggesting that activation based on specific
MHC differences potentiates the role of these two cytokines. With respect to IL-4, the
ratio of its expression to that of IFNy is dramatically increased in the MLRs.
The effect of adding the previously determined therapeutic concentrations of PPAR
agonists to both cultures was determined for the day of peak IFNy mRNA expression
yields. The expression profiles of selected cytokines from the two panels tested are
shown in figure 3.10. As expected, based on the extensive proliferation and cytokine
production data presented in the previous figures, all PPAR agonists markedly and
significantly decrease expression of IFNy mRNA, to approximately 50% of the original
value. However, there are no significant effects on IL12-p35, no decreases in IL-12p40 or
IL-18. In fact, with the exception of WY, PPARa agonists statistically, yet to a small
degree, increase IL-12p40 and IL-18 in both cultures.
In comparison to IFNy, the effects on other cytokines are less marked. Thus, changes in
IL-2 and IL-6 mRNA are less dramatic in comparison to the effect on IFNy. Interestingly,
PPARc agonists increased IL-2 mRNA expression in both ConA and MLRs, while
PPARy agonists had no significant effects in the ConA cultures and mixed effects on the
MLR (BRL had no effect on IL-2, PGJ2 increased it). With respect to IL-6 mRNA, it was
significantly decreased by PGJ2 in the ConA cultures, and significantly increased by WY
in the MLRs. It must be emphasized that the initial level of IL-6 expression was quite
low, less than 0.05 when normalized to GAPDH, and no agonist raised it above 0.05,
rendering it a relatively insubstantial player in the culture. As a group, PPAR agonists
had no significant effects on IL-4 mRNA expression under either stimulation, although
they significantly increased IL-10 mRNA expression in the ConA cultures. In the MLR,
however, only WY and PGJ2 increased IL-10 mRNA expression to a varying extent.
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Figure 3.9: Cytokine mRNA expression as a function of time: a) ConA stimulation, IFNy
is the dominant cytokine, with a peak at day 1, followed by a return to baseline and a
potential beginning of a second wave of cytokine production on day 3; b) MLR
stimulation, IFNy is also the dominant cytokine in this culture, with a peak occurring at
day 2. As a technical note, cultures for the top and bottom of the figure were set up
simultaneously, such that comparison between them shows that IFNy at peak times is
significantly higher for ConA mitogenic stimulation.
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Figure 3.10: Effect of PPAR agonists on cytokine mRNA expression on the day of
maximal IFNy mRNA expression: a) ConA, day 1; b) MLR, day 2. The most marked
effect of PPAR agonists as a group is decreased IFNy expression. Statistical significance
(p<0.05) relative to cultures without PPAR agonist treatment is denoted by an asterisk
(*). Legend key is as follows: 0 for 0 FtM (control, no PPAR agonist), F for FENO, W for
WY, B for BRL, J for PGJ2.
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Because reduced IFNy could conceivably lead to augmented expression of IL-4 and IL-
10, levels of' IL-4 and IL-10 mRNA were examined throughout the culture time course.
Figure 3.11 displays the results of this analysis. While the other PPAR agonists tend to
increase IL-4, WY is the only one that consistently results in increased IL-4 mRNA
expression. On day 4 of the MLR, WY continues to sustain a significant increase in the
expression of IL-4 mRNA. With the exception of BRL, early effects of PPAR agonists
enhance IL-10 mRNA expression. Following a transition on day 3, where agonists such
as FENO begin to exhibit inhibitory effects on the expression of IL-10 mRNA, the last
day of MLR culture shows that IL-10 mRNA expression is not significantly affected by
WY or BRL but is significantly decreased by FENO and PGJ2. Looking at the decreasing
trend exhibited by WY over the duration of the culture, it appears that at culture times
past day 5, WY may result in a significant decrease in IL-10 mRNA expression
a) IL-4 mRNA
b) IL-10 mRNA
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Figure 3.11: Effect of PPAR agonists on IL-4 and IL-10 mRNA expression in the MLR
over time: mRNA expression of a) IL-4 and b) IL-10 in the MLR changes in response to
the addition of PPAR agonists to the cultures as a function of time. While the other
cytokines tend to increase IL-4 mRNA, WY is the only one that consistently results in
increased IL-4 mRNA expression. On day 4 of the MLR, WY continues to sustain a
significant increase in the expression of IL-4 mRNA. Expression of IL-10 mRNA is not
significantly affected by WY, but is significantly decreased by FENO and PGJ2, and not
affected by BRL.
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The expression of chemokine and their receptors as a function of time for both ConA and
MLR cultures is shown in figures 3.12 and 3.13. Once again, as in the analysis of
cytokine mRNA expression, there are several differences between the ConA and MLR
profiles. In the ConA cultures, there is a steady decrease in chemokine expression,
beginning at 12 hours; the chemokine with the highest expression is MIP-1, with the
next two being RANTES and MCP-1. The MLRs demonstrate a clear peak in expression
at day 2 of all chemokine mRNA species except MCP-1, whose expression on days 1 and
2 is roughly the same. In the MLR, RANTES is by far the most dominant chemokine
with mRNA expression levels two fold higher than the next two most abundantly
expressed, MIP-13 and MIP-lc, in that order. In both cultures, the least expressed
chemokine is IP-10. Chemokine receptor expression is also different between the two
cultures. Overall, the level of mRNA expression is higher in the MLR cultures. In the
MLRs, CCR5 appears to be the dominant receptor expressed on days 2 and 4, with CCR2
emerging as the second most abundant chemokine receptor by day 4. In the ConA
cultures, CCR5 and CCR4 are the two most abundantly expressed receptors over all days,
except 3, where CCR4 expression falls to levels of CCR1 and CCR2.
The effects of PPAR agonists on chemokines and chemokine receptors are shown in
figures 3.14 and 3.15, respectively. In the ConA cultures, on the day of maximal mRNA
expression (0.5 day), RANTES, MIP-la, MIP-11 and IP-10 are all significantly
decreased by addition of PPAR agonists, while MCP-1 remains unchanged. On day 2 of
the MLR, however, mRNA expression of all the chemokines tested is not significantly
affected by addition of the PPAR agonists. With respect to chemokine receptor mRNA
expression, in the ConA cultures, PPARca agonists significantly increase CCR1 and
CCR2, have no significant effect on CCR4, and demonstrate variable effects on CCR5.
PPARy agonists have no significant effect on CCR1 and CCR4, significantly decrease
CCR5, and increase CCR2 with variable significance. In the MLR, there is great
variability, particularly with respect to PPARa agonists: fenofibrate decreases CCR1,
tends to increase CCR4 and CCR5 (without reaching statistical significance) and
increases in CCR2; WY causes significant and marked increases in expression of all
receptors tested. PPARy agonists have no significant effects on CCR1, CCR2 or CCR4;
as to CCR5, BRL has no effect, while PGJ2 significantly decreases. The relative control
mRNA expression of chemokines and receptors is consistent with that in figure 3.13.
Finally, in light of the increase in RANTES mRNA on day 4 in the MLR, as well as the
overall increase in chemokine receptor mRNA expression, the effect of PPAR agonists
was assessed on day 4 of the MLR, as shown in figure 3.16. All of the PPAR agonists,
except FENO, cause modest decreases in RANTES and dramatic increases in MIP-la
and MIP- 13 (two- to four-fold) mRNA. FENO, on the other hand, results in only modest
increases in RANTES and MIP-1, and does not affect MIP-lac mRNA. The only other
significant changes are the increases in IP-10 by WY and in MCP-1 by WY and PGJ2.
With respect to receptors, all agonists have no effect on CCR1 and markedly decrease
CCR2 and CCR5 mRNA. The effect on CCR4 is variable, ranging from a decrease
(FENO) to no change (WY and BRL) to an increase (PGJ2). Relative expression of
chemokines in control samples is consistent with that shown in figures 3.13 and 3.14.
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Figure 3.12: Chemokine mRNA expression as a function of time: a) ConA, mRNA
expression decreases as a function of time, with MIP-f and RANTES as the chemokines
with highest: levels of mRNA expression at the peak time of 12 hours; b) MLR,
chemokine mRNA expression peaks on day 2 (with the exception of MCP-1), with
RANTES appearing to be the most dominant cytokine on the day of peak mRNA
expression.
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Figure 3.13: Chemokine receptor mRNA expression as a function of time: a) ConA
stimulation, CCR5 and CCR4 are the two most abundantly expressed receptors over all
days except the third and last day, where CCR4 levels falls to similar levels as CCRland
CCR2; b) MLR stimulation, CCR5 appears to be the dominant receptor, with mRNA
expression peaking on days 2 and 4; CCR2 emerging as the second most abundantly
expressed chemokine receptor by the fourth and last day of culture.
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Figure 3.14: Effect of PPAR agonists on chemokine mRNA expression: a) ConA, 12
hours, decrease in all chemokines except MCP-1 by all agonists (exception IP-10 by F);
b) MLR, day 2, no significant changes by any of the agonists tested. Statistical
significance (p<0.05) relative to cultures without PPAR agonist treatment is denoted by
an asterisk (*). Legend key is as follows: 0 for 0 tM (control, no PPAR agonist), F for
FENO, W for WY, B for BRL, J for PGJ2.
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Figure 3.15: Effect of PPAR agonists on chemokine receptor mRNA expression: a)
ConA, day 1, PPARca agonists increase CCR1 and CCR2, while PPARy agonists increase
CCR2 and decrease CCR5; b) MLR, day 2, WY increases all chemokine receptors, while
FENO increases CCR2 and PGJ2 decreases CCR5. Statistical significance (p<0.05)
relative to cultures without PPAR agonist treatment is denoted by an asterisk (*). Legend
key is as follows: 0 for 0 i[M (control, no PPAR agonist), F for FENO, W for WY, B for
BRL, J for PGJ2.
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Figure 3.16: Late effects of PPAR agonists on chemokine and chemokine receptor
mRNA expression on day 4 of the MLR: a) chemokines, marked increase in MIP-ola and
MIP-13 by all agonists, except fenofibrate, which, increases RANTES, while other
agonists decrease it; b) chemokine receptors, uniform decrease in CCR2 and CCR5.
Statistical significance (p < 0.05) relative to cultures without PPAR agonist treatment is
denoted by an asterisk (*). Legend key is as follows: 0 for 0 fM (control, no PPAR
agonist), F for FENO, W for WY, B for BRL, J for PGJ2.
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3.4 Discussion
For the first time the effects of four PPAR agonists, two PPARca agonists (fenofibrate and
Wy14643) and two PPARy agonists (BRL49653 and 15-deoxy A'12 14 PGJ2), have been
examined in an in vitro model of an alloresponse, namely the mixed leukocyte reaction.
Experiments were also performed with ConA-stimulated splenocytes and comparison
revealed critical differences, pointing to the need for specific testing in the alloresponse
setting for potential translation to in vivo transplant rejection. Dose response studies
identified the "therapeutic" dose, defined as the dose at which a decrease in IFNy is
achieved without a concomitant decrease in proliferation; flow cytometric analysis of
propidium iodide staining confirmed cell viability at therapeutic doses. The effects of
PPAR agonists at therapeutic concentrations on cytokine, chemokine and chemokine
receptor expression profiles was determined, following a thorough examination of the
same as a function of time. Based on effects on the in vitro alloresponse, implications for
PPAR agonist therapy in transplant rejection are discussed in depth and a candidate for in
vivo trials in transplant rejection is identified.
Dose response results using fenofibrate show that 20 FiM significantly decreases IFNy
production without decreasing proliferation or affecting viability. This result is in line
with the observations of functional effects without decreased cell viability in other
assays, e.g. decreased VCAM-1 expression and monocyte adhesion l;ivati tH ' i; '2/C~321.
The decreased proliferation observed in the results of this chapter at 100 FM of
fenofibrate suggests a possible detrimental effect on viability and hence a potential
difference compared to the literature sia 2'S'.? .2'2 c~ ' 2( i-210. Two reasons
could be responsible. One could be in the varying exposure times; studies in the literature
treated the cells for only 2 hour s5I;X 2 ': : .X 2o( )('1 I v:l c: as ' : /0i2 i. 21, while in this thesis,
there was continuous treatment. This hypothesis finds support in the propidium iodide
results showing that even at the highest doses, PPAR treatment for only 2 hours does not
diminish cell viability. Another potential explanation is that human and murine cells may
have differential sensitivity to fenofibrate i :..')'"t C'l ' 2'1 3
Dose response results identified 100 tM of WY as sufficient to significantly decrease
IFNy, with no decrease in proliferation. These results are consistent with other studies
that find no significant effects on cell proliferation or viability up to 100 tM t \';amr'5 <Iel c:;
'.. i xs .M3... $ 0,~. '','.' ~.(' '5 i c:' '3, at which concentration significant
reduction in the levels of IFNy are found in treated anti-CD3 stimulated human T cells
1i :si.?- ~': a;k "i. i2% S.. Results in this thesis suggest possible effects on proliferative capacity
at 250 EM, more so in the MLR setting, compared to ConA stimulation, where the
decrease in proliferation was not sustained by the third day of culture (further implying
that studies done at that time point alone may not show decreases in proliferation).
However, this was not investigated further, since the goal of this research was to find the
lowest possible dose that would reach the desired endpoint; this is particularly important
with PPAR agonists, since high doses can activate PPAR isoforms other than the ones
classically ascribed to an agonist I 3 2i st'h '.:i 13n i;: i:,.,~,.~
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With respect to BRL, dose response results show that at 10 FM, a significant decrease in
IFNy production is seen, while proliferation is not affected. This is consistent with
experiments using human anti-CD3 stimulated T cells, which also showed decreased
TNFa INl\ - ,,- f '.¥,'2.:02 ~?. The concentration of 10 [tM has been widely used in the
literature to demonstrate effects, including decreased vascular smooth muscle cell
migration 1e,:'.Qfe .,.? ?.: ~.,t)I, and endothelial cell MHC-II expression l Kw:vk ;i ' s'?
'002 f. It should be noted that the effects of BRL are affected by stimulation conditions
and cell type. For example, treatment with 10 gM had no effect on IL-6 production by
human smooth muscle cells 1'i:;eds " i ? !?~9¢t``, yet significantly reduced the IL-6
produced by human monocytes .i'.c <*S.is , ,(!2 !. BRL doses above 10 M may have
PPARy-independent effects \te!h .,' ,.? 2't'II3; , supporting the choice of 10 FiM as the
"therapeutic" concentration.
Finally, using PGJ2, the decrease in proliferation and cell viability observed at 10 tM is
in agreement with other results documenting a decrease in proliferation in murine and
human T cells I Y'N .*? /', ?d _,tio; ~ --' Ui S,S , ., as well as the induction of apoptosis
in murine T cells iHirS :nd i: hipj 2i01 . At lower concentrations (e.g. 3 FiM), there
was no effect on human endothelial cell or murine macrophage viability t1Covis eN,,Ql .-'
?,'' ziv?'7!^4 [,.l tit ~:.' ?"/2 !(f). The decrease in proliferation observed around 3 FM by some
'-Xari 5 tn- -d. i5ip. 2 ( .?lt tar ' c  ?)() Imay be specific to a particular assay, since in
one of the same studies, stimulation with IL-2 increased the rate of T cell proliferation at
these same concentrations i('iulk (o.: K'2(0 . The ability of PPARy agonists to induce
apoptosis in murine DO. 11-derived T cells were not recapitulated in C3H/10T 1, 2-derived
T cells, suggesting strain-specific sensitivity It-.rrK'is :, i Ptil¥>: .0t i. One of the first
studies reporting immunomodulatory effects in macrophages following PPARy activation
used 3 tM PGJ2 I.te i.- , o ( I' 5 8. Therefore, the lack of an effect on proliferation or
viability observed at 3 FM of PGJ2 is not inconsistent with the existing literature.
IFNy is the only cytokine of the ones tested whose expression is uniformly and markedly
decreased by all of the PPAR agonists used at the therapeutic concentrations described
above. The decrease is to approximately 50% of initial levels. As can be seen from the
graphs of cytokine expression profiles as a function of time, IFNy is the dominant
cytokine in culture. Consistent with the proliferation and protein concentration profiles
shown in the dose response figures, IFNy expression is different between ConA and MLR
cultures. In the ConA cultures, it begins earlier and is higher than in the MLRs,
explaining the earlier appearance of IFNy protein, as well as the higher concentrations. It
should be noted that for each panel of cytokines the ConA and MLR analyses were
performed at the peak of IFNy mRNA expression. The differences between peak values
of IFNy expression between the two panels of cytokine expression for the same culture
condition underscore the sensitivity of mRNA expression to time.
Given the reported IFNy-inducing abilities of both IL-12 and IL-18 I S:tlerxsalsa ad.l
;r~e >r i i'~:.' X,.':! ir -} ')0(.XX:' i:' ect. ,.' ~ , e' A i" , ( 1 the finding that PPAR agonists diminish
IFNy without causing a concomitant decrease in either IL-12 or IL-18, suggests a direct
effect of PPAR agonists on IFNy. Recent evidence corroborates a direct effect of PPAR
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activation on IFNy, with one study demonstrating attenuation of IFNy-induced STAT1
phosphorylation, nuclear localization and DNA binding E tVbebr . al 2.OO31. PPARa
agonists, fenofibrate and WY, increase IL12-p40 only in the MLR and increase IL-18 in
both ConA and MLR cultures. PPARy agonists, BRL and PGJ2, have no effect on IL-12
and tend to increase IL-18. The tendency to increase IL-12 or IL-18 could possibly
represent a feedback loop in the attempt to increase IFNy. An increase in IL-12 could
imply an increase in T cell proliferation and survival -i i t< ; /2)2 I, while an increase
in IL-18 has been associated with rejection when seen in association with elevated IFNy
-i i~;ix ii:::' 2:Si(::Ii i. However, the increase in both IL-12 and IL-18 mRNA expression is
small, suggesting that PPAR activation of these pathways is not likely to play a large role
in vivo.
Since inhibition of IFNy expression could augment that of IL-4 and IL-10, the expression
levels of these two cytokines were specifically examined. PPAR agonists do not
significantly affect IL-4 expression on the days of peak IFNy expression in either ConA
or MLR culture but exert variable effects in the MLR over time, such that by day 4 of the
MLR, WY markedly increases IL-4 expression. This is consistent with results from the
literature that find increased concentrations of IL-4 on day 4 following WY pretreatment
of murine ConA-stimulated T cells .id ; E: ;,? i 002 t. Given that IL-4 stimulates the
generation of PPARy ligands :lii ... s . , there is potential for this to occur with
PPARca ligands as well. However, despite the identification of IL-4 as an inhibitor of the
macrophage-activating effects of IFNy :I ' elton. diidt ~.isav ?('Xi,', a review of the
data with respect to potential benefits on allografts has shown equivocal results, with
some reports documenting increased rejection severity with increased concentrations of
IL-4, and a number of others reporting a positive correlation between IL-4 and graft
survival i '- 't iti: i l : :^  i. This could imply that the increase in IL-4 by WY could
make it a less than ideal candidate compared to the other agonists for testing in vivo.
With respect to IL-10, a number of in vivo studies show a stimulatory effect on IL-10
secretion upon treatment with PPARa and PPARy agonists :I M artiw.iesia :,- t"3 20'.)2,
'4 .nit- Sl' S ''.x)i S.l' S i},i 2')"'l1. This is consistent with the small, yet
statistically significant increase in IL-10 expression seen with all agonists in the ConA
culture on the day of peak IFNy expression. In the MLR there is also a tendency to
increase IL-10 by PPARa agonists (WY>FENO) with mixed results seen when using
PPARy agonists; PGJ2 showed increased IL-10, while BRL showed no significant effect.
However, by day 4 of the MLR, fenofibrate and PGJ2 both decrease IL-10 expression.
The decrease in IL-10 by fenofibrate and PGJ2, particularly at the late stage, may be of
importance in light of reports that increased levels of IL-10 exacerbate allograft disease
in vivo i, th: ',;3 :' t' ~! , and suggest potential benefit of these two agonists in vivo.
In any event, it is apparent that generally PPAR inhibition of IFNy expression does not
induce net IL,-4 or IL-10 differentiation in lymphocyte stimulated cultures.
Under the specific culture conditions in this chapter, PPARa agonists statistically
increase IL-2 in both cultures, while PPARy agonists have no statistically significant
effects in the ConA cultures, and variable effects on the MLR, with PGJ2 causing an
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increase IL-2 and BRL a decrease. These effects are internally consistent with the
tendency to observe increased proliferation in the dose response curves at the
"therapeutic" concentrations. However, they sharply contrast with studies reporting a
decrease in IL-2 production upon PPAR activation by WY in human T cells I M,.:1~ ':a ·.
iu,2Xe iand murine splenocytes i(Sarl:i; ¢: , , : 2('.23/'. This could potentially represent
another instance of differential effects or sensitivities between human and rodent cells, as
has been previously discussed. The literature provides some corroboration in that while
100 [tM of WY was sufficient to inhibit IL-2 in human cells, murine experiments showed
no decrease until 250 FiM "f,'',ri;·\ d ur :sii US i., ; in fact, average IL-2 concentration in cells
treated with 100 E[M of WY was higher than controls, although statistical significance
was not reached. Experiments using splenocytes congenitally absent in PPARa may aid
in the clarification of its role in IL-2, and are presented in Chapter 5. With respect to the
PPARy agonists, the results in this thesis using BRL trend in the same general direction
as earlier literature reports .e "'2::r,:i : _,, ' ri:',:, , 2(:):-'!':~ ,,' ..  , The increase in IL-2 in the
PGJ2-treated MLR cultures does contrast with results obtained in other stimulation
assays with either human or murine cells 2.. 'I" uz .. ,,, ,9 g,,< .: u:: .. .'
">r2x) i. In the context of the paradigm of cytokine grouping c t' 2.'.. 2... . I, it is possible
that a feedback loop to counter the decrease in IFNy may yield augmented IL-2. In any
event, the result supports the conclusion that alloresponses are unique stimulatory settings
not entirely analogous to ConA mitogenic stimulation :.le ' x ' ? I c , :( If I))0,,1.
Regarding IL-6, the results in this thesis are roughly consistent with reports in the
literature. Overall, there were no dramatic changes in expression, with the only
statistically significant changes associated with WY in the MLR and PGJ2 in the ConA
cultures. The lack of effect of FENO is consistent with a study using endothelial cells
where a decrease in IL-6 was not observed until 50 [xM of drug I SX u i, :? 2(1(')t I. The
increase in the MLR IL-6 expression by WY could represent an increasingly sensitive
response to decreased IFNy levels, similar to the significantly increased IL-6 seen in
acutely rejecting cardiac allografts in recipients lacking in IFNy *tStiku- t.JS Y llU,, ~,,;
conversely, congenital deficiency of IL-6 in this setting leads to increased IFNy I Xi S- .'"
99 i :)Xt, l. Alternatively, the increase in IL-6 by WY could represent a direct comparable
to the increase in IL-6 in adenomas from mice treated with WY :-'-x.P r ,,? ~i 2
and contrasting with the decrease seen in smooth muscle cells ct!St'.,i .,' 1"? 998¢. The
lack of effect on IL-6 when using PPARy agonists (besides PGJ2 which attenuates IL-6
production) has been a recurrent theme .'^ l ir ' } 3c, 'l (. >> .. , 2.''3, In fact,
experiments have shown the ability of PGJ2 to directly interact with transcription factors
independently of PPARy .Ij-:s : <.: c:l A_,.)tat The inability of PGJ2 to significantly
decrease IL-6 production in the MLR may be another example of a feedback mechanism,
or of the uniqueness of the alloresponse.
The differences between ConA and MLR cultures are more dramatically evidenced in the
profiles of selected chemokines before and after treatment with PPAR agonists. In ConA
cultures, chemokine mRNA expression decreases as a function of time, with MIP-1p
being the most abundant, closely followed by RANTES and MCP-1. In the MLR, there is
a clear peak at day 2, with RANTES being by far the most dominant chemokine (by over
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a factor of 2), followed by MCP-1 and MIP-la. The experiments were performed
concurrently such that time points and relative transcript expressions correspond.
Based upon the uniform decrease in IFNy, it was expected that a similarly uniform
decrease would be seen in the IFNy-inducible chemokines, such as RANTES and IP-10.
In fact, in the ConA cultures, incubation with PPAR agonist results in a uniform decrease
in both chemokines on the day of peak expression, a finding consistent with a number of
other studies, albeit in different in vitro systems, with reported decreases in RANTES and
IP-10 gd:is:.: .' i. s i l. :a, u~ .s S ... Ie .3Mi-, :,,~ 0i0'f)) However, this does not
extend to the MLR. Peak chemokine expression occurred one day later than in ConA
cultures. No decrease in IP-10 mRNA expression was observed for any agonist, where no
decrease was observed and WY significantly increased expression. RANTES displayed
the expected decrease with WY and PPARy agonists, suggesting an eventual change to an
IFNy-dependent effect. Fenofibrate results in a small (- 10%), yet statistically significant,
increase in RANTES expression, possibly representing a kinetic issue (i.e. a delay in the
change from an IFNy-independent to an IFNy-dependent pathway), or could be based on
downstream signaling issues specific to fenofibrate. The lack of a decrease in RANTES
and IP-10 with PPAR treatment renders unavailable a substantial benefit associated with
a decrease in IFNy. A number of reports have established these chemokines as important
mediators in the cardiac allograft rejection t:-i;t i: ' d es ;, 97 ~: ,,S / e0 !.j 2 :' cxc
To date, no studies have tested the effects of PPAR activation on either the expression or
production of MIP-1 a or MIP-11. Recent evidence has identified these MIP chemokines
(along with RANTES) as functioning in concert with IFNy on target cells I l)orier ,.:~ (t
2(321. Consequently, decreased MIP expression would be expected based on the
decrease in IFNy. This is clearly observed on the day of maximal chemokine expression
in the ConA cultures, where all agonists uniformly and significantly decrease expression
of MIP-la and MIP-1IP. However, once again it does not apply to the MLR, where on the
day of maximal mRNA expression, there is no significant effect on MIP expression. The
suggestion of a direct stimulatory mechanism is clearly suggested on day 4 of the MLR
where all of the agonists, except fenofibrate, result in a dramatic two to three-fold
increase in MIP expression. A recent study reports increased secretion of a number of
cytokines by T cells from immunized mice receiving exogenous MIP-la or MIP-13
I.itlia'rd te. 20i.0 1)1. This suggests that the increase in these chemokines elicited by
PPAR agonists may have consequences on cytokines and could be one of the reasons
why MLR increases in IL-2 and IL-6 were associated with PPAR activation by selected
agonists such as WY and PGJ2 (these have the most marked increase in MIP-la and
MIP-11). The effect on these chemokines could also explain some of the differences
between ConA and MLR cultures, in that higher expression may lead to more
pronounced chemokine-mediated effects. The properties of the MIP-1 proteins as both
macrophage activators and lymphocyte chemoattractants I Vlter c at/ 9; 9ci>j1 have given
them roles in the development of PR and TxAA S-IrZ lc i d tc lt 'I () 0 . Based on
their function and implications for rejection, the PPAR agonist with the highest
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probability of maximizing the cytokine benefits is the one that minimizes chemokine
expression and subsequent cellular graft infiltration. Hence, of the agonists tested,
fenofibrate emerges as the most likely candidate for success in vivo.
The importance of timing and stimulus type is once again exemplified in the PPAR
effects on NICP-1 expression. While PPAR activation has no effect on either ConA or
MLR associated early mRNA expression, by day 4 of the MLR, PPARa agonist WY
resulted in a marked increase, while others continued to have no significant effects.
Studies on human endothelial cells confirm an induction in MCP-1 by WY in when
stimulated by oxidized phospholipids i e a:: al:i 2.!0('1 yet report suppression when
stimulated by C-reactive protein It'.s-.:1-ri :f ,i 2(1t i. These raise the issue of whether
suppression is a result of an effect on C-reactive protein, rather than on MCP-1 directly
(not tested in the study). Unlike the in vitro results reported here where no effects were
found, the literature suggests that fenofibrate has the potential to decrease MCP-1
expression in certain in vivo models O , Ii /? 2- )C:21, possibly due to an effect on
endothelial cells I !i.atl -Xi : 2t':)i. Results of PPARy activation on MCP-1 typically
show a lack of effect with BRL and other thiazolidinediones, while significant effects
with PGJ2 <tX Ii ,'I ,.: 0 Ji' s,t(' 1I  ... Jii t 'Ii 'f 2()')21, are potentially attributable to PPARy-
independent effects fI,tZ.i . ,i 200}(0'l. The ability of MCP-1 to directly stimulate
vascular smooth muscle cell proliferation elzmi;uat :,: 2{i02I, as well as its more
traditional role in monocyte attraction, activation and adhesionI %,b>lz I I 1': 997/ Gc-x:' z'¢l ,'::'
:,I/ ! i3tDIf, has attracted interest in MCP-1 modulation for coronary artery diseases l ke~t
,'~ ¥?g 2{~,d,21 and has suggested that it may be an important factor in the process of
rejection, particularly TxAA : ai- ~'n ; ;l "i . st 0,.li~ . This suggests that the PPARcC
ligand WY would possibly contribute to vascular smooth muscle cell proliferation in the
transplant setting, thus exacerbating the overall process.
The multiplicity of chemokine ligand-receptor interactions suggests that targeting
chemokine receptors (rather than chemokines) is a potentially more useful therapeutic
strategy in the attenuation of rejection .-d;ac"c 0.r 3r; ::,)(¢( l. This prompted examination
of PPAR effects on chemokine receptor mRNA expression. CCR1, CCR4 and CCR5
serve as receptors for RANTES, MIP-lct and MIP-1fI, while CCR2 serves as the receptor
for MCP-1 (details are reviewed in chapter 2). These are the first experiments to
comprehensively evaluate the effects of PPAR activation on these receptors. On day 1
post ConA stimulation, PPARca agonists increase CCR1 and CCR2, have no effect on
CCR4 and have variable effects on CCR5. PPARy agonists have no effects on either
CCR1 or CCR4, increase CCR2 and decrease CCR5. On day 2 of the MLR, PPARa
agonists have variable effects on CCR1, CCR4 and CCR5 and increase CCR2, while
PPARy have no significant effects on CCR1, CCR2, CCR4 and variable effects on
CCR5. By day 4, all PPAR agonists showed no effect on CCR1, variable effect on CCR4
and uniform decrease in CCR2 and CCR5. In general, MLRs exhibit higher levels of
receptor expression, with the peak level of the most abundant chemokine receptor, CCR5,
over a factor of two higher in the MLR compared to ConA. CCR4 is more comparable to
CCR5 in ConA cultures for a majority of the days. CCR1 and CCR2 have the lowest
levels of expression compared to other chemokine receptors in both cultures.
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Potential PPAR-mediated effects on PPAR expression on cytokines and/or chemokine
receptors chemokine receptors may offer explanations for the some of the ConA and
MLR results. As shown previously, ConA cultures have substantially higher expression
of IL-2, and PPARac agonists increased it significantly. Reports have shown that IL-2
may upregulate CCR1 and CCR2 it ...t l. I9fI6; consequently early upregulation
of CCR1 and CCR2 with PPARa agonists may be an indirect result of IL-2 modulation.
By day 4 of the MLR, IFNy protein is present in high concentrations and can thereby
mediate secondary effects, such as downregulation of CCR2 ije`0 &c),,i-Ix,~R c2 'o 10;98I.1.
Consequently, decreased IFNy caused by PPAR agonists could lead to increased CCR2
expression. However, PPAR agonists uniformly decrease CCR2 expression, suggesting
an IFNy-independent effect. The downregulation of CCR2 upon treatment with PPAR
agonists is consistent with the only two reports in the literature I ": i 0/2 A(}st), i i aS UZi
,· (.:?i _ I. Decreased CCR5 expression observed on day 4 of the MLR, on the other
hand, may be an IFNy-dependent effect. The association of CCR5 with IFNy Sa ksto (.,
-i. ;0)0 W.S; L f efd 2a1,3i suggests that a decrease in IFNy could lead to decreased
CCR5, which is, in fact, observed. This is further supported by the varied response on
day 2, when essentially no IFNy protein is present. Effects on day 2 of the MLR may
therefore be interpreted as IFNy-independent and possibly directly mediated by PPAR
agonists. Nevertheless, the conclusions herein are largely speculative without definitive
promoter and transcription analysis.
The ConA vs MLR presented in this chapter highlight that type of splenocyte stimulation
can affect regulation of chemokine receptors. For example, examination of the natural
time course of chemokine receptor expression shows that in ConA cultures, CCR5
expression at early and late times is roughly unchanged, while in the MLR, the level of
expression increases over two-fold during that interval. The difference between the first
and last time points in the ConA cultures is that by the last time point, expression of the
other chemokine receptors in the panel is diminished; despite the lack of a change in
absolute mRNA expression, the relative mRNA expression compared to other receptors
makes it the dominant receptor in the ConA, as well as the MLR, cultures. However,
consideration of the absolute level of expression shows the comparative inability of
ConA to upregulate CCR5 expression. This is consistent with studies in the literature that
found upregulation of CCR5 in antigen-activated T cells, in contrast to stimulation with
mitogens, phorbol esters, or anti-CD3 acting alone or in concert with anti-CD28 [I iber '
, ~,,al f Mc ~ol ,zl . An implication of this is that the varying experimental results
achieved with PPAR agonists using different stimulation assays may yield varying results
due to differences in baseline levels, or possibly effect of PPAR activation on the
stimulus itself, rather than on the consequence of the stimulation. This is particularly
applicable to studies where PPAR-modulated cytokines have downstream effects, raising
the issue of whether the endpoint change is mediated directly by PPAR or by the
stimulating cytokine (for example, TNFa-induced adhesion molecule expression). The
use of cytokine neutralization experiments, in addition to signaling experiments, could
such issues.
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Regardless of cytokine-dependence, attenuation of CCR2 and CCR5 by PPAR agonists in
the late stage MLR is of particular interest for modulating transplant rejection and
suggests possible benefit of PPAR administration in vivo. Murine recipients of MHC-II
mismatched allografts congenitally lacking CCR5 demonstrate diminished PR and
abrogation of TxAA al ,< r< .t200) t and a recent study documents similar benefits upon
the administration of an agent antagonistic to CCR1, as well as CCR5 I)¥ Bll < cd 20(0) i.
Graft survival time also increases when recipients are congenitally deficient in CCR2,
with a concomitant decrease in macrophage number in the graft l}:'ernk:~w:~ ' Al/
. 1), 1i:h;h,, ;,i i. Deletion of CCR2 in the recipient does not have as pronounced of an effect
on TxAA, but still significantly reduces it with transient early decreases in macrophage
infiltration I ' k :v : \< : >d>; :>I.e 1: !1.
Given the apparent differences between ConA stimulation and MLRs, determination of
PPAR-mediated effects potentially translated to the in vivo setting should likely be based
on the MLR results alone. As a group, PPAR agonists displayed several "anti-rejection"
effects, including a decrease in IFNy, CCR5 and CCR2. With respect to other cytokines,
PPARcL agonists displayed some potentially pro-rejection effects such as a small, yet
statistically significant increase in IL-2, IL12-p40 and IL-18, while PPARy agonists had
no effects on either IL12-p40 or IL-18 and displayed drug-specific effects on IL-2. More
compelling, however, is examination of PPAR-mediated effects on chemokine
production in the late stage of the MLR. Despite causing a 30% decrease in RANTES
(potentially attenuating graft infiltration, thus "anti-rejection"), PPARy agonists resulted
in a 200 to 300% increase in MIP-la and MIP-13 (potentially causing a severe
augmentation of graft infiltration, thus "pro-rejection"). PPARa agonists had mixed
results, with WY closely mimicking the PPARy agonist behavior. FENO, on the other
hand, did not decrease RANTES (actually increased by 20%) but had significant
enhancement of MIP-1 expression (increased MIP-la by -10% and had no effect on
MIP- 1 ).
Therefore, fenofibrate minimizes the chemokine-mediated "pro-rejection" properties of
WY and the PPARy agonists, while continuing to take advantage of the "anti-rejection"
properties of PPAR agonists. The extent of the additional "pro-rejection" properties
displayed by fenofibrate, such as increased pro-inflammatory cytokines, are small
compared to the extent of the chemokine effects of WY and the PPARy agonists.
Fenofibrate appears to allow minimization of cellular infiltration and subsequent
maximization of the "anti-rejection" benefits from the decrease of IFNy, CCR2 and
CCR5. Furthermore, other potentially beneficial (or "anti-rejection") effects, such as
decreased VCAM-1 (appealing in light of the above chemokine-related issues), are
reported to be associated only with PPARa and not PPARy agonists I Iari' .' i( 190)%I .
Thus, fenofibrate emerges as the candidate most likely to be successful in the attenuation
of rejection mechanisms in vivo.
In conclusion, the experiments presented in this chapter constitute the first evaluation of
the effects of PPAR activation on an alloresponse, for possible translation to the in vivo
setting of cardiac transplantation, and also included one of the most detailed analyses
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available to date of cytokine, chemokine, and chemokine receptor expression following
antigen and mitogen mediated splenocyte stimulation. Dose response studies performed
in both mixed leukocyte reactions, as well as following ConA-stimulation with two
agonists per PPAR isoform, in order to discern potential drug-specific effects, identified
the following therapeutic doses (defined as the doses at which a decrease in IFN is
achieved without a concomitant decrease in proliferation): 20 tM for fenofibrate, 100
[iM for WY 14643, 10 tM for BRL49653 and 3 tM for 15-deoxy-A1'2' 4-prostaglandin J2.
Flow cytometric analysis of propidium iodide staining confirmed cell viability at these
doses, at least up to 12 hours of continuous treatment. Normal cell proliferation at these
doses also supports the contention that these doses of PPAR agonists do not affect cell
viability.
Using these doses, effects of the PPAR agonists on cytokine, chemokine and chemokine
receptor expression were investigated and discussed both in the context of internal
networks, as well as findings from the literature. Comparison between results achieved in
mixed leukocyte reactions and following ConA stimulation revealed critical differences
and pointed to the need for specific testing of the alloresponse for potential translation of
PPAR effects to in vivo transplantation rejection. Based on the results presented in this
chapter, as well as ancillary results from the literature, fenofibrate has emerged as the
most likely PPAR agonist to have beneficial effect in the attenuation of mechanisms of
rejection in vivo. The next chapter presents the in vivo evaluation of fenofibrate in a
murine heterotopic model of cardiac transplantation.
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Chapter 4. In vivo evaluation of a PPARa agonist
4.1 Introduction
As discussed in the last chapter, PPAR agonists display several potential "anti-rejection"
effects, including markedly decreased IFNy, CCR2 and CCR5. Of the PPARca and
PPARy agonists tested, fenofibrate emerged as the most promising candidate for
attenuation of rejection mechanisms in vivo. Despite some "pro-rejection" actions such as
small, yet statistically significant, increases in a several cytokines (e.g. IL-2, IL12-p40,
IL-18 and RANTES), fenofibrate, unlike the other PPAR agonists, did not markedly
enhance the overall chemokine expression. Fenofibrate displayed the greatest potential
for minimizing potential chemokine-mediated "pro-rejection" properties, while
continuing to take advantage of the "anti-rejection" properties of PPAR agonists.
Fenofibrate has several other potential "anti-rejection" mechanisms of action. In light of
the regulatory role of IFNy in the expression of MHC-II t t ii 1t)~)71, the
fenofibrate-mediated decrease in IFNy should result in decreased MHC-II expression and
subsequently result in decreased CD4+ T cell activation. However, direct examination of
PPARa ligands effects on MHC-II induction demonstrated no inhibition Wak t. . .
20(2 . Moreover, fenofibrate may decrease the expression of ICAM-1 andVCAM-1 and
subsequent monocyte binding to endothelial cells M ' A t :ti !9t'99>, 1Ad Rdi ci t 'a";"'
~I'"-.t;.i..i <at ... ^'t'3( " . This may be particularly important in light of the potentially
increased level of RANTES expression in the setting of fenofibrate administration, which
may enhance the mononuclear cell infiltrate. Fibrates may also suppress both vascular
endothelial and smooth muscle cell activation 15 : lt ..~ i X6)¥~: I [t gal ,:.if i. Finally,
evidence from the clinical literature suggests that dyslipidemia may contribute to
rejection F:i- 'egiE et l ?20(00¢ and that fenofibrate is effective in decreasing lipid levels
in heart transplant recipients I Ke i a i J O' s.i, ;l 20 KY . Since PPARcr activators may
have species-specific effects i t..:\w st c t ii .20(1i , these effects may not be fully
recapitulated in murine studies. Nevertheless, there is evidence that hyperlipidemia may
be associated with increased lesion frequency in rodent cardiac allografts 1:'!':;,trkas , 1
-i Q:kJ.t and that fenofibrate may lower lipid levels in mice , Itt i > i potentially
resulting in attenuation of lesions in murine cardiac allografts.
Therefore, based on the results of the previous chapter, it was reasonable to suggest that
fenofibrate has the greatest likelihood of success in attenuating rejection mechanisms in
vivo. Furthermore, results from the literature suggested additional potentially beneficial
effects. However, the balance between potentially "pro-rejection" and "anti-rejection"
effects remains to be determined by experimental testing, which is especially important
given the uniqueness of the alloresponse setting. This chapter presents the first evaluation
of fenofibrate, a PPARa agonist, on mechanisms of PR and TxAA in a murine model of
cardiac transplantation.
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4.2 Methods
Animals and Diet
Three inbred strains of mice, C57/BL6, Balb/c and B6.C-H-2bml2KhEg (bml2 mice that
are MHC-II mismatched with C57/BL6 but on the same background), approximately six
to eight weeks old (Jackson Laboratories, Bar Harbor), were housed in the animal facility
of Harvard Medical School on acidified water and chow ad libitum. Sentinel mice were
co-housed in each room and were surveyed to ensure that that the facility was free of
pathogens. Experiments were done according to protocols approved by the animal care
committee. Recipients were started on a chow containing 0.2% w/w fenofibrate
(Research Diets Incorporated, New Brunswick) three days after transplantation due to
excessive bleeding. The fenofibrate diet was monitored by weekly measurement of food
intake. The fenofibrate chow was continued until the time of organ harvest. In
experiments on non-transplanted C57/BL6 mice, aimed at determining whether the effect
of fenofibrate treatment was sustained over time, the fenofibrate chow was stopped one
week before harvest and mice were returned to regular chow ad libitum.
Heterotopic Heart Transplantation
Heart transplantation of donor bm12 hearts into C57/BL6 recipients was performed
according to the heterotopic technique described in the literature l:(~ry et l t)7.3
-':: %-i~>ti~w A -I'l t'21,,' i and in accordance to protocols approved by the Harvard Medical
School Animal Care Committee. After administration of inhalation anesthesia, cold
heparinized saline was injected into the inferior vena cava of the donor heart. Then, the
inferior vena cava, as well as the superior venae cavae and pulmonary veins, were
ligated. The donor heart was removed and placed in cold sterile saline. Preparation of the
recipient initially entailed opening the abdominal cavity and identifying both abdominal
aorta and inferior vena cava. After making careful incisions on those vessels, the donor
aorta and pulmonary artery were ligated to the recipient abdominal aorta and inferior
vena cava. The abdominal cavity was then closed and the animal kept under a warm lamp
until recovery from anesthesia. For evaluation at 8 weeks, a total of 22 transplants were
performed, with n=12 mice on regular chow (denoted as control) and n=10 mice on chow
with fenofibrate (denoted as treated). Further study also involved a pilot study at 2 weeks,
with an n=3 in the control group and n=4 in the treated group. At the time of harvest, the
heterotopically transplanted heart was divided transversely in three sections, representing
the base, middle and apex, each to be used for separate purposes as described below.
Plasma measurements
At the time of cardiac allograft removal, blood was obtained by cardiac puncture of the
recipient's native heart. It was immediately transferred to vacutainer tubes with 0.135 M
of sodium citrate at a 1:10 dilution and centrifuged at 10,000 rpm for 5 minutes. Plasma
was then transferred to 1.5 ml centrifuge tubes where it was frozen at -200 C until
analysis. Samples were sent to the Clinical & Epidemiologic Research Laboratory at
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Children's Hospital Boston for analysis of triglycerides, total cholesterol, glucose,
fibrinogen, ALT and AST plasma concentrations. Due to limitations in sample volume,
not all laboratory markers were obtained for all transplants and the number of mice is
specifically noted.
Histological staining and scoring
The base of the heart and a liver section were fixed in 10% buffered formalin for staining
with hematoxylin and eosin. The heart was also stained for elastic tissue and was scored
for extent of PR and TxAA. The grading scheme for PR was modified from the
International Society for Heart and Lung Transplantation scale and is described as
follows: 0, no rejection; 1, mild interstitial infiltrate without necrosis; 2, focal interstitial
with necrosis; 3, multifocal interstitial with necrosis; 4, widespread infiltrate with
hemorrhage and/or vasculitis. The extent of TxAA was determined by average the scores
of over 10 arteries where the scoring scheme is based on occlusion: 0, no occlusion; 1,
<10%; 2, 10 to 25%; 3, 25-50%; 4, 50-100%. The liver was evaluated on the presence or
absence of increased granularity and eosinophilia, representing increased peroxisome
proliferation. The distinctness of the staining in the treated group led to a binary scoring
of "control" and "PPAR liver".
Immunohistochemical staining and scoring
The middle transverse section of the cardiac grafts and sections of the recipient liver were
frozen in optimal cutting temperature (OCT) compound (Ames Co, Elkhart) and stored at
-800C. Heart sections were stained for expression of MHC-II, ICAM-1, VCAM-1, CD4,
CD8 and CDllb, while the liver was stained for peroxisomal membrane protein 70
(PMP-70). Sections were cut at a thickness of 5 tm and stored at -20 °C until staining
was performed. Unless otherwise noted, all steps were preceded by three washes in
phosphate-buffered saline for three minutes each. Slides were first air dried for
approximately 20 minutes and then fixed with 4% paraformaldehyde for 5 minutes at
room temperature. After washing three times for three minutes each with distilled water,
sections were covered with 0.5% hydrogen peroxide (Sigma, St, Louis) for 15 minutes.
Sections were then blocked with either rabbit or goat serum for 1 hour and with avidin
and biotin for 15 minutes each. Primary antibodies (Pharmingen, San Diego) ranging
from in concentration from 1:40 to 1:200 were applied for times ranging from 30 minutes
to 3 hours. If applicable, biotinylated secondary antibody (Pharmigen, San Diego) was
added. Chrornogen was added and development times were established by microscopy to
ensure that the isotype controls did not show staining. After development, slides were
counterstained in hematoxylin for 1 minute and washed under running water for 15
minutes. Excess water was removed and Aqueous Quick Mount was applied, before
covering sections with a coverslip. Heart sections were scored (3 blind observers)
according to the following scheme: 0, no staining; 1 focal weak; 2 focal moderate, diffuse
weak; 3 focal strong, diffuse moderate; 4 diffuse strong. For the liver, the scoring scheme
was simplified to either absence or presence of peroxisomal proliferation, since typically
the effect is observed throughout the liver.
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RNase Protection Assay
The apex of the heart was frozen at -700 C until isolation of mRNA. Tissue was placed in
1 ml of TRIZOL (Invitrogen, Carlsbad) and homogenized using an electric homogenizer.
The technique used for isolating the mRNA is fully described in chapter 3. Aliquots with
10 [tg of mRNA were stored in RNase-free DNase-free water at -700 C. Analysis of
mRNA expression was performed via the RNase protection assay (RPA) with a custom
multi-template probe (for IFNy, IL-4, IL-6, IL-10, IL-12p35, IL12-p40, IP-10, RANTES,
CCR2 and CCR5). Quantification of band intensities was performed using the
ImageQuant software (Molecular Dynamics). The volume integrations of each band were
normalized to the bands for GAPDH in the corresponding lane. Samples were run in
triplicate and results are presented as the average and standard deviation per group
Mixed Leukocyte Reaction
The technique used for splenocyte isolation and culture in a mixed leukocyte reaction
(MLR) is fully described in chapter 3. Briefly, splenocytes from transplant recipients
(n=22) obtained at the time of organ harvest were restimulated in vitro with bm12
splenocytes, as well with third-party Balb/c stimulators. Experiments were also
performed with splenocytes from non-transplanted C57/BL6 (n=6) recipients of
fenofibrate to determine whether the effect observed in the transplant recipients would be
sustained. Proliferation was assessed by incorporation of 3 H-thymidine and supernatants
collected for analysis described below.
Enzyme-Linked Immunosorbent Assays
The concentration of IFNy in the supernatants of the proliferation assays was determined
using enzyme-linked immunoassays (ELISAs), per the manufacturer's protocol
(Pharmingen, San Diego). Details of the procedure employed are fully described in
chapter 3. Optical density of the solutions in the wells was measured using an ELISA
plate reader and converted to pg/ml using a calibration curve prepared from recombinant
IFNy standards. Analysis of optical density and protein concentrations was done using
"Softmax" (Molecular Devices Corporation).
Data Analysis
Results in bar and line graphs are presented as the mean and standard error of the mean,
while results in scattered plots represent the mean only. Statistical significance for
histological and immunohistochemical staining results, where scores ranged from 0 to 4,
was determined using the Mann-Whitney test for non-parametric values with a two-tailed
p-value criteria of less than 0.05. For immunohistochemical staining, the Kruskal-Wallis
test, a one-way analysis of variance (ANOVA) for non-parametric values, was also
performed to ensure that there was no statistically significant difference between the
three, blinded observers. Statistical significance of other values was determined using the
Student's t-test for unpaired samples with two-tailed distribution and a p value less than
0.05. The "Prism" statistical software (Graphpad) was used for statistical analysis.
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4.3 Results
Recipients of MHC-II mismatched murine cardiac allografts were sacrificed at both 2 and
8 weeks after transplantation and treatment with fenofibrate-laden chow (0.2% wt/wt).
With the exception of findings common to both times, results are grouped and presented
according to time of harvest.
Figure 4.1 shows representative photomicrographs of morphological changes in the livers
of the murine allograft recipients at both time points. The livers of treated mice display
increased granularity and hypereosinophilia on histological sections, as well as increased
PMP-70 expression by immunohistochemical staining. It is emphasized that there were
no histologic signs of liver damage but rather, the changes were a result of increased
peroxisomal proliferation. This change is not likely to be observed clinically, since
PPARa agonists do not induce peroxisomal proliferation in human hepatocytes
o .... rl. ' I ,, c .e ' " ~ ~ X X
Figure 4.1: Fenofibrate-induced effects on livers of murine cardiac transplant recipients:
Appearance (via routine hematoxylin & eosin staining) and PMP-70 expression (via
immunohistochemical staining). Fenofibrate treatment results in increased granularity
and hypereosinophilia in sections stained with hematoxylin and eosin, and increased
peroxisomal proliferation as shown by diffusely increased PMP-70 staining. These
photomicrographs are representative of sections from livers harvested at both 2 and 8
weeks after transplantation.
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2 weeks
To check the early effects of fenofibrate, a small set of transplants (n=3 control and n=4
treated) with a 2-week survival time was performed. Physiological measurements
confirmed the presence of fenofibrate in the treated group. Wet liver weight of treated
mice, shown in figure 4.2, more than doubled (from 1.2 + 0.2 to 2.8 + 0.1 g; p < 0.05).
Liver enzymes (ALT and AST) tended to increase with the increase in liver weight. Other
plasma markers, shown in figure 4.3, varied without reaching statistical significance.
Notably, fibrinogen tended to decrease, as did triglycerides and glucose, while cholesterol
tended to increase. The lack of statistical significance may potentially be due to the low
numbers of mice in this set of transplants.
Allografts were analyzed to determine the immunomodulatory effect of fenofibrate
administration. Analysis of the mRNA expression of selected cytokines, chemokines and
chemokine receptors tested, in figure 4.4, showed that fenofibrate tended to have a broad
immunosuppressive effect. Allografts of treated mice demonstrated attenuated mRNA
expression IFNy, IL-6, IL-4, IL-10, RANTES, IP-10, CCR2 and CCR5.
The immunohistochemical appearance of the graft was examined to assess the effect of
fenofibrate treatment on graft activation and infiltration. Fenofibrate had no substantial
impact on graft activation; specifically, as shown in figure 4.5. there was no effect on
MHC-II expression and only a tendency to decrease VCAM-I and ICAM-1 expression.
On the other hand, dramatic immunosuppressive effects were observed in terms of graft
inflammatory infiltrate. Figure 4.6 shows that at 2 weeks, fenofibrate significantly
reduced infiltration by CD4+ T cells and CD1 lb+ macrophages. Specifically, CD4+ cells
decrease from 161 + 24 to 22 + 4 cells per high power field (p < 0.05) and CD1 lb+ from
167 27 to 74 ± 10 cells per high power field (p < 0.05). CD8+ T cells also decreased
(from 12 + 3 to 4 + 4 cells per high power field) without statistical significance.
In order to examine functional leukocyte effects of fenofibrate treatment, splenocytes
from recipients were restimulated ex vivo with bm12 (same party), B/c (third party) and
ConA (mitogenic). Figure 4.7 shows the effects on proliferation and IFNy production. In
broad terms, fenofibrate treatment does not significantly affect proliferation. The
concentration of IFNy is significantly decreased in all cultures on the third and fourth
days. This decrease is sustained with both third party and mitogenic stimulation, but
disappears by the last day of culture when leukocytes restimulated with bm12.
8 weeks
Physiological measurements once again confirmed the presence of fenofibrate-mediated
effects. The mean wet liver weight figure 4.8 more than doubled in the treated group
(from 1.6 + 0.08 to 4.1 0.33 g; p < 0.05). This correlated with significantly increased
concentrations of the liver enzymes ALT (86 + 10 to 148 _ 14 mg/dl; p<0.05) and AST
(10 ± 2 to 68 + 23 mg/dl; p < 0.05). Linear regression analysis revealed strong correlation
between food intake and the AST liver enzymes (R2=0.86), and a moderate correlation
with ALT (R 2=0.39). Measurements of circulating levels of plasma metabolic markers,
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presented in figure 4.9, further corroborated physiological effects; fenofibrate
significantly decreased mean levels of triglycerides (41 4 to.31 + 3 mg/dl; p<0.05) and
glucose (201 11 to 159 + 11 mg/dl; p<0.05) and significantly increased cholesterol
from 83 + 9 to 107 + 6 mg/dl (p<0.05). There was no significant correlation between food
intake and any metabolic markers (R2 < 0.15). Fibrinogen was not significantly affected.
The immunosuppressive effect on mRNA expression of selected cytokines, chemokines
and chemokine receptors seen at 2 weeks was not sustained. By 8 weeks, as shown in
figure 4.11, fenofibrate actually augmented the mRNA expression of IFNy, IL-4, IL-6
and IL12-p40, while not affecting that of IL-10 and IL12-p35. Of this panel of cytokines,
IFNy was the dominant cytokine in terms of expression level. Furthermore, as shown in
figure 4.12, fenofibrate significantly increased IP-10 mRNA expression, but did not
significantly affect the expression of RANTES, CCR2 and CCR5.
Fenofibrate also markedly augmented the allograft inflammatory cell infiltrate, as shown
in figure 4.13. Specifically, fenofibrate significantly increased the CD4+ T cells (from
119 + 12 to 139 _ 16 cells per high power field; p < 0.05) and dramatically increased the
number of CDl lb+ cells (from 35 4 to 138 _ 24 cells per high power field; p < 0.05).
There was no difference in the number of graft infiltrating CD8+ T cells (39 + 5 cells per
high power field; p<0.05).
To examine functional effects of in vivo fenofibrate administration, splenocytes from
both control and treated mice were restimulated ex vivo with the same (bm12) and third
(B/c) party stimulators. As shown in figure 4.14, fenofibrate does not significantly affect
proliferation but consistently attenuates IFNy production on the third day of culture
(which is the first day that substantial protein concentrations are present). The effect on
IFNy, however, was transient and disappeared by day 4, raising the question of whether
the disappearance was a result of diminished drug effect given the duration of the culture.
Thus, to test whether the effect was a function of time, splenocytes from wild-type mice
(n=6) treated with fenofibrate for 8 weeks, were taken off the diet one week before
harvest (rather than at the time of harvest). Figure 4.13 presents the results of the ex vivo
restimulation with allomismatched B/c splenocytes. As expected, proliferation was not
affected. However, IFNy production was diminished for the entire duration of the assay.
This suggests that the transience of the effect on IFNy was not due to time, but rather
represents a more fundamental alteration in leukocyte activity following transplantation.
Finally, the overall effect of long-term fenofibrate administration on allograft activation
and pathology were examined. The results pertaining to allograft activation are shown in
figure 4.14. Fenofibrate resulted in a small, but statistically significant decrease in the
expression of MHC-II but did not affect the expression of the VCAM-1 and ICAM-1
adhesion molecules, such that there was essentially no net effect on markers of allograft
activation. However, fenofibrate administration did have significant effects on allograft
pathology, per figure 4.15. Long-term fenofibrate treatment significantly augmented PR,
without ameliorating (or exacerbating) TxAA.
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Figure 4.2: Effect of fenofibrate on liver weight and enzymes at 2 weeks: Liver weight
increased by a factor of 2, while ALT and AST also increased, but not significantly.
Statistical significance between the control (I, n=3) and treated ( , n=4) groups was
determined using Student's t test (p<0.05 ); the bar indicates the mean value.
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Figure 4.3: Effect of fenofibrate on plasma markers at 2 weeks:There was no statistically
significant effect on any markers. However, it should be noted that fibrinogen and
glucose demonstrated downward tendencies. Triglyceride levels remained unchanged and
cholesterol levels tended to rise. Statistical significance between the control (i, n=3) and
treated ( , n=4) groups was determined using Student's t test (p<0.05); the bar indicates
the mean value.
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Figure 4.4: Effect of fenofibrate on graft expression of selected cytokines, chemokines
and chemokine receptors at 2 weeks: Fenofibrate reduces the expression of IFNy, as well
as the other cytokines tested (IL-4, IL-6, IL-10). Accordingly, fenofibrate also
substantially reduces IP-10. Despite the decrease in IFNy, however, fenofibrate does not
affect the expression of RANTES. Finally, fenofibrate reduces expression of both CCR2
and CCR5. I'he lack of statistical significance may be attributable to the low numbers of
transplants in this group. Results are normalized to the expression of GAPDH. Statistical
significance between the control (, n=3) and treated ( , n=4) groups was calculated
using the Student's t-test (p < 0.05).
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Figure 4.5: Effect of fenofibrate on the graft expression of activation markers at 2 weeks:
Fenofibrate treatment had no effect on MHC-II. It tended to decrease VCAM-1 and
ICAM-1. The Kruskal-Wallis test was used to ensure that there were no significant
differences between the three, blinded observers. Statistical significance (*) between
control (1, n=3) and treated ( , n=4) groups was determined using the Mann-Whitney
test (p<0.05). Results are expressed as the mean and standard error of the mean.
Figure 4.6: Effect of fenofibrate on graft infiltrating cells at 2 weeks: Fenofibrate
treatment significantly reduced the numbers of CD4+ and CDllb+ cells, while not
affecting CD8+ cells. For each cell type, five fields per section were counted by two,
blinded observers. Statistical significance (*) between the control (, n=3) and treated
( , n=4) groups was calculated using the Student's t-test.
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Figure 4.7: Effect of fenofibrate on recipient splenocyte proliferation and IFNy
production ex vivo at 2 weeks: a, b) restimulated with bml2; c,d) stimulated with B/c; e,f)
stimulated with ConA. In broad terms, there are no dramatic differences in proliferation.
The concentration of IFNy is significantly decreased in all cultures on days 3 and 4.
Furthermore, IFNy is also decreased on days 2 and 5 in the bml2 cultures, as well as on
day 5 in the ConA culture. Results are presented as the mean and standard error of the
mean of all recipients in triplicate to quadruplicate samples. Statistical significance (*)
between the control (, n=3) and treated ( , n=4) groups was calculated using the
Student's t-test (p<0.05).
Page 91
a)
.o
0
E
u
ct
rA
eq
c)
. W
ca *.'" 10
on 4
_
e)
0
a .re
.- 0
aba
o
r,,
0Q
ZUUU
20000
2 15000
U 10000
5000
0
- Control
-- Treated
ZbUUUU
200000
X 150000
U 100000
51000
0
15M--- Control
.. 1000 Treated
12 3 4 5
Day
1--'-
Eminuela Rinelln 14.T
-
Emanuela Binello
Wet Liver Weiaht
0000
*-0*3-- p<0.001
200
15D
E oo
5o
Treated
0
o
I n.,r p<O.05
00
Ili
Contol Treated
Figure 4.8: Effect of fenofibrate on liver weight and enzymes at 8 weeks: Liver weight
increased by a factor of 3, while ALT and AST also significantly increased. Statistical
significance between control (, n=12) and treated (El, n=10) groups was determined
using Student's t test (p<0.05), and the bar indicates the mean value.
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Figure 4.9: Effect of fenofibrate on plasma markers at 8 weeks: Fenofibrate treatment
significantly increases mean levels of total cholesterol, and significantly decreases the
mean levels of both triglyceride and glucose. Fibrinogen levels are not significantly
affected. Statistical significance between the control (, n=12) and treated (, n=10)
groups was determined using Student's t test (p<0.05); the bar indicates the mean value.
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Figure 4.10: Effect of fenofibrate on the intragraft mRNA expression of selected
cytokines at 8 weeks: Fenofibrate treatment statistically increased expression of IFNy, IL-
4, IL-6 and IL12-p40, while not affecting the expression of other cytokines (IL-10 and
IL12-p35). In control allografts, IFNy was the cytokine with the highest expression, while
IL12-p35 is that with the lowest. IL-6, IL-10 and IL-12p40 had comparable expression,
while IL-4 was approximately an order of magnitude lower. All mRNA expression levels
are normalized to GAPDH. Statistical significance between control (, n=9) and treated
(0, n=9) groups was determined using Student's t test (p<0.05); the bar indicates the
mean value.
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Figure 4.12: Effect of fenofibrate on graft infiltrating cells at 8 weeks: there was a small,
but statistically significant (p< 0.05) increase in CD4+ cells, and dramatically increased
the number of CD1 lb+ cells (p < 0.05). There was no difference in the number of CD8+
cells. Five fields were counted per section (two blinded observers). Statistical
significance (*) between the control (, n=12) and treated (n=10) groups was calculated
using the Student's t-test.
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Figure 4.13: Effect of fenofibrate on splenocyte proliferation and IFNy production ex
vivo at 8 weeks: a, b) recipient splenocytes restimulated with bml2; c,d) recipient
splenocytes stimulated B/c; e,f) comparison to results with splenocytes from C57/BL6
mice who were taken off the fenofibrate chow 1 week before harvest (denoted as "off 1
wk") and stimulated with B/c. Fenofibrate does not significantly affect proliferation on
any day, while significantly reducing IFNy production on day 3. Please see text for more
details. Statistical significance (*) was calculated using the Student's t-test (p < 0.05).
Results are presented as the mean and standard error of the mean of quadruplicate
samples for the control (, n=10), treated (El, n=9) and ""off 1 week" (U, n=6) groups.
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Figure 4.14: Effect of fenofibrate on allograft activation at 8 weeks: Representative
photomicrographs of isotope control and examples of high expression show that the
distribution of MHC-II tends to be diffuse, while the distribution of the VCAM-1 and
ICAM-1 adhesion molecules tends to be localized to large vessels. Fenofibrate treatment
results in a small but significant decrease in the expression of MHC-II. It does not
significantly affect the expression of VCAM-1 or ICAM-1. Sections were evaluated
(three, blinded observers) according to the following scheme: 0, no staining; 1 focal
weak; 2 focal moderate, diffuse weak; 3 focal strong, diffuse moderate; 4 diffuse strong.
The Kruskal-Wallis test was used to ensure that there were no significant differences
between the three, blinded observers. Statistical significance (*) between control (,
n=12) and treated (, n=10) groups was determined using the Mann-Whitney test
(p<0.05). Results are expressed as the mean and standard error of the mean.
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Figure 4.15: Effect of fenofibrate on allograft pathology at 8 weeks: Fenofibrate did not
ameliorate TxAA, but significantly increased PR. Photomicrographs show representative
vessels with TxAA scores ranging from 0 to 4. Statistical significance (*) between
control (, n=12) and treated (, n=10) groups was determined using the Mann-Whitney
test (p<0.05). Results are expressed as the mean and standard error of the mean.
4.4 Discussion
This chapter presents the first evaluation of fenofibrate treatment in a heterotopic murine
cardiac transplant model where recipients and donors are mismatched across MHC-II.
Fenofibrate administration resulted in distinct physiological and pharmacological effects
on liver and plasma markers. Results show that at early times, fenofibrate had largely
immunosuppressive effects and significantly reduced graft inflammatory cell infiltration.
However, long-term fenofibrate treatment significantly augmented graft inflammatory
cell infiltration and the expression of inflammatory molecules, thereby resulting in
enhanced PR without amelioration of TxAA.
The choice of 0.2% wt/wt of fenofibrate is supported by a number of in vivo studies that
used the same dose to achieve immunomodulatory effects i ti i' ii 999,. Kock,,' ix., !
J.ti .l'9 M'i ,? :, / 2 %'()2.. (l.I':;:'..l iCi :' .7! X')()4j. In fact, this concentration is toward the high
end of the range used in mice, with immunomodulatory and metabolic effects already
present at a dose of 0.05% wt/wt of fenofibrate jCu ..rr~,n5'iiloe al a< 2()t( D) ez ic: in
2ii( ,7. Mice (with roughly comparable weights and food intake) on 0.2% wt/wt of
fenofibrate-chow have plasma concentrations of up to 15 gM i .'a:ir5 i:: I'fs 2( iX2v. This is
comparable to the concentrations of fenofibric acid (active metabolite of fenofibrate)
readily available in humans after fenofibrate administration l aM,;a ,~f, I- , iir 9.i¢': :i<
i::'i 5.: 2(i0t', 5i..-~,,5x : ' ,: , 2i()! I and to the dose required for IFNy attenuation in vitro (as
presented in the previous chapter).
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The murine liver highly expresses PPARcc and fenofibrate, as a PPARC agonist, induces
peroxisomal proliferation i :,c':r wind WuVai1 20()001. Increased liver weight is an
established pharmacologic effect of PPARQ ligand-activation :'uh,' '1' c ' t,/) .
Results in this chapter are consistent with previously published increased liver weight
following treatment with fenofibrate I [1)--,Ue .s (/.!, i. Notably, the increase was
observed within two weeks and subsequently continued to increase. Histological
evaluation o)f the livers confirmed the presence of a physiological effect from the
fenofibrate-laden chow and immunohistochemical staining of PMP-70 recapitulated
results from the literature of PPARct activation [ta..x'w'c >c d I ) i 1 1{,. The increases in
ALT and, in particular, AST, strongly correlate with the total amount of fenofibrate
consumed and likely reflect the increase in liver size (since there was no histologic
evidence of liver damage). It should be noted that this effect is likely not present in
humans, given that PPARcc agonists do not induce peroxisome proliferation-associated
genes in human hepatocytesi : ; : )A i.
The total increase in liver size may account for the lack of effect on fibrinogen. At 2
weeks, plasma fibrinogen displayed a strong tendency to decrease. However, by 8 weeks,
fenofibrate had no significant effect on plasma levels of fibrinogen. This is contrary to
observations from the clinical i i:ti : t (;mrod. 2002 and rodent I oc x \ I /
i ct;c) literature. However, the clinical literature may not be particularly germane, given
the differential expression and effects of PPARx activators on human hepatocytes
iF',: it 2' ,, I Y' V :;',iti ,) (~ i. , 1 ,' c :';. I'1C . , 2(: "''Il i l. Insofar as the rodent literature,
experiments were limited to two weeks in duration and the decreased fibrinogen
expression was normalized to hepatocyte quantity Ix \ cxx :'/ 9 :)09. By 8 weeks, liver
weight is significantly higher in the treated mice and the lack of effect may be a result of
having reached a threshold where the decrease in levels of fibrinogen made by
hepatocytes is overwhelmed by the increase in hepatocyte size and number.
Fenofibrate decreased triglyceride levels, while elevating total cholesterol (the results at 8
weeks were statistically significant, while at 2 weeks, results constituted trends only
likely due to small sample size). These findings are consistent with reports documenting
that PPARa agonist administration decreases triglycerides and increases cholesterol
levels in mice fed a standard diet 2 ria: cv (/ Et;7 0:"a ; 1 (/ . As a clinical
agent for dysplipidemia, the ability of fenofibrate to reduce triglyceride levels is firmly
established t :, -Od~ .: r'ir<l 2X)rI I and similar findings in mice fed a standard diet
(and thus not exhibiting increased triglyceride levels) suggest that this is a particularly
robust result that is not sensitive to negative feedback mechanisms. The effect of
fenofibrate on total plasma cholesterol levels appears to be affected by whether baseline
levels are associated with an underlying metabolic syndrome. In other words, when total
cholesterol levels are elevated due to an underlying metabolic syndrome, fenofibrate
treatment reduces total cholesterol in both clinical !i< Q, :,i -?, .xd n'x 2(X' } and
experimental Oi- ' J -:':, settings. However, when total cholesterol levels are at
baseline, experiments in murine models demonstrate that fenofibrate significantly
increases total plasma cholesterol, by increasing HDL to a greater extent than reducing
LDL tivio c > I¢.
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Although hypoglycemic actions are traditionally ascribed to PPARy agonists Itl.x
v :,', Ithe present results show a significant reduction in glucose levels following
PPARa agonist treatment. This effect has been previously observed in a murine model of
endotoxemia 1'11ii c , ti9iY)j and potential mechanisms include a decrease in hepatic
gluconeogenesis subsequent to decreased 1 -hydroxysteroid dehydrogenase- 1 activity
1.) 4-,S ooS `V Pf)' I shlP ; I) and increased insulin sensitivity reducing adiposityi ,~;'~,,:r,::'~ ;'li <,~~ i:s: >s ,s I.It should be noted that this regulation is a sexually dimorphic
phenomenon, with females not exhibiting the same response to fenofibrate as their male
counterparts i r are -4 2:;:2 io
The effect of fenofibrate treatment on allograft expression of cytokines, chemokines and
chemokine receptors at 2 weeks exhibited results roughly consistent with the in vitro
results presented in the previous chapter, namely a decrease in IFNy, CCR2 and CCR5,
and increase in RANTES. However, by 8 weeks, fenofibrate displayed mixed results. The
lack of effect on IL-10 and IL12-p35, together with an increase in IL12-p40, was
hypothesized based on the results of the previous chapter. However, the increased mRNA
expression of IFNy, as well as IL-4 and IL-6, was contrary to expectations based of the
previous chapter (where IFNy was significantly and robustly reduced, while no effect was
observed on IL-4 and IL-6). Similarly, while the tendency to increase RANTES was
regarded as a potential effect, it was expected that fenofibrate would reduce the mRNA
expression of CCR2 and CCR5 and not influence IP-10. Instead, CCR2 and CCR5
remained unchanged and IP-10 increased.
In the analysis of mRNA expression, results are normalized to the housekeeping gene and
are thus proportional to cell number. While in splenocyte cultures, results expression
closely corresponds to the numbers of lymphocytes, in the allografts, the correspondence
is not as direct. The vast majority of the signal from the allograft RNA derives from
myocytes rather than lymphocytes. Consequently, any potential increase in graft
infiltration is not likely to be large enough to affect the housekeeping gene in proportion
to the increased cytokine signal.
Consideration of this led to the hypothesis that the allograft expression of IFNy (as well
as other cytokines and chemokines) may be influenced by the extent of graft infiltration
by inflammatory cells. It should be noted that masking of potentially anti-inflammatory
activity of PPARa ligands by other effects has been previously reported; in a murine
model of endotoxemia, fenofibrate decreased cellular TNFa production; yet mice on a
fenofibrate diet had five-fold higher circulating TNFca levels upon stimulation with LPS
and significantly lower lethal dose /I11L< t-i.i r /9:)"1. Accordingly, the increased mRNA
expression of IFNy (as well as IL-4, IL-6 and IP-10) seen in the 8-week allografts could
be the result of an increased number of graft infiltrating cells, rather than an augmented
expression of IFNy by the leukocytes themselves.
Support for this hypothesis derives from the examination of graft infiltrating profiles, as
well as functional effects of fenofibrate on recipient splenocytes upon restimulation ex
vivo. At 2 weeks post transplantation and treatment, fenofibrate markedly diminishes
graft infiltration by significantly reducing graft infiltrating CD4+ T cells and CDlb+
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macrophages. This implies that the decreased cytokine and chemokine, as well as
chemokine receptor mRNA expression at 2 weeks could be a result of diminished graft
infiltration alone and requires the consideration of functional effects on leukocytes to
determine the direct contribution of fenofibrate on a per cell basis. Examining this issue
for IFNy alone (given its particularly important role in allograft rejection as discussed in
chapter 2) showed that, upon restimulation ex vivo with both same party (bm12), third
party (B/c) stimulation, as well stimulation by a mitogenic agent (ConA), splenocytes
from treated recipients produced significantly less IFNy on the third day of culture (that
corresponds to the first day of significant protein present in culture).
At 8 weeks, fenofibrate treatment significantly augmented the number of CD4+ T cells
and CDllb+ macrophages infiltrating into the graft. The ability of CD4+ T cells to
produce IFNy upon stimulation is a fundamental property and there are a growing number
of reports that document IFNy production by antigen-presenting cells, including CD1 lb+
macrophages .i(-;,;,i:~:~ 'i :;k : l l I" , , ':i"'.l ' . 2t;' ()2. This implies that the
increase in IFNy could be a consequence of increased graft infiltration and once again,
requires the consideration of functional fenofibrate-mediated effects on leukocytes. Upon
restimulation ex vivo with either same party (bml2) or third party (B/c), splenocytes from
8-week recipients treated with fenofibrate produced significantly less IFNy on the third
day of culture (that corresponds to the first day when substantial concentrations of protein
are present in culture).
Interestingly, the attenuation of IFNy production in splenocytes from mice treated short
term and restimulated ex vivo with same (bm12) party stimulators was not sustained for
the entire duration of cultures. More evident is that lack of a sustained decrease in IFNy
production by splenocytes from 8-week treatment restimulated with both same (bml2)
and third (B/c) party stimulators. This raised the question of whether this effect was a
function of time, diminishing the ability of fenofibrate to influence IFNy production.
However, splenocytes from non-transplanted mice taken off the diet one week before
harvest sustained the decrease in IFNy for the entire duration of the culture. This suggests
that time was not the issues but rather that an alteration in leukocytes activity following
transplantation such that fenofibrate is less able to mediate its effects. One potential
mechanism could be downregulation of T cell PPARca expression t':-r i2.f.. l 2 )"2,, .'
There are several potential mechanisms contributing to the overall increased graft
infiltration in long-term allograft recipients treated with fenofibrate. At 2 weeks, despite
an overall immunosuppressive effect, RANTES notably was not effect. This finding,
taken together with the previously presented in vitro data showing a significant increase
in RANTES expression from fenofibrate treatment (20%), suggests that RANTES may
be contributing to graft infiltration. Even a small increase in RANTES production can be
significant due its particularly high level of expression in the alloresponse (dominant
chemokine) and rejecting murine cardiac allografts (from this thesis). As graft
inflammatory cells infiltration increases, net allograft expression of IFNy also increases.
This is likely responsible for the increased IP-10 expression seen at 8 weeks that, in turn,
further contributes to the augmentation of graft infiltration.
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Fenofibrate had time-dependent effects on graft expression of MHC-II, one of the
markers of graft activation. At 2 weeks, graft expression of MHC-II was not influenced
by fenofibrate, while at 8 weeks it decreased. The lack of an effect at 2 weeks is
consistent with findings that fenofibrate had no effect on IFNy-induced MHC-II promoter
activity of the major transactivator factor CIITA in macrophages Kak 2 02 ()  1. By 8
weeks, however, despite an increase in IFNy, there is a small, yet statistically significant
decrease in MHC-II. This is contrary to expectations based on overall graft expression of
IFNy, but may be attributable to the increased expression of IL-4 in the graft, given the
reported ability of IL-4 to induce the production of PPARy ligands I}Ital i r tI al 1999]
and subsequent, profound attenuation of MHC-II by PPARy activation at the
transcriptional level by inhibiting promoter activity I Kw'tk ei a/ 2002) 1.
There were no statistically significant changes at either time points in the expression of
the adhesion molecules, VCAM-1 and ICAM-1, two other markers of graft activation.
However, the observed trends are still worth discussing in light of the reported effects of
PPARa activators on these molecules IN Mar tcl 199%. Rival t al 2)U02 Deplaticlute /'
al 2(i0) , as well as their relevance to transplantation I Iee 'i ua 1(-99. S tznki at i J 9991
and the responsiveness to IFNy I'lNarSx t I/ )1999b)1. It should be noted that, while the
inhibitory effects on VCAM-1 are consistent and well documented I lNlrx c: ( )' I999b.
Riva.l i/ .i// q()()2, Dcpl(tn.ue / ! 20()31, the effects on ICAM-1 are somewhat
controversial Vi \M6rx rt i 1999%. Deplanqcitti i..' 203 j
At early times, fenofibrate tended to decrease the expression of both graft adhesion
molecules, VCAM-1 and ICAM-1. This is consistent with the literature describing a
decrease following fenofibrate treatment in vivo I Deplalnque aet a/l 200(3 . The decrease in
VCAM-1 is also consistent with findings in vitro [Narx et ail I991), Rival ' a:i 202( I.
The decrease in ICAM-1 may be reconciled with in vitro literature latlax ci It l9 )9bIt by
considering that IFNy expression was reduced in the treated grafts, leading to a decrease
in ICAM- 1 independent of PPARa activation.
By 8 weeks, there was essentially no difference in VCAM-1, while ICAM-1 tended to
increase. These findings may be once again reconciled with the literature by considering
the expression of IFNy; contrary to expectations, IFNy expression increased in long-term
fenofibrate-treated allografts. This may account for the tendency of ICAM-1 to increase,
given its responsiveness to IFNy larx ctl ai I)99b9 , and may shed a different perspective
on the effect on VCAM-1. According to its induction by IFNy, VCAM-1 should have
increased, such that the lack of an increase may actually be a reflection of the suppressive
effect of fenofibrate on VCAM-1, thereby making it consistent with the literature t \al1tn'
I.XZ ik 9 |)99b, ta t ci; f J, al 2002. )ept Ilail-l i a! 0 .
Given the central role of IFNy in allograft rejection 11lidal gou ald HIFlacl 221i and the
overall increase in allograft IFNy expression, it is not surprising that long-term allografts
of fenofibrate-treated recipients display increased PR, without amelioration of TxAA.
Moreover, potential effects from the augmented mRNA expression of other cytokines and
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chemokines on allograft pathology are also worth considering, particularly with respect to
potential effects on PR and TxAA.
The augmented intragraft expression of IL4, IL-6, and IP-10 at 8 weeks following
continual fenofibrate treatment of recipients is likely not beneficial for cardiac allografts,
given the roles of these mediators in transplant rejection. Although controversial,
especially in light of the generally accepted paradigm that IL-4 is a "protective" cytokine,
a review of the literature highlights several reports indicating that increased graft
expression of' IL-4 is deleterious IPiccotti tt I t1 971. IL-6, typically considered a "pro-
inflammatory" cytokine, plays a role in the development of PR If I)ng ( a/i 20' 21 and
increased concentrations are associated with an increased incidence of clinical TxAA
I jilesitiad a, > 19991. IP-10, particularly when donor derived, has a pivotal role in the
development of PR; mice congenitally deficient in IP-10 showed reduced graft
infiltration and injury I i lancock f i a 2001 . Although persistent PR is not required for
the development of TxAA Ilzttini ct fl 1t95. Nagali.o cr a!' )99f1j, studies have found
that episodes of PR may potentiate the development of TxAA I lltit 9i? .: 1iCo().
N,,) ka -,; a ie ii 1995
The relevance of the increase in graft expression IL12-p40 merits discussion based on its
high level of mRNA expression (same order of magnitude as IFNy mRNA). Given that
the formation of functional IL-12 requires an increase in IL12-p35 and IL12-p40 (to form
the p35/p40 dimer or p75), the increase in IL12-p40 alone affect IFNy expression
t PLcce aS ci,: )20021. Several disease states are associated with increased IL12-p40 tabdi
2i(2 i2. However, its role has not been specifically addressed in transplantation and thus
discussion is limited to extrapolations from the literature. Along these lines, the finding
that IL12-p40 inhibits T lymphocyte generation Ahbdi and -1ficrtl i r 9i)97 , suggests
potential benefit in the attenuation of the alloresponse. On the other hand, increased
IL12-p40 is associated with pulmonary fibrosis, suggesting a potentially profibrotic and
consequently deleterious for TxAA i i ax ct al 2)()2 I.
In conclusion, fenofibrate treatment reduces early graft expression of IFNy, as well as
other proinflammatory genes, with concomitant reductions in IP-10, CCR2 and CCR5.
This results in a significantly diminished mononuclear cell infiltrate. However, the
tendency to increase RANTES (despite the decrease in IFNy), an effect that is consistent
with the in vitro results presented in chapter 3, is likely one of the mechanisms
contributing toward the eventual increase in graft infiltration (as the effect of RANTES
becomes more dominant). The increase in long-term graft inflammatory cell infiltrate
eventually results in an overall increase in the graft expression of IFNy, although
fenofibrate does continue to attenuate production of IFNy on a per cell basis.
Moreover, the net effect is a significantly increased level of PR, without amelioration of
TxAA. This suggests that in order to fully realize the benefit of diminished cytokine
production by fenofibrate in the graft, concomitant administration of agents reducing
graft infiltrate may be required. This may involve either agents directly attenuating
recruitment by targeting the chemokine or chemokine receptors, or agents directed at
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preventing adhesion and/or extravasation of circulating lymphocytes into the donor
vasculature.
Page 103
EmanIiela_ BIn--1o FIST
Chapter 5. Role of PPARa in vitro and in vivo
5.1 Introduction
Generally, PPAR ligands are ascribed a particular receptor specificity and receptors are
ascribed specific activation and signaling pathways. However, there is growing evidence
for "cross-talk" between various ligands and receptors. At selected doses, typical PPARca
ligands may activate PPARy in addition to PPAR, and vice versa l -.,l alf \,V'ahli
200')0() . This phenomenon may result from the large PPAR binding pocket, conducive to
the accommodation of a variety of ligands ` ..i:!!,0,:' 01 :'l .iti;))i. Studies have also
shown "cross-talk" between other nuclear receptors. For example, pituitary-dependent
hormones specifically regulate PPARa expression in the liver ,!thlio<t 't:i I /2(!)I, while
activation of the growth hormone receptor leads to activation of a signal transduced and
activator of transcription (STAT) protein that can inhibit PPARy-regulated transcription
The development of mice congenitally deficient in PPARa L i.tc, (.;.'(,,ztoz i.9,)6
potentially allows the elucidation of ligand and receptor specificity, as well as the
accurate identification of processes regulated by PPARs. One of the primary PPARc
targets is the liver, and studies have documented the specificity of PPARa-mediated
effects, e.g. the reduction in the hepatic activity of 11p-hydroxysteroid dehydrogenase
- : and expression of fibrinogen iKock c ' .? 99 j)I.
Recent evidence, using chimeric livers, has also shown that peroxisomal proliferation
does not require PPARa in all hepatocytes t'!'z :t'ie 5ct;:,:.il 2()-.l. Several
experiments have examined PPARa-mediated cardiac actions. Myocardial pump function
and male mortality were negatively affected in mice lacking PPARa and overexpressing
lipoprotein lipase !Ni'o7&slni. (; I , /2t(!')1. Congenital deficiency of PPARa protected
against myocardial ischemic injury and improved endothelial vasodilatation l':ri:ark )
! ,/ s:1i .)-3 i. Finally, mice congenitally deficient in PPARc display an exaggerated
response to lipopolysaccharide with significantly increased plasma levels of IL-6
! ix,,a5l 3 : ii ~, f,:. I' 't )l : and TNFac t i i ' I ,99.) i. Demonstrating the relative a-specificity
of fenofibrate, treatment with that agent in PPARca-deficient mice had no effect on IL-6
production ,>:c :ia :: (,.Y 2 11'4 I.
This chapter utilizes mice congenitally deficient in PPARc to explore the specificity of
the fenofibrate-mediated immunomodulatory effects in vitro (specifically with respect to
IFNy) and to identify potential regulatory roles of PPARa in the expression of selected
cytokines, chemokines and chemokine receptors. It also examines the influence of
congenital PPARca deficiency in vivo on both donors and recipients in murine heterotopic
cardiac transplantation between strains disparate in MHC-I and MHC-II (a model of PR).
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5.2 Methods
Animals and Diet
Inbred strains, 129Sv (129WT) and Balb/c, were purchased (Jackson Laboratories, Bar
Harbor), while breeding pairs of mice congenitally deficient in PPARa (PAKO) on a
129Sv background were a generous gift from Dr. Jorge Plutzky. Mice were housed in the
animal facility of Harvard Medical School on acidified water and chow ad libitum, as
previously described, and experiments were done according to protocols approved by the
animal care committee.
Mixed Leukocyte Reaction
The technique used for splenocyte isolation and culture in a mixed leukocyte reaction
(MLR) is fully described in chapter 3. Experimental cultures were performed in vitro and
used Balb/c splenocytes as stimulators with either 129WT or PAKO as responders. In the
cultures testing fenofibrate specificity, samples were plated in quadruplicate and
proliferation was measured on days 2 through 5. In the cultures testing for PPARc
regulation, mRNA was isolated on days 1 through 3.
Enzyme-Linked Immunosorbent Assays
The concentration of IFNy in the supernatants of the proliferation assays was determined
using enzyme-linked immunoassays (ELISAs), per the manufacturer's protocol
(Pharmingen, San Diego). Details of the procedure are fully described in chapter 3.
Optical density was measured using an ELISA plate reader and converted to pg/ml using
a calibration curve prepared from recombinant IFNy standards.
Propidium iodide staining
Details of this procedure have been described in chapter 3. Briefly, splenocytes from both
129WT and PAKO mice were incubated with 1 tg/ml of ConA for 12 hours, at which
time point, cells were directly stained with propidium iodide (PI) and immediately
analyzed by flow cytometry.
RNase Protection Assay
Details of this procedure are fully described in chapter 3. In brief, RNA from either
cultures or allografts was isolated using TRIZOL (Invitrogen, Carlsbad). For in vitro
samples, aliquots of 5 I[g mRNA were prepared, while for the allograft samples, aliquots
were prepared containing 10 !xg of RNA. Aliquots were stored in RNase-free DNase-free
water at -70 0 C and analysis of mRNA expression was performed via the RNase
protection assay (RPA). Volume integrations of bands were normalized to GAPDH in the
corresponding lane, using ImageQuant (Molecular Dynamics). Results of triplicate
samples are presented as the average and standard deviation per group.
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Heterotopic heart transplantation
As previously described, murine cardiac transplantation .u :; rd f ala .1a~'a I -i .
2ifa:*til i was performed in accordance with protocols approved by the Harvard Medical
School Animal Care Committee. In brief, the donor heart was removed after
administration of inhalation anesthesia and injection of cold heparinized saline. The
donor aorta and pulmonary artery were ligated to the recipient abdominal aorta and
inferior vena cava, respectively. At the time of harvest, the allograft was divided
transversely in three sections, representing the base, middle section and apex of the
allograft, each to be used respectively for histological, immunohistochemical and RNA
analysis. Transplants (n=11) were divided into four groups, with Balb/c (B/c) donors for
both 129WT and PAKO recipients (2 groups), and 129WT and PAKO donors with B/c as
recipients (2 groups). Allografts were harvested at 1 week post-transplant.
Histological staining and scoring
The base of the heart and liver sections were fixed in 10% buffered formalin for staining
with hematoxylin and eosin. The heart was also stained for elastic tissue and was scored
for extent of PR. The grading scheme for PR was modified from the International Society
for Heart and Lung Transplantation scale and is described as follows: 0, no rejection; 1,
mild interstitial infiltrate without necrosis; 2, focal interstitial with necrosis; 3, multifocal
interstitial with necrosis; 4, widespread infiltrate with hemorrhage and/or vasculitis.
Immunohistochemical staining and scoring
The methodology used has been described in chapter 4. Briefly, the middle transverse
section of the cardiac grafts and sections of the recipient liver were frozen at -800 C until
analysis of MHC-II, ICAM-1, VCAM-1, CD4, CD8 and CD1 llb. Slides were air dried
and fixed with paraformaldehyde. Sections were blocked with hydrogen peroxide,
followed by blocking with either rabbit or goat serum, in addition with avidin and biotin.
Primary antibody was applied and if applicable, a biotinylated secondary antibody was
also used. Chromogen was added and development observed under a microscope until
isotype controls showed early substrate reduction. Slides were then counterstained in
hematoxylin and washed under running water. Heart sections were scored (3 blinded
observers) according to the following scheme: 0, no staining; 1, focal weak; 2, focal
moderate, diffuse weak; 3, focal strong, diffuse moderate; 4, diffuse strong.
Data Analysis
Results in bar and line graphs represented as the mean and standard error of the mean.
Statistical significance for staining results was determined using the Mann-Whitney test
for non-parametric value with a two-tailed, p < 0.05. For immunohistochemical staining,
the Kruskal-Wallis test ensured that there was no statistically significant difference
between the three, blinded observers. Statistical significance of other values was
determined using the Student's t-test for unpaired samples with two-tailed and a p value
less than 0.05.
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5.3 Results
In vitro
The in vitro evaluation of congenital deficiency of PPARca had two aims. The first was to
establish if the effects of the fenofibrate doses previously employed to decrease IFNy
were largely attributable to pure PPARa activation. The second was to identify whether
PPARa plays a regulatory role in the expression IFNy and RANTES, as well as other
cytokines, chemokines and chemokine receptors.
Figure 5.1 presents the evaluation of varying doses of fenofibrate on IFNy production in
the alloresponse using B/c stimulators and both WT and PAKO responders. At 20 CFM
(the dose previously identified as "therapeutic" based on the significantly attenuation of
IFNy, without effects on proliferation), fenofibrate significantly reduces the production of
IFNy in cultures with both 129WT and PAKO responders. This suggests "cross-talk"
with either PPARy or PPAR6, or a potentially drug-specific and PPAR-independent
effect. At doses higher than 20 [FM, fenofibrate reduces both proliferation and IFNy
production, indicating potential toxicity. To determine whether this was a result of
toxicity, propidium iodide staining was performed at each of the fenofibrate doses. Figure
5.2 shows that doses of 4 and 20 [tM do not affect cell viability, while doses of 100 and
500 [FM result in significant cell death. PPARca deficiency results in no observable
differences in fenofibrate toxicity at these concentrations.
The identification of PPARca regulatory roles was performed by examining the change in
mRNA expression resulting from PPARa deficiency in responders compared to WT.
Figure 5.3 shows that, when stimulated with B/c splenocytes, PAKO responders express
higher levels of IFNy compared to WT, thereby indicating a regulatory role in the
expression of IFNy. PPARca deficiency also increased expression of IL-6 and IL-12p40,
also indicating PPARca regulation. The lack of an increase in IL-12p35, despite the
increase in IL-12p40, implies that there is no increase in the expression of IL-12, further
pointing to a direct regulatory role of PPARca in IFNy expression. Figure 5.4 displays the
influence of PPARc deficiency on chemokine and chemokine receptor expression
(RANTES, IP-10, CCR2 or CCR5). At early times, PPARca had no significant effects on
the expression. However, late in culture, when there is a significantly elevated level of
IFNy in culture, congenital deficiency of PPARa has significant effects. Based on
traditional knowledge of IFNy-mediated effects, elevation in IFNy should increase
RANTES. However, PPARca deficiency significantly decreases expression of RANTES,
indicating a direct regulatory role of PPARa. This is consistent with the significant
increase in RANTES expression observed with fenofibrate activation of PPARc. Taken
together, these suggest a direct regulatory role of PPARa on RANTES expression that is
dominant over the influence of IFNy. The increased expression of IP-10, CCR2 and
CCR5 are consistent with an elevation of IFNy (again based on traditional knowledge of
IFNy-mediated effects) and thus does not constitute evidence of direct PPARa regulation.
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In vivo
The in vivo evaluation of congenital PPARa deficiency involved the examination of the
influence on PR in the heterotopic murine cardiac transplant model, particularly on graft
infiltration. The effect on TxAA could not evaluated because of the background strain of
the PAKO mice (129Sv) and consequent unavailability of an MHC-II mismatched strain.
A limited number of mice were available per treatment arm; consequently, emphasis is
placed on the examination of trends, in addition to statistical significance.
The first set of transplants examined the effect of congenital PPARa deficiency on the
allograft recipient. Figure 5.5 shows that PAKO recipients have significantly more
CD1 lb+ graft infiltrating cells (146+i4 vs. 208+22 cells per high power field; p<0.05)
and fewer CD8+ cells (17+4 vs. 31 cells per high power field; p<0.05), with the former
result being more substantial due to the relative quantities of cell types. Infiltration by
CD4+ cells is not significantly affected. There are no statistically significant effects on
MHC-II, VCAM-1, or ICAM-1, as shown in figure 5.6; however, both MHC-II and
VCAM-1 display a tendency to increase, while ICAM-1 tends to decrease. Examination
of graft mRNA cytokine expression, presented in figure 5.7, reveals a tendency toward
increased IIFNy expression, providing in vivo corroboration for PPARa regulation in
IFNy expression. Results of chemokine and chemokine receptor expression are shown in
figure 5.8. There is a slight tendency for RANTES to decrease, which would be
consistent with in vitro results. Furthermore, IP-10 and MCP-1 tend to increase.
Pathology results, shown in figure 5.9, show that substantial differences arise from
PPARca deficiency on the recipients; allografts from PAKO recipients display the
formation of thrombi, in the absence of vascular edema, while those from WT recipients
show edema without thrombus formation. This likely represents systemic effects (such as
elevated fibrinogen levels) overwhelming local ones. Consistent with an increased graft
infiltrate, PR. modestly increases with PPARca recipient deficiency.
The second set of transplants examined the effect of PPARca deficiency on donors.
PPARa donor deficiency affects augmented graft infiltration, as shown in figure 5.10, by
increasing CD4+ (19+3 vs. 71+10 cells per high power field; p<0.05) and CDllb+
(142+23 vs. 204+15 cells per high power field; p<0.05) graft infiltrating cells, without
affecting the number of CD8+ cells. As presented in figure 5.11, donor deficiency has
mixed effects on graft activation; there is a decrease in MHC-II (trend) and ICAM-1
(significant), while VCAM-1 tends to increase. With respect to cytokine expression,
presented in figure 5.12, PPARca deficiency on donors clearly tended to increase graft
expression of IFNy, once again providing in vivo confirmation of in vitro results. In
addition, IL-4, IL-6 and IL-12 tend to increase. Most notable among the effects on
chemokines and chemokine receptors, shown in figure 5.13, is a clear trend towards
decreased RANTES expression, which would be consistent with the in vitro results.
Pathology results are summarized in figure 5.14. Contrary to PPARcadeficiency on
recipients, PPARa deficiency on donors results in edema, without thrombus formation.
The pathological appearance of allografts with and without donor PPARa deficiency is
not substantially different. Consistent with an increased graft infiltrate, PR modestly
increases.
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Figure 5.1: Varying doses of fenofibrate in vitro with 129WT and PAKO responders:
MLR with B/c stimulators and a, b) 129WT responders or c, d) PAKO responders. For
both, the left panel represents proliferation, while the right panel represents IFNy
production. No effect is seen on either proliferation or IFNy production at 4 FM. At 20
EM, however, fenofibrate significantly reduces the production of IFNy in cultures with
both 129WT and PAKO as responders. This indicates that fenofibrate either "cross-talks"
with other PPARs (notably PPARy or PPAR6) or has drug-specific and thus completely
PPAR-independent effect. At doses higher than 20 FiM, fenofibrate reduces both
proliferation and IFNy production, indicating potential toxicity (to be specifically
addressed in the next figure). The bolded lines represent the day of peak proliferation and
initial IFNy production, respectively. Representative results are shown as the average and
standard deviation of triplicate samples.
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Figure 5.2: Cell viability after a 12 hour incubation with fenofibrate: flow cytometric
analysis of PI staining of ConA-stimulated a) 129WT and b) PAKO splenocytes. The
light-colored line represents control cultures (with no fenofibrate) while the filled area,
represents splenocytes incubated with varying fenofibrate doses. A shift toward the M1
marker represents increased cell membrane permeability, allowing the propidium to bind,
and thereby denoting cell death. Doses of 4 and 20 [tM of fenofibrate did not affect cell
viability in any culture, while doses of 100 and 500 [IM resulted in significant cell death.
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Figure 5.3: Influence of PPARa deficiency on cytokine mRNA expression in vitro:
When stimulated by allomismatched B/c splenocytes, PAKO splenocytes express
substantially higher levels of IFNy compared to WT, indicating a regulatory role in the
expression of IFNy. Similarly, PPARc also significantly increases expression of IL-6 and
significantly decreases expression of IL-12-40, thereby denoting regulatory role in the
expression of both of these cytokines. The lack of an increase in IL-12p35 indicates that
there is no increase IL-12 and corroborates a PPARct-dependent role in the regulation of
IFNy. Results are normalized to the expression of GAPDH and observed on the day of
maximal cytokine expression (day 2 for IFNy and day 1 for the remainder).
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Figure 5.4: Influence of PPAR deficiency on chemokine expression in vitro: The early
(and maximal) expression of RANTES, IP-10, CCR2 or CCR5 are not affected by
PPARca deficiency. This is similar to the findings in chapter 3, where PPAR activation
had no significant effects on chemokine expression. However, late in culture, PPARa
deficiency significantly decreases expression of RANTES and increases IP-10, CCR2
and CCR5. The significantly elevated IFNy levels and known IFNy-mediated effector
functions suggest that IP-10, CCR2, and CCR5 should also significantly increase. This is,
in fact, observed and indicates that the effect is IFNy-mediated and thus only indirectly
influenced by PPARcc. On the other hand, the decrease in RANTES (in the setting of
increased IFNy, which normally increases RANTES) suggests a direct PPARc regulatory
role on RANTES expression. Results are normalized to the expression of GAPDH. Early
and late refer to days 2 and 3, respectively.
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Figure 5.5: Influence of recipient PPARa deficiency on allograft cellular infiltration:
The dominant graft infiltrating cell subtype is the CDllb+ macrophage and PPARa
recipient deficiency results in significantly increased CD1 lb+ graft infiltration. Despite a
small attenuation in CD8+ T cells, overall graft infiltration is augmented. This indicates
that PPARcc is not necessary for graft infiltration. Five fields were counted per section
and statistical significance was tested using the Student's t-test (p < 0.05). Allografts
were harvested at 1 week post-transplantation.
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5.6: Influence of recipient PPARa deficiency on allograft activation markers:
Although there are no statistically significant differences and thus no overall effect, the
trends merit some mention. MHC-II and VCAM-1 tend to increase, while ICAM-1 tends
to decrease. Sections were evaluated according to the following scheme: 0, no staining; 1
focal weak; 2 focal moderate, diffuse weak; 3 focal strong, diffuse moderate; 4 diffuse
strong. Statistical significance (not affected by observer) was tested using the Mann-
Whitney test (p<0.05). Allografts were harvested at 1 week post-transplantation.
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Figure 5.7: Influence of recipient PPARa deficiency on cytokine expression: The most
marked and noticeable trend is the increase in IFNy mRNA expression. This is consistent
with the in vitro results demonstrating a regulatory role for PPARa in IFNy expression.
The lack of statistical significance may be a result to the low number of samples in this
set of transplants and the typical heterogeneity exhibited by transplant recipients. D and
R refer to donor and recipient, respectively. Statistical significance was tested using
Student's t test (p<0.05). Results are normalized to the GAPDH housekeeping gene and
are represented as the mean and standard error of the mean. Allografts were harvested at
1 week post-transplantation.
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Figure 5.8: Influence of recipient PPARa deficiency on chemokine and chemokine
receptor expression: There is a slight tendency to decrease RANTES, consistent with in
vitro studies. In addition, there is a tendency to increase IP-10 and MCP-1. D and R refer
to donor and recipient, respectively. Statistical significance was tested using Student's t
test (p<0.05). The bar indicates the mean value and standard error of the mean. Results
are normalized to GAPDH expression. Allografts were harvested at 1 week post-
transplantation.
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Figure 5.9: Influence of recipient PPAR deficiency on allograft pathology: PAKO
recipients display the formation of thrombi, in the absence of vascular edema (see
photomicrograph of sample vessel). The presence of PPARct, on the other hand, induces
edema and does not result in thrombi formation. These results suggest effects of systemic
factors, such as increased fibrinogen levels in PAKO mice, on local allograft pathology.
Consistent with an increased graft infiltrate, PR is modestly increased in the PAKO
recipients.
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Figure 5.10: Influence of donor PPARq deficiency on allograft infiltration: PAKO donor
allografts have significantly increased numbers of CD4+ and CD1 lb+ graft infiltrating
cells (CD8+ cells are not affected). Interestingly, PPARa deficiency on recipients had no
effects on CD4+ but rather influenced graft infiltration by CD8+ cells. Overall, graft
infiltration by inflammatory cells is augmented. This also suggests that PPARa is not
necessary for this process. Five fields were counted per section and statistical
significance was tested using the Student's t-test (p < 0.05). Allografts were harvested at
1 week post-transplantation.
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Figure 5.11: Influence of donor PPARq deficiency on allograft activation: While
VCAM-1 tends to increase, MHC-II tends to decrease and ICAM-1 is significantly
attenuated in PAKO donors. Sections were evaluated as follows: 0, no staining; 1 focal
weak; 2 focal moderate, diffuse weak; 3 focal strong, diffuse moderate; 4 diffuse strong.
The Kruskal-Wallis test was used to ensure that there were no significant differences
between observers. Statistical significance was determined using the Mann-Whitney test
(p<0.05). Results are expressed as the mean and standard error of the mean. Allografts
were harvested at 1 week post-transplantation.
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Figure 5.12: Influence of donor PPAR deficiency on cytokine expression: PPARc
donor deficiency tends to increase graft IFNy expression, consistent with the in vitro
findings supporting a regulatory role of PPARca in IFNy expression. In addition, PPARa
donor deficiency tends to decrease IL-10 and increase IL-4, IL-6 and IL-12. D and R
refer to donor and recipient, respectively. Results are normalized to the GAPDH
housekeeping gene and are represented as the mean and standard error of the mean.
Statistical significance was tested using Student's t test (p<0.05). Allografts were
harvested at 1 week post-transplantation.
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Figure 5.13: Influence of donor PPAR deficiency on chemokine and chemokine
receptor expression: There is a tendency to decrease RANTES, consistent with in vitro
studies. In addition, donor deficiency of PPARca tends to increase MIP-2 and decrease
MCP-1, MIP-la and MIP-1. D and R refer to donor and recipient, respectively.
Statistical significance was tested using Student's t test (p<0.05). The bar indicates the
mean value and standard error of the mean.
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Figure 5.14: Influence of donor PPARa deficiency on allograft pathology: Deficiency of
PPARa on donors results in edema, without thrombus formation (see photomicrograph of
sample vessel). The pathological appearance of allografts with and without donor PPARa
is not substantially different. Consistent with an increased graft infiltrate, PR modestly
increases.
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5.4 Discussion
This chapter utilized mice congenitally deficient in PPARa to explore the specificity of
the fenofibrate-mediated immunomodulatory effects in vitro. It specifically addressed the
production and expression of IFNy, in addition to the expression of a number of other
cytokines, chemokines and chemokine receptors. This chapter also investigated the
influence of PPARca in vivo on parenchymal rejection, via murine heterotopic cardiac
transplants between strains mismatched in both MHC-I and MHC-II, where either the
donors or recipients were congenitally deficient in PPARca.
The findings in this chapter support PPARc-independent, as well as PPARa-dependent,
effects on IFNy. At 20 EtM, fenofibrate reduces the in vitro production of IFNy by
splenocytes congenitally deficient in PPARc, without affecting cell proliferation or
viability. This suggests the existence of cross-talk that could possibly exist at several
levels; one is at the level of receptor, since there is evidence that at particular doses,
ligands initially specific to one PPAR isoform, can also begin to activate others ~':i l"
:.i ~ :ti@ ;!!~i. Sa$).There could also be drug-specific effects or cross-talk downstream at
the level of signaling molecules, for example on IKB, as with PGJ2 i ~: i~ ( ). i.
This raises the issue of whether the PPARa agonist effect on IFNy production was
mediated even in part by PPARca. Data in chapter 3 documented a significant (-50%)
decrease in IFNy expression and production upon PPARca activation by two different
ligands (fenofibrate and WY 14643). This leads to the hypothesis that if PPARcC were
involved in the inhibition (and/or regulation) of IFNy, then deficiency in PPARct should
lead to increased expression of IFNy. Indeed, upon stimulation with allomismatched cells
in the MLR, PPARa-deficient splenocytes expressed higher levels of IFNy message,
suggesting that, independently of possible fenofibrate-specific effects, PPAR does play
a regulatory role in the expression of IFNy.
Other cytokines significantly affected in vitro by congenital PPARa deficiency were IL-6
and IL-12p40. The increased expression of IL-6 is entirely consistent with previous
reports documenting inhibition of IL-6 production by vascular smooth muscle cells upon
PPARc activation by several ligands ISl u> : d i9: 9:' and an increase in IL-6
expression by cells from PAKO lipopolysaccharide-stimulated male mice i le'ive: X : in 
! :t't. Regarding IL-12p40, there is no prior literature available for comparison. Data in
previous chapters demonstrated a small but significant augmentation IL-12p40 resulting
from PPARct ligand-activation. If this effect were indeed mediated by PPARa, then
congenital deficiency of PPARc should lead to a decrease in IL12-p40. This hypothesis
finds support in the attenuated expression of IL12-p40 by the PAKO splenocytes. The
other subunit of IL-12, namely I1l2-p35, is not significantly affected, such that functional
IL-12 (which requires both subunits) is not increased. This further suggests that the
PPARc-mediated regulation of IFNy is direct and not through upstream cytokine
signaling pathways.
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Early in culture, PPARc deficiency has no significant effects on the mRNA expression of
either chemokines or chemokine receptors. This is consistent with results in chapter 3
where PPARa ligand-activation also had no observable effects. However, late in culture,
as in the setting of PPARa ligand-activation, significant effects are observed. Despite the
four-fold increase in IFNy, the expression of RANTES significantly decreases. This
indicates that PPARa plays a regulatory role in the expression of IFNy, and that
furthermore this role overrides IFNy-mediated pathways (which would have led to an
increase in RANTES expression). These results are consistent with the increase in
RANTES expression achieved with fenofibrate during the alloresponse (shown in chapter
3) and also suggest that the attenuation of RANTES expression observed with WY
activation may have been a PPARa-independent or drug-specific effect (also presented in
chapter 3). As expected, based on augmented IFNy expression and downstream effects,
the expression of IP-10 increased, as well as that of CCR2 and CCR5; thus, the effect of
PPARa deficiency is mediated by IFNy and only indirectly influenced by PPARa.
Comparisons to the literature cannot be made because there is no literature available on
PPAR effects on the alloresponse and, as shown in chapter 3, results using mitogenic
stimulation do not necessarily translate to the alloresponse.
Congenital deficiency of PPARa on recipients (implying circulating leukocytes)
influences the immunohistochemical appearance of the allografts. The dominant cell type
in the acutely rejecting grafts is CD1 lb+, constituting approximately 75% of all graft
infiltrating cells. Allografts from the PAKO recipients have a significantly increased
number of CD1 lb+ cells (30%), while graft infiltration of CD8+ cells is significantly
attenuated (75%); however, given that the CD11+ cells are vastly more numerous, the
overall effect is an increase in graft infiltration. This suggests that PPARa is not
necessary for graft infiltration. Furthermore, augmented cell infiltration is consistent with
the tendency of graft activation markers to increase (MHC-II and VCAM-1), although
ICAM-1 tends to decrease, suggesting differential sensitivity to PPARa deficiency.
Overall, the inflammatory state of the allografts is worsened in the absence of recipient
PPARa.
Analysis of intragraft cytokine, and chemokine profiles, corroborates the presence of
increased inflammation. Consistent with the above-discussed in vitro findings, PPARa
deficiency on recipients (i.e. on the circulating lymphocytes) tends to increase intragraft
expression of IFNy. Based on the potent inflammatory activities of IFNy, this may
explain the tendency to increase MHC-II and VCAM-1 expression. The expression of
ICAM-1 is unexplained based on IFNy expression, but may be possibly be affected by
mechanisms discussed below. The chemokines, IP-10 and MCP-1 tended to increase,
potentially contributing to the increased inflammatory infiltrate.
Allograft pathology of recipients congenitally deficient in PPARa is substantially
different compared to WT recipients. The allografts from PAKO recipients demonstrated
widespread thrombi without vascular edema, compared to WT recipients that displayed
the opposite, namely the presence of edema and absence of thrombi. This is similar to the
results achieved with IFNy knock-out recipients of completely allomismatched grafts
i' '<'::~<: ~:' ./"'; 3it3C;i. However, the mechanism is likely to be different since PAKO
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recipients have increased levels of IFNy. It is more likely that the thrombus formation is
associated with increased systemic fibrinogen concentration that manifests itself in
PAKO mice I oc .. :, i - This may, in turn, predispose recipients to an increased
chance of clotting; in fact, fibrinogen has been associated as an independent risk factor
for stroke and coronary artery disease i:)\b';:i: !':::~i. This also suggests that in GKO
recipients, compensatory mechanisms may result in the upregulation of systemic markers
that dominate over the local environment. The PPAR literature offers precedent for this
type of phenomenon; fenofibrate reduced lipopolysaccharide-stimulated TNFa
production in aortic smooth muscle, yet the circulating values of TNFa were five-fold
higher in mice treated with fenofibrate -lii :' .
Congenital deficiency of PPARca on donors (on graft endothelial and vascular wall cells)
also influences the immunohistochemical appearance of the allografts. With respect to
graft infiltration, PPARa deficiency significantly changed not only the number, but also
the relative proportions of infiltrating cells. The dominant cell type in the acutely
rejecting grafts is CD1 lb+; donor PPARca deficiency significantly increases the number
of CD1 lb+ cells (-30%), as well as triples the number of CD4+ cells. This also shifts the
balance between CD4+ and CD8+ cells, which contribute roughly equally to the graft
inflammatory milieu. Overall, these results indicate that PPARca is not necessary for graft
infiltration. With respect to graft activation, results are mixed; VCAM-1 tends to
increase, while MHC-II tends to decrease and, notably, ICAM-1 is significantly
attenuated (p<0.05). This demonstrates a clear difference between the VCAM-1 and
ICAM-1 adhesion molecule sensitivity. Differential effects of these two adhesion
molecules in pathological states are evident from the literature; for example, VCAM-1
but not ICAM-1 is critical in the initiation of traditional atherosclerosis I'''"bil:k? a: i
(iX i; in the transplant setting, antibody treatment targeting ICAM-1 was associated with
IL4 and IL-10, while antibody treatment targeting VCAM-1 was associated with an IFNy
phenotype SW rB ' .. I.,
Analysis of intragraft cytokine profiles shows that, similar to PAKO recipients,
congenital PPARc deficiency on donors also tends to increase the expression of IFNy.
This may explain the tendency of VCAM-1 expression to increase; however, it is
paradoxical to the significant decrease in ICAM-1 expression. As mentioned above, there
may be a correlation to IL-10, which is the only cytokine tested that tended to decrease,
thereby suggesting a possible connection. Recent evidence suggests that IL-10 may play
a part in ICAM-1 regulation .Sc<:r e: i :a' rk :I i  Another potential mechanism involves
the retinoic acid receptor (RAR) to which PPARs must heterodimerize in order to bind to
the PPRE (as described in chapter 2); RAR activation inhibits ICAM-1 expression at the
transcriptional level .tdJ'k' c<6'I oi` 'ei-)4 (.'ge0tl, :.,Q' , 1. Deficiency of PPARa may
induce dysregulation of its required co-receptor, leading to increased activation and
subsequent inhibition of ICAM-1. Regarding possible downstream consequences of
ICAM-1 suppression, it should be noted that murine cardiac transplant studies using
donors congenitally deficient in ICAM-1 did not affect either allograft survival in
rejecting hearts or lesion development R':aliskA; c: I'l .- H,. ', such that this is not a critical
mediator of allograft rejection mechanisms.
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Donor-deficiency of chemokines, however, may have significant effects on allograft
survival; for example, using mice congenitally deficient in IP-10, investigators identified
a critical role for IP-10 in the initiation and development of PR and allograft survival
i l-.t s:cc,~ M, :!," `~ () I . PPARaX donor deficiency tended to increase the average expression
of IP-10, which would suggest a worsening of PR. Such an increase in graft infiltration is,
in fact, observed. Since grafts were all harvested at one week (without letting the allograft
fail) the effect of PPARa on allograft survival was not formally investigated.
Furthermore, PPARca donor deficiency clearly tended to decrease RANTES expression,
confirming the previously described regulatory role of PPARc on RANTES.
Interestingly, contrary to the substantial differences elicited by congenital deficiency of
PPARca on the recipient, congenital deficiency of PPARc on the donors do not markedly
affect allograft pathology. The grade of PR is modestly increased. However, edema is
present in both, with complete absence of thrombi. The lack of appearance of thrombi in
the grafts from PAKO recipients supports the contribution of systemic factors, such as
increased fibrinogen expression in PAKO hosts, to the local graft environment. Certainly,
other graft-dominant hitherto-unrecognized effects may be playing critical roles. Part of
the complexity of examining the effects of PPARct deficiency is the still evolving
understanding of basic allograft immunobiology.
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Chapter 6. A novel tool for examining mechanisms of rejection
6.1 Introduction
Despite the increasingly large amount of knowledge regarding mechanisms of rejection
in heart transplantation, the time point at which a graft is committed to a particular
outcome remains unknown. In other words, it is not known how long antigenic
simulation needs to persist to induce the secondary cell recruitment that will ultimately
develop into parenchymal rejection (PR) or transplantation-associated arteriosclerosis
(TxAA) in a graft. This knowledge would not only be important regarding the
relationship between PR and TxAA, but would also provide insight into potential pitfalls
of experimental design. For example, in Chapter 4, the PPARc agonist was not
administered to the recipients of heterotopically transplanted cardiac grafts until the third
day post-transplant. No effect beneficial was observed. However, if the outcome of a
graft were already determined by the second day after transplantation, then the lack of
effect observed with PPARac agonist treatment may be a result of experimental technique,
rather than a true absence of therapeutic benefit. If so, then any other experiments
examining the effect of treatment with either PPAR agonists or other agents may suffer
the same pitfall.
The studies examining the relationship between PR and TxAA performed to date have
several important limitations. Initial studies used immunosuppressive agents t tl:3: \I : f
'i3~:;:}) s.'f:ici+i~ .:'.~ .:(;~ ft' 2 ; however, these treatments suffer from additional potentially
confounding factors and also do not allow the abrogation of specific cell subsets. An
improvement on this approach used T cell antibodies ! !':t:.''if. s,: :! 'i:i! f '$8 l. However, the
depletion of T cells occurred mainly in the periphery and not in the graft. An additional
approach involved adoptive transfer i2't :1 : 2).!. Allografts placed in mice
genetically deficient in the production of the recombinase gene (and thus unable to
produce mature T or B cells) survive indefinitely, regardless of the level of
immunohistocompatibility complex matching. Purified T cells specific for the cardiac
graft may be injected and their particular effects examined by sacrificing the mouse at the
desired time points. While this approach allows control over the time of antigenic
stimulation, it is not possible to selectively and effectively remove the transferred T cells
to look for effects mediated through secondarily recruited cell populations.
As mentioned above, the ability to selectively and rapidly inactivate adoptively
transferred cells at specific times after transfer could yield useful temporal information
about requirements of antigenic stimulation and the relationship between PR and TxAA.
After inactivation of the adoptively transferred cells, the graft could be allowed to
function for varying times in order to assess various stages of lesion formation. There
currently are no readily available tools to accomplish this.
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Manipulation of the boron neutron capture reaction may allow this type of detailed
temporal examination to take place. Readers are referred to chapter 2 for a more complete
discussion of this reaction. In brief, °'B has a high probability of capturing thermal
neutrons and subsequently emitting two highly energetic particles that deposit their
energy within a distance that is comparable to the diameter of a cell. Thus, cells that
contain the boron may be inactivated by the intense energy deposition and subsequent
damage following neutron irradiation.
A schematic of the use of the boron neutron capture reaction as a novel immunologic
research tools is shown in Figure 6.1. In the proposed experiment, boron-loaded T cells
would be adoptively transferred into a mouse that has lacks the recombinase gene and has
received a heterotopic transplant. After a determined amount of time, neutron irradiation
could take place, thereby inducing the boron neutron capture reaction and cell
inactivation in the adoptively transferred boron-loaded graft-infiltrating T cells.
1) injection ofboron-loaded
T cells
it
cardiac graft
2) neutron irradiation
at defined times
post transplant
Figure 6.1: Use of the boron neutron capture reaction as an immunologic research tool:
Mice genetically unable to produce T or B cells would receive a heterotopic cardiac
transplant, followed by the injection of boron-loaded T cells. After defined times, neutron
irradiation would be performed, inducing the boron neutron capture reaction in the
adoptively transferred T cells.
Many of the design parameters for this application may be drawn from those established
from other applications. Based on the shallow depth of the target area (thereby not
contributing much to neutron moderation), it is estimated that a thermal beam is required
for this application. Design parameters include a target dose of 3000 rads, based on the
dose delivered in the inactivation of stimulator cells in the mixed leukocyte reaction, and
a target deletion rate of 90%, based on the depletion rates achieved using T cell directed
antibodies it; ( ' l . With respect to boron concentration in T cells, it should
be noted that typical concentrations used for tumor cell killing ranges from 30 to 50 parts
per million (ppm). This represents a likely target range of boron concentration, although
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higher concentrations would certainly be desirable in that they would reduce neutron
irradiation time and consequently reduce dose to surrounding healthy tissue.
The overall focus of the work presented in this chapter is the evaluation of potential
boron compounds for using the boron neutron capture reaction to deplete adoptively
transferred immune cell populations. This was done by testing the uptake of boron
compounds by murine T cells, and by ensuring that the uptake would not have functional
consequences, as measured by T cell proliferation and cytokine production; this is
particularly important for this application, where the goal is to have fully functional T
cells before their inactivation. Unlike other studies ,y;. ~' ;:i 3':9,11  no attempt is
made to determine the subcellular distribution of the boron; only to measure boron
association with the cells that is termed "uptake" herein.
The first boron compound that was tested was K2B12H12 (KBH), a compound containing
the polyhedral closed-form borane ion, B12H122 , a schematic of which is shown in figure
6.2. The structure of KBH was confirmed by an X-ray diffraction study ld : r-il' ~,(.t
I.ilsc:~,ir~ 2I X20X. The B 12H2 2- ion occupies a volume equivalent to that of a benzene
molecule spinning on a twofold axis and has high resonance stabilization V Mt':~:ic,'*;i::
2:2v<t A.i O~:t!! i). I.i>. Advantages of KBH include its ease of availability; it is commercially
produced and may be acquired with either unenriched or enriched boron. Previous
experimental have shown high uptake by human monocytic cells iUi:3i'i !!: :.
Disadvantages include a relatively low overall fraction of boron retention, as well as
concerns for possible leakage. Given the lack of specificity of the compound, the
postulated mechanism of uptake is pinocytosis. This predisposes the cellular distribution
to be cytoplasmic and/or endosomal, requiring potentially higher boron concentrations.
The other compounds tested were boronated nucleosides. A small library of thymidine
derivatives, containing o-carboranylalkyl groups linked at the N-3 position via alkyl
spacers of 2 to 7 methylene units, has been recently synthesized I:i. ,M;-,dhotnn c- . '?
2~'!2i. The library also included hydrophilically enhanced carboranyl thymidine analogs
i'.'' :2\§'"2.ti ~)~, : ~t~ 22'100)2, the structure of which is shown in figure 6.3. Biological
evaluation has focused on their phosphorylation rates by two enzymes that are pyrimidine
nucleoside specific, thymidine kinase 1 and thymidine kinase 2, both of which are
pyrimidine nucleoside specific; studies found that enzymatic activities of carboranyl
thymidine analogs ranged from 10% to 40% those of regular thymidine i -Jli:rt:2 (>.
ir .2()2i1. The highest efficiencies relative to thymidine, based on enzymatic kinetic
parameters, were found with boronated nucleosides having tether lengths of four and five
methylene groups i \,,,!l'tih i?2;! 1,2 go, and these represent the boronated
nucleosides tested in this thesis. Advantages include their metabolic potential for
incorporation into cellular nuclear material, thereby vastly reducing the risk of leakage
and potentially increasing the efficacy of dose delivery, as well as providing high degree
of specificity when stimulated in vitro. Disadvantages include the potentially low boron
incubation concentrations, limited by compound toxicity, as well as limited availability
(or not commercially available) and experience in cellular uptake.
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Figure 6.2: Schematic of the boron cage in K 2B,2Hl (KBH): Advantages of this boron
compound include ease of availability and previously reported high uptake in monocytic
cell line. Disadvantages include likely endosomal or cytoplasmic distribution and unclear
pathway of uptake, leading to concerns of leakage.
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Figure 6.3: Schematic of hydrophilically enhanced carboranyl thymidine analogs: The
lengths of the methylene chains of the two nucleosides tested are four (N4-20H) and five
groups (N5-20H), respectively. These were chosen on their optimal efficiency compared
to thymidine. Advantages of these compounds are their incorporation into nuclear
material of a cell, thereby reducing risk of leakage and leading to a potentially more
effective dose delivery, as well as specificity if loading is accomplished during in vitro
stimulation. Potential disadvantages are limited boron incubation concentrations due to
compound toxicity, and overall lack of experience in T cells. Readers are referred to the
literature cited in the text for a more chemically accurate depiction of structure.
Page 126
F annf-In Rinf-Uno T
FmIIUnLVl2 PInLnI HST 
6.2 Methods
The first step involved the isolation of murine T cells isolation, as described in the
following subsection. Optimal parameters for testing uptake were determined for each
compound, as described in the subsequent subsection. Finally, functional assays were
performed, including measurement of proliferative capacity and production of cytokines.
T cell isolation
Spleens were extracted from C57/BL6 mice (Jackson Laboratories, Bar Harbor) and
ground, using the barrel of a 5 ml syringe, against fine silver mesh screen in a sterile
culture dish. C-10 medium (described in previous chapters) was added to the dish and the
resulting solution was transferred to a 15 ml conical tube. The tubes were then
centrifuged in a Beckton table top centrifuge for 5 minutes at 800g. Supernatant was
aspirated and cells were resuspended in 5 ml of tris ammonium chloride buffer (1:10
dilution of tris buffer and 0.83% NaCl) for 5 minutes at 370 C to lyse erythrocytes. C-10
medium was added to a volume of 15 ml and centrifuged for 10 minutes at 1200 rpm
Supernatant was aspirated, cells resuspended in 10 ml of C-10, and the suspension passed
through a nylon mesh of 45 [tm and cells were counted with a hemocytometer.
T cells were then isolated from the splenocytes using a magnetic cell sorting system
(Miltenyi Biotec, Auburn), with beads directed against the CD90 murine marker (also
known as Thyl.2) and developed for a positive selection of the CD90+ T cells.
Specifically, cells were washed with buffer, made of phosphate buffered saline pH 7.2,
supplemented with 5% bovine serum albumin (Sigma, St. Louis). Following supernatant
aspiration, cells were suspended at a volume of 90 1tl per 107 cells. Then, 10 l of beads
per 10 7 cells were added and mixed well by repetitive pipetting. The solution was
incubated for 15 minutes at 40 C. The cells were washed by adding 10 to 20 times the
volume of beads (i.e. 100 to 200 [l per 107 cells), centrifuging for 10 minutes at 800 g,
aspirating the supernatant completely and resuspending the cell pellet in 1 ml of buffer
per 108 cells. An LS column (Miltenyi Biotec, Auburn) was placed in the magnetic field
of an appropriate MACS separator and rinsed with 3 ml of buffer. The cell suspension
was added to the column and the negative cells were allowed to pass through. The
column was rinsed three times with 3 ml, before removal from the separator and
placement on a collection tube. Then 5 ml of buffer were loaded onto the column and the
positive fraction was firmly flushed out using the specially provided column plunger. To
ensure that a maximum yield of cells would be obtained, an additional 5 ml of buffer
were loaded and again flushed out. Cells were counted for final yield and resuspended at
107 cells per ml in C-10.
To determine the purity of the T cell isolation, three aliquots of 5x105 cells were taken
and distributed in three plastic tubes. Cells were centrifuged for 5 minutes at 1200 rpm
and supernatant was decanted. To each tube, 100 itl of 1% paraformaldehyde was added.
Incubation was carried out for 5 minutes at 40 C. Then, phosphate buffered saline (PBS)
was added and cells were washed. One tube was then left on ice, as the "unstained"
control, while the other two received 12.5 1tl of phycoerythrin-labelled antibodies
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(Pharmingen, San Diego), one against CD3, a T cell marker, and the other, hamster IgG,
serving as the "isotype control". Tubes were incubated for 30 minutes, in the dark, at
40C. Cells were then washed again with PBS, resuspended, and covered with foil and
stored at 4°C until analysis by flow cytometry.
Boron uptake
In order to determine appropriate boron uptake incubation times, T cell proliferative
activity was measured in response to a powerful stimulus, namely antibody to CD3, or
anti-CD3 (Pharmingen, San Diego), The wells in the 96-well cell culture plates
designated for anti-CD3, were pre-coated in quadruplicate with 1 Itg/ml of anti-CD3 and
incubated at 370C for over 5 hours. The antibody was aspirated and 100 l of C-10 was
added. Then 100 1l of cells from a suspension at 107 cells per ml was added to each of
the wells. To measure proliferative capacity, 25 [tl of 3 H-thymidine was added to the
plates every day, and after six hours, the plates were placed in the freezer to stop the
reaction. This was repeated for 5 days, and on the last days, plates were analyzed using a
standard beta scintillation counter. Results showed an initially low proliferation rate at
day 1, followed by peak at day 2, with subsequent rapid decrease by day 3 and resting
levels by days 4 and 5. The proliferation rate at the peak was over 100-fold that observed
at resting levels. All T cell stimulations were performed with 1 tg/ml of anti-CD3.
Bulk cultures were used for the determination of uptake. The two boron compounds were
prepared and incubated with T cells. For testing KBH (Strem Chemicals, Newburyport),
cells were incubated in medium containing 1 mg/ml and reincubated in boron-free
medium for two to three days. For testing the boronated nucleosides (Dr. W. Tjarks, Ohio
State University), cells were pulsed for 12 hours at a compound concentration of 50 tM
ending on days two and three post-stimulation. Cell pellets were washed with PBS and
supernatants were saved analysis.
The boron concentration was measured both in the cells and supernatants using prompt
gamma neutron activation analysis (PGNAA), a technique where sample irradiation and
spectroscopic analysis occur simultaneously. Measurements were made at the PGNAA
facility at the MIT Research Reactor, using a focused diffracted neutron beam with a
neutron flux at the sample position of lx107 n/cm2 s and a high purity germanium detector
positioned at 900 from samples l Riii.. 'ati,'. ' 1tiltiiq ii9;i. Gamma rays were detected
from the boron capture (478 keV) and hydrogen capture (2.2 MeV) reactions.
The count rates of the gamma rays coming from both reactions was determined by
measuring the area under the appropriate gamma peak and dividing by irradiation time.
The background counts for the gamma rays resulting from boron capture were measured
by counting an empty teflon vial, while the background rate for the gamma rays resulting
from the hydrogen capture reaction were measured by counting a vial with deionized
water at a volume comparable to those of the cell solutions. Following the determination
of both count rates and the subtraction of the appropriate backgrounds, the 'OB/LH (B/H)
ratio was calculated and the final 'OB concentration was calculated against a calibration
curve generated from boric acid standards. The use of the B/H ratio reduces effects of
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inconsistent sample positioning in the beam and variations in the thermal neutron flux
measurement. A calibration curve, relating B/H ratio to boron concentration (ppm) was
constructed each time, using boric acid standards prepared by those responsible for
maintenance: of the PGNAA facility. Measurement error was calculated according to
standard counting statistics formulas .ikii ' C-,',t)A!i. Based on the relatively high
concentrations measured in the samples, there was no need to calculate the lower limits
of detection for any of the samples.
With respect to the measurement of boron in cells, the B/H ratio was scaled to take into
account the volume the cell pellet, as per a protocol developed using a monocytic cell line
[Binello 1999]. The protocol is based on the fact that the B/H ratio obtained for a cell
suspension will give the concentration of the entire suspension, including the PBS used
for the final resuspension (since the hydrogen is in the denominator), rather than the cell
pellet. Thus, the microcentrifuge tubes that are used to store the cells and suspension are
weighed three times, i.e. when they are empty, when they contain the cell pellet, and after
the pellet has been resuspended into a cell suspension. The boron concentration is
multiplied by the volume of the cell pellet and divided by the volume of the cell
suspension, thereby yielding the boron concentration of the cell pellet, or cellular
"uptake". In other words, (tg of 'l°B/g of solution)*(g of solution/g pellet)=ftg/g of pellet.
Scaling the ratio is allowed because the suspension is homogeneous. In order to decrease
the amount of error with respect to weighing and effect of a potential drop of liquid not
aspirated from the cell pellet, large amounts of cells were used to generate the cell pellet,
i.e. approximately 30 million cells. Finally, it should be noted that all PGNAA counting
errors were kept well below 10%, in order to keep a propagated total error below 10%.
Functional assays
The first of two functional assays tested the effect of boron uptake on proliferative
capacity. This was only tested with KBH. As previously described, proliferation was
measured by the addition of 3 H-thymidine to cell cultures for 6 hours, ending on days 1
through 5. At the end of the pulse, plates were either read or frozen, until they could be
read using a scintillation counter. Proliferation was not tested with the boronated
nucleosides, out of concern for possible competition of thymidine substrates and/or
interference with uptake.
The production of IFNy was performed using enzyme-linked immunoassays (ELISAs) as
per the manufacturer's protocol (Pharmingen, San Diego) and is fully described in
chapter 3. Briefly, plates were coated with purified antibody against IFNy, and
subsequent to overnight incubation, blocked and loaded with both samples and standards.
Following another overnight incubation, a secondary biotinylated antibody that binds to
IFNy was added. Subsequent incubation with avidin-conjugated horse-radish peroxidase
then allows chromogenic development by addition of an appropriate substrate (in this
case, ABTS). Optical density was measured and IFNy concentrations were determined
using a calibration curve of known standards. Results were analyzed using "Softmax"
software (Molecular Devices Corporation).
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6.3 Results
T cell isolation
Figure 6.4 shows a representative result of over 95% T cell purity, following isolation via
the magnetic cell sorting system and analysis using flow cytometry. The isolation
technique was robust and yielded an average of 90% purity, as determined the fraction of
cells positive for the CD3 T cell marker.
,I M I1I
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Figure 6.4: Representative T cell purity as determined by flow cytometry: On the left,
the filled area corresponds to unstained cells while the solid line cells stained with the
isotype control (hamster IgG). The curve on the right, toward the M1 marker,
corresponds to cells positively staining for the T cell marker, anti-CD3. Flow cytometric
analysis showed that the fraction of positively staining cells, corresponding to the purity
of isolation, was approximately 95%.
Boron uptake
Results of the KBH uptake by T cells are shown in figure 6.5. The average boron
concentration achievable in T cell upon incubation with KBH was approximately 300
ppm (scaled to enrichment). The average boron concentration in supernatants from day 2
and 3 samples was less than 5 ppm, indicating retention against a concentration gradient
and no significant cell death.
Results showing the uptake of the two hydrophilically enhanced carboranyl thymidine
analogs are shown in figure 6.6. The uptake of N4-20H was 80 + 10 ppm and 290 + 40
ppm on days 2 and 3, respectively, while the uptake of N5-20H was 140 + 20 ppm and
250 30 ppm also on the respective days 2 and 3. The overall average uptake was 200
ppm over both days for both compounds.. The boron concentration in the supernatants
was minimal, ranging from 5 to 15% that measured in the cells, indicating retention of
the boron against a concentration and consistent with the degree of cell apoptosis that
may normally occur in immune cell cultures undergoing stimulation.
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Figure 6.5: Uptake of KBH by murine T cells: Average boron concentration in cells and
supernatants (denoted as sup) were 300 ppm and 5 ppm, respectively. There was no
significant difference between the two days tested (p ns). The low concentrations in the
supernatants indicate retention against a gradient.
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Figure 6.6: Uptake of two carboranyl thymidine analogs by murine T cells: The average
boron uptake of the N4-20H and N5-20H boronated nucleosides was approximately 200
ppm for both of the boron compounds over both days. The boron concentration in the
supernatants ranged from 5% to 15% of that measured in cells, which is comparable to
the normally occurring level of apoptosis in culture and indicate retention against a
concentration gradient.
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Functional Assays
Representative results of the functional T cells assays using KBH are presented in figure
6.7, expressed as the average and standard deviation of samples cultured in quadruplicate.
Proliferation following stimulation with anti-CD3 peaked at day 2 and then went to the
resting level (it should be noted that although the proliferation assay was carried out for
five days, the fourth and fifth day are not shown on the graph because they were similar
to the third clay). There was no significant difference in proliferation between control and
KBH-treated T cells on any of the days tested (p ns). Similarly, the concentration of IFNy
in the supernatants of the proliferation cultures on days 2 and 3 also did not differ
significantly (p ns) upon treatment of the T cells with KBH. The average concentration of
IFNy in control cells was 12,600 + 2,900 pg/ml over both days, compared to the average
of 13,500 ± :5,000 pg/ml in KBH-treated cells.
With respect to T cell function, addition of the boronated nucleosides did not have
significant effects as determined by the production of IFNy, as shown in figure 6.8.
Results are expressed as the average and standard deviation of samples cultured in
quadruplicate. It is hereby noted that proliferative capacity was not evaluated out of
concern for possible competition since the technique readily available in the laboratory
for measuring proliferation depends on the incorporation of 3H-thymidine. However, it
should be noted that it is unlikely for cells to incorporate the boronated thymidine unless
they are proliferating Following anti-CD3 stimulation, murine T cells produced an
average of 12,700 1,700 pg/ml of IFNy over both days, between which there was no
significant difference over the days tested (p > 0.5). The addition of N4-20H resulted in
an average IFNy concentration of 12,100 + 1,800 pg/ml, while addition of the N5-20H
compound yielded an average of 12,600 11,200 pg/ml, both not significantly different
(p > 0.5) compared to the controls pulsed with medium alone.
Proliferation IFNy production
Figure 6.7: Results of functional T cell assays using KBH: There is no significant
difference in either proliferation or IFNy concentration between days following treatment
with KBH on any of the days tested (p ns).
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Figure 6.8: Results of functional T cell assays using carboranyl thymidine analogs:
There is no significant difference in IFNy concentration between days or following the
addition of N4-20H or N5-20H to the cultures on any of the days tested (p ns).
Proliferation was not measured out of concern for possible competition between
thymdine substrates since the technique readily available in the laboratory for measuring
proliferation depends on the incorporation of 3 H-thymidine.
6.4 Discussion
A novel tool has been presented to investigate the temporal relationship between PR and
TxAA, as well as requirements of antigenic stimulation, in the attempt to determine the
time point at which a heart transplant is committed to a particular pathological outcome.
Existing immunological techniques have limitations that preclude the ability to remove
the graft-infiltrating T cells and allow the mouse to survive in order to determine the
effect on the lesion formation. Manipulation of the boron neutron capture reaction may
allow this type of investigation to be performed. This method represents a novel
application of the boron neutron capture reaction as an immunologic research tool rather
than solely as a therapeutic modality.
The focus of the work presented in this chapter is examination of boron uptake by T cells.
Boron uptake by murine T cells in vitro is required for potentially using the boron
neutron capture reaction as an immunologic tool in the context of heart transplantation
research. Boron compound evaluation also involved the examination of possible effects
of uptake on T cell function, namely proliferative capacity and production of IFNy. These
functional assays are particularly important for this application of the boron neutron
capture reaction where the goal is to have fully functional T cells present in the
transplanted heart for specified times before their inactivation via the boron neutron
capture reaction induced upon neutron irradiation.
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Several compounds were screened, including KBH and two boronated nucleosides, i.e.
hydrophilically enhanced carboranyl thymidine analogs, with tether lengths of 4 and 5
methylene groups, i.e. N4-20H and N5-20H. Uptake of both compounds was high. The
average uptake of KBH was approximately 300 ppm, consistent with experiments using a
human monocytic cell line iB i.e!i(t 9i~ )1 .I. The uptake of the boronated nucleosides was
roughly similar, with the averages ranging from 200 to 300 ppm, a factor of ten higher
than the concentrations typically observed in clinical studies of boron neutron capture
therapy. Supernatant concentrations were minimal with all of the compounds, indicating
retention against a concentration gradient and no significant cell death. Functional assays
demonstrated no adverse effects on T cells. Treatment of T cells with KBH had no
significant effects on T cell proliferation, and neither KBH nor the boronated nucleosides
had significant effects on IFNy production. The effect of the boronated nucleosides on
proliferative capacity was not tested due to concerns of possible competition given that
the measurement technique is based on the incorporation of 3H-thymidine.
In light of the comparable uptake and lack of significant effects on T cell function, the
preferred compounds for this application are the boronated nucleosides. The advantages
of these compounds are reduced risk of leakage and potentially increased effectiveness of
dose delivery, as well as uptake specificity following in vitro stimulation, all resulting
from their metabolic incorporation into cellular DNA. Overall, their excellent uptake,
taken together with their advantages, make them ideal compounds for this novel
application of the boron neutron capture reaction. Thus, consideration of the high uptake
levels achieved in vitro, taken together with the lack of adverse effects on cell function
and design goals, suggests that boronated nucleosides have a high likelihood for success.
One potential biological effect of T cell inactivation in vivo is decreased local
macrophage activity. However, the extent of this effect is dependent on the dynamics of
T cell function in the graft and is not yet fully understood, despite active investigation.
Further development of this immunologic research tool is warranted. This could entail the
use of high-resolution quantitative autoradiograph °ci 2t.}/)N of frozen heart tissue
sections after in vivo administration of boron-loaded T cells to ensure that the T cell
concentrations achieved in vitro are retained in vivo. This is particularly important given
the likelihood of T cell proliferation in vivo, thereby potentially diluting initial boron
concentrations. Given positive results, effort could then directed toward testing the
proposed tool in mice. Finally, it is emphasized that if successfully developed, this
application of the boron neutron capture reaction could have wide application in
immunology research.
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Chapter 7: Summary and recommendations for future work
Over the last several years, PPARs have emerged as immunomodulatory agents. They are
expressed in cells of the vascular and immune systems, including vascular endothelial
and smooth muscle cells, as well as monocytes/macrophages and T cells. Based on the
reported anti-inflammatory and anti-atherosclerotic effects of PPAR activation both in
vitro and in vivo, there was reason to hypothesize beneficial effects of PPAR agonists on
parenchymal rejection and transplantation-associated arteriosclerosis. Moreover, given
the current broad use of several PPAR ligands in the clinical setting, a demonstration of
benefit in transplant rejection could translate rapidly to clinical application, strengthening
the motivation for pursuing study. Thus, the overall goal of this thesis was to investigate
the role of PPARs in mechanisms of rejection in heart transplantation.
Evaluation of PPARs in mechanisms of rejection began in vitro. For the first time the
effects of four PPAR agonists, two PPARa agonists (fenofibrate and Wy14643) and two
PPARy agonists (BRL49653 and 15-deoxy A12' 14 PGJ2), were examined in the mixed
leukocyte reaction (MLR), serving as a surrogate for the alloresponse. All agonists had
the ability to significantly decrease production of IFNy, without affecting proliferation or
viability. Dose response studies identified the "therapeutic" dose for each PPAR agonist.
A thorough examination of cytokine, chemokine and chemokine receptor expression
profiles as a function of time in the alloresponse and following ConA simulation was
performed. Comparison of these profiles revealed critical differences between ConA and
MLR stimulation, pointing to the need for specific testing in the alloresponse setting for
potential translation to in vivo transplant rejection. Therefore, only the highlights of the
results obtained in the alloresponse are summarized here. Future work could be aimed at
defining signaling pathways involved in the differences.
There were multiple (and occasionally unpredictable) effects of PPAR agonists on the
cytokines, chemokines and chemokine receptors expressed in the alloresponse. IFNy is
typically the dominant cytokine expressed and PPAR activation uniformly decreased
expression by -50%. The lack of a concomitant decrease in either IL-12 or IL-18,
suggests a direct effect of PPAR agonists on IFNy, which has been recently substantiated
by data showing PPAR effects on STAT 1 phosphorylation, nuclear localization and DNA
binding. Based on known roles of IFNy on chemokine expression, a decreased chemokine
profile was expected. Initially, PPAR activation had no significant effects on any of the
chemokines or receptors tested. Later in culture, when high concentrations of IFNy were
present in culture, PPAR agonists diminished CCR2 and CCR5. Given the implications
of these two receptors in mechanisms of rejection, the decrease in CCR2 and CCR5 is
beneficial. However, PPAR ligands (with the exception of fenofibrate) significantly
augmented chemokine production, thereby rendering unavailable a substantial benefit
associated with a decrease in IFNy.
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Thus, in vitro, PPAR agonists display several "anti-rejection" effects, including marked
decreases in IFNy, CCR5 and CCR2. Of the PPARca and PPARy agonists tested,
fenofibrate emerged as the most promising candidate for attenuation of rejection
mechanisms in vivo. Unlike the other PPAR agonists, it did not markedly enhance the
overall chemokine expression. Fenofibrate displayed the greatest potential of minimizing
chemokine-mediated "pro-rejection" properties, while continuing to take advantage of the
"anti-rejection" properties of PPAR agonists. Moreover, reports from the literature
suggested that fenofibrate could decrease the expression of VCAM-1 and subsequent
monocyte binding to endothelial cells, as well as ICAM-1. The literature also suggested
that fibrates could suppress both vascular endothelial and smooth muscle cell activation.
Fenofibrate treatment was consequently administered to MMHC-II mismatched
recipients of heterotopic murine cardiac allografts. After two weeks, fenofibrate
administration reduced the intragraft expression of IFNy, as well as other
proinflammatory genes, with concomitant reductions in IP-10, CCR2 and CCR5. Graft
infiltration by mononuclear cells was markedly attenuated as a result of the fenofibrate.
At this early, time point (2 weeks), the in vivo results closely recapitulated the in vitro
results described above.
However, by 8 weeks, graft infiltration was substantially increased, likely a result of
sustained RANTES production. Fenofibrate continued to attenuate production of IFNy on
a per cell basis. However, the increased number of cells in the graft led to paradoxically
increased levels of IFNy in the graft. Final pathological analysis of the grafts reflected
this result; there was no change in transplantation-associated arteriosclerosis (roughly
proportional to IFNy), in the face of increased parenchymal rejection (roughly
proportional to graft cellular infiltration). This suggests that in order to fully realize the
benefit of diminished IFNy by fenofibrate in grafts, concomitant administration of agents
reducing graft infiltrate will be required. Future work may involve the co-administration
either of agents attenuating recruitment by targeting the chemokine or chemokine
receptors, or of agents directed at preventing adhesion and extravasation of circulating
lymphocytes into the donor vasculature.
The availability of mice congenitally deficient in PPARca (PAKO) allowed the
examination of PPARca requirement both in vitro and in vivo. Experiments specifically
addressed whether, in the setting of congenital PPARca deficiency, fenofibrate could
affect the production and expression of IFNy, in addition to other cytokines, chemokines
and chemokine receptors. The influence of PPARa in vivo on parenchymal rejection was
investigated via murine heterotopic cardiac transplants between strains mismatched in
both MHC-I and MHC-II, in combinations where either the donor or the recipient were
congenitally deficient in PPARa.
In vitro experiments with PAKO leukocytes support a role for both PPARa-independent
and PPARa--dependent effects in the MLR. At 20 [tM, fenofibrate reduces the in vitro
production of IFNy by splenocytes congenitally deficient in PPARca, without affecting
cell proliferation or viability. This suggested the existence of "cross-talk" at several
levels and raised the question of whether the effect on IFNy was mediated even in part by
Page 136
HST
T1-TYIIIUIIL·VILCX~~~~~w^"~~~~~~~~~~~~ YIIIVItl~~ IV I I
PPARa. Using mice congenitally deficient in PPARa, allogeneic stimulation led to
higher levels of IFNy expression, suggesting that PPARa does indeed play a regulatory
role in the expression of IFNy. With the accumulation of IFNy in culture, PPARa also
influenced chemokine and chemokine receptor expression. As expected, based on
augmented IFNy and downstream effects, the expression of IP-10, CCR2 and CCR5
increased. However, RANTES expression decreased, suggesting a regulatory role of
PPARca in RANTES production.
Transplants performed using mice congenitally deficient in PPARa as either recipients or
donors showed significantly increased graft infiltration by CDllb+ cells. Analysis of
intragraft cytokine, and chemokine profiles demonstrated increased intragraft expression
of IFNy and decreased expression of RANTES, implying PPARca regulation for both of
these proteins. Cardiac allograft pathology of PAKO recipients distinct and demonstrated
widespread formation of thrombi without vascular edema (compared to WT recipients
that displayed edema, in the absence of thrombi). It is likely that thrombus formation is
associated with increased systemic fibrinogen concentration in PAKO mice. In
comparison, congenital donor deficiency of PPARa did not markedly affect allograft
pathology, with both WT and PAKO donors displaying edema and no thrombi. Future
work should be aimed at increasing the number of transplants per arm, in order to
discriminate subtle changes in expression profiles, potentially contributing to
mechanisms of rejection.
Finally, one technical issue was considered with respect to fenofibrate treatment of
transplanted mice. Drug administration was not started until day 3 post transplant due to
concerns over coagulation. However, it is not known when a graft becomes committed to
a particular outcome. If the outcome of a graft were already determined by the second
day after transplantation, then the lack of fenofibrate effect in vivo could be a result of
experimental technique, rather than a true absence of therapeutic benefit. There are no
readily available tools allowing the removal of T cells at determined times after
infiltration into the graft and the survival of the murine transplant recipients, in order to
assess the effect on lesion formation.
A novel tool based on the boron neutron capture reaction was presented and design goals
for this application were delineated. Experimental work addressed the potential of
achieving high boron uptake by T cells, without adversely affecting production of IFNy.
Optimal compounds tested were boronated nucleosides, with average uptake ranging
from 200 to 300 ppm (a factor of ten higher than the concentrations typically observed in
clinical studies of boron neutron capture therapy), without significant effects on IFNy
production. Advantages of the boronated nucleosides include the reduced risk of leakage
and potentially increased effectiveness of dose delivery (both resulting from their
metabolic incorporation into cellular DNA). Future work should involve high-resolution
quantitative autoradiography on frozen sections of cardiac grafts after the adoptive
transfer of boron-loaded T cells, to ensure that the uptake achieved in vitro is retained
following injection in vitro. A positive result would then justify moving to an in vivo
proof of concept in allograft rejection. If successful, this technique could have wide
application i immunological research.
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